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Abstract 
Objectives:  
Tolerance is a hyporesponsive state caused by repeated exposure to a stimulus. In the intestine, 
dysregulation of tolerance to luminal stimuli may lead to chronic and deleterious inflammation, 
such as characterizes Inflammatory Bowel Disease. The role of T-cells in immune tolerance is 
well known, but that of the epithelium requires investigation. Epithelial tolerance is gene-specific 
and differentially regulated, but the role of and involvement of epigenetics in tolerance regulation 
is unknown. We hypothesized that prior stimulation may cause epithelial cells to become 
hyporesponsive (tolerized) and that modification of histone methylation may alter the response to 
pro-inflammatory stimulation. The aim of this work was to examine if known inhibitors of histone 
methylation modifying enzymes affected the expression of CXCL8 in response to IL-1β. 
 
Methods:  
CXCL8 production of intestinal epithelial cells was measured by ELISA after stimulation with the 
pro-inflammatory stimuli P3CK and IL-1β and small molecule epigenetic inhibitors. The CXCL8 
production of cells stimulated with a pro-inflammatory stimulus was compared to pre-stimulated 
cells after a second stimulus. CXCL8 production of IL-1β-pre-stimulated cells was also compared 
to CXCL8 production when these cells were incubated with epigenetic inhibitors. The effects of 
these inhibitors on histone methylation levels were examined by Western blotting for the global 
effect and by ChIP-qPCR for specific effects at the CXCL8 locus. 
 
Results:  
Intestinal epithelial cells stimulated with pro-inflammatory stimuli produced a large CXCL8 
response. Pre-stimulation significantly decreased CXCL8 production after a second stimulus. The 
time-coiurse of CXCL8 expression was measured to ensure that CXCL8 expression due to pre-
5 
 
stimulation was over before the second IL-1β-stimulation. In the presence of specific epigenetic 
inhibitors, pre-stimulation by IL-1β did not reduce CXCL8 production after a second IL-1β-
stimulation. The specific effect of these inhibitors on the epigenetic signature at the CXCL8 locus 
was confirmed by ChIP. Thus, histone methylation modification disrupted tolerization of intestinal 
epithelial cells to a pro-inflammatory stimulus. 
 
Conclusion:  
The inflammatory response of the intestinal epithelium can be tolerized by prior stimulation with 
pro-inflammatory cytokines. Tolerization is lost after incubation with inhibitors known to modify 
histone methylation status, indicating for the first time, the involvement of histone methylation in 
this phenomenon. 
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1 Introduction 
 
1.1 Inflammation 
 
1.1.1 Inflammation and its Clinical Consequences 
Inflammation is a complex protective response to infection and trauma (1). Acute or temporary 
inflammation is essential to combat infection by killing the pathogens and any infected host cells. 
It also prevents further microbial invasion and heals the ensued tissue damage from both the 
infection itself and the immune response. However, dysregulated or chronic inflammation is 
deleterious, causing persistent tissue damage (2) and a wide range of diseases including 
Rheumatoid arthritis, cancer, Inflammatory Bowel Disease (IBD), coeliac disease, 
atherosclerosis, systemic lupus erythematosus (SLE), asthma and sepsis, among many others 
(1). It is essential that the inflammatory response is strictly controlled in order to combat infection, 
but not result in adverse consequences. 
 
The critical importance of inflammation is highlighted by the increased probability of fatal 
infections in people with a genetic mutation in one or more of the genes encoding a component of 
the inflammatory pathway. For example, mutations causing a deficiency in mannose-binding 
lectin (MBL) predisposes people to infections (3), including meningococcal disease (4) and > 90% 
of those with a rare genetic deficiency of C1q develop SLE (5). There are several mutations to 
NLRP3 (NLR family, pyrin domain containing 3) that are associated with an increase in the 
production of IL-1β (interleukin-1 beta) and three autosomal dominant diseases characterised by 
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chronic inflammation: Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous 
and articular syndrome (CINCA) and familial cold autoinflammatory syndrome (FCAS) (6). 
 
30 000 cases of severe sepsis occur every year in the UK (7); 2.9 million people are living with 
diabetes (8); 580 000 people suffer from rheumatoid arthritis (9) and over 150 000 people are 
affected by IBD (10). It is difficult to determine exactly how many people are living with diseases 
caused by dysregulated inflammation; but it is easy to see how wide-ranging the effects are on 
the body in the large number of diseases and how debilitating they can be on the patient’s quality 
of life. In addition, they are a significant burden on clinical services. 
 
An inflammatory response is induced upon detection of infection. Vasodilation, an increase in 
respiration and increased permeability of the blood vessels, causes the characteristic redness, 
heat and swelling (due to exudation of plasma proteins and fluid into the tissue) (11). The 
extravasation of neutrophils from the blood vessels to the site of infection is the next step to 
phagocytose the infectious organism (11). Other cytokines and chemokines are released to 
activate the complement system thereby promoting opsonisation, chemotaxis, coagulation, 
fibrinolysis and tissue damage repair (11). Once the inflammatory stimulus is removed, acute 
phase inflammation ceases due to the short half lives of the inflammatory mediators (12), and the 
initiation of anti-inflammatory pathways (such as resolvins).  
 
Systemic inflammation occurs when the infectious organism cannot be confined to the local area 
and the organism can access the lymphatic or circulatory systems. If the infection is still not 
confined, it is possible for inflammation to surmount the host and a systemic inflammatory 
response syndrome develops, which progresses to sepsis ultimately leading to multiple organ 
failure, septic shock and death (13). Other systemic effects of inflammation are an alteration in 
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leukocyte number, both leucocytosis (an increase of, usually, neutrophils) and leukopenia (a 
decrease in white blood cells, often as a result of neutrophilia, seen in certain diseases e.g. viral) 
(14). 
 
However, not all cases of inflammation have infectious origins (2). Many inflammatory diseases 
show no evidence of infection and are idiopathic in origin. For example, obesity is significantly 
associated with a low level of chronic inflammation (as seen by an increase in IL-6, CXCL8, TNF 
and insulin etc levels affecting the endothelium), which then presents its own complications 
including an increased risk of type II diabetes, heart disease, renal and hepatic failure etc (15). 
Persistent inflammation in coeliac disease results in villous atrophy and consequent 
malabsorption (16). Loss of the epithelium due to continual inflammation, as seen in IBD, can 
require surgical removal of the affected area, if anti-inflammatory drugs are not effective. 
 
 
1.1.2 Inflammation and the Innate Immune System 
The innate immune system is the body’s first line of defence against pathogenic invasion. It 
recognises “danger” signals or PAMPs (pathogen-associated molecular patterns) that are 
common to microorganisms but are not found in the human body e.g. lipopolysaccharide (LPS) (a 
major component of Gram negative bacterial cell walls), bacterial lipoproteins (present in bacterial 
cell membranes), flagellin (protein component of the bacterial flagellum), double-stranded RNA 
(forms some viral genomes) etc. Pattern recognition receptors (PRRs) recognise and bind to 
PAMPs and DAMPs (damage-associated molecular patterns). DAMPS are cellular components 
released upon damage e.g. stress. The signal cascade that is initiated upon interaction of the 
PRR and its ligand activates the inflammatory responses.  
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PRRs include Toll-like receptors (TLRs), NOD-like receptors (NLRs and NALP/NLRPs) and C-
type lectin Receptors (CRPs). There are thirteen classes of TLRs, each with a specific ligand, as 
shown in Figure 1-1. TLR1 and TLR6 recognise triacyl and diacyl lipopeptides, respectively; 
TLR2’s ligand is lipoteichoic acid and other lipoproteins; TLR3 recognises double-stranded RNA 
whilst TLR7 and TLR8 recognise single-stranded RNA and small synthetic compounds (TLR8 
only); TLR4 binds to lipopolysaccharide; TLR5 recognises flagellin; TLR9’s ligand is unmethylated 
CpG oligonucleotides; and TLRs 10 – 13 are only found in certain cell types so are not as 
ubiquitous as the first 9. NLR ligands include peptidoglycans (NOD1 binds to meso-DAP (meso-
diaminopimelic acid) whereas NOD2 binds to muramyl dipeptide (MDP), both of which are 
peptidoglycan components of the bacterial cell wall (17)); other NLR ligands include nucleoside 
triphosphates, bacterial DNA, toxins, double-stranded RNA, ATP and uric acid crystals (18). 
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Figure 1-1 TLRs and IL-1 Receptor Agonists 
TLRs and IL-1R are PRRs located at both the cellular membrane and at intracellular compartments. The association 
between individual TLRs/IL-1R and their specific ligand is depicted in the above figure. After receptor and agonist 
bind, a signalling pathway resulting in activation of NF-κB and induction of pro-inflammatory cytokine expression is 
initiated.  
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Once the ligand (PAMP) has bound to the receptor (PRR), the TLR dimerises and adaptor 
molecules are recruited (Figure 1-2) via the association of the TIR (Toll/Interleukin-1 receptor 
homology) domains located in both the receptor and the adaptor molecules. The majority of TLRs 
form homodimers however a selection of TLRs in specific circumstances for heterodimers. TLR2 
forms heterodimers with TLR1, TLR6 (19) and TLR10 (20). Both TLR4 and TLR5 usually form 
homodimers, but they can also form heterodimers, which causes an increase in this activity. 
Conversely, heterodimers between TLR4 and TLR1 appear to inhibit TLR activity (21). TLR4 also 
requires an extracellular co-factor, MD2, for optimal ligand-receptor binding (22). After TLR 
dimerization, adaptor molecules are recruited and the signalling pathways initiated for expression 
of pro-inflammatory and anti-microbial genes. The same pathways are also activated via binding 
of IL-1β to interleukin-1 receptor (IL-1R). 
 
All TLRs, except TLR3 and including IL-1R, recruit MyD88 whereas TLR3 (and TLR4) recruit 
TRIF. The sorting adaptors TRAM and TIRAP determine whether MyD88 or TRIF, respectively, is 
recruited to the receptor and which subsequent pathway is activated. Whilst both pathways result 
in the activation of NF-κB (p50-p65 complex), the TRIF-dependent pathway also activates TRAF3 
which activates the kinases TBK1 and IKKε, which phosphorylate and activate IRF3 (Interferon 
regulatory factor 3). IRF3 induces transcription of type I interferon (interferon-β) and interferon-
inducible genes. One of those genes is IRF7, which interacts with IRF3, leading to transcription of 
NF-κB and interferon-α and the subsequent expression of pro-inflammatory cytokines and the 
transcription factor TNF (tumour necrosis factor α) (18).  
 
 NF-κB is activated via both MyD88- and TRIF-dependent signalling pathways following TLR and 
IL-1R activation (Figure 1-2). MyD88 recruits IRAK4, IRAK1, IRAK2 and TRAF6 via a 
phosphorylation cascade. TRAF6 transduces the signal amplified by the phosphorylation cascade 
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and activates the kinase TAK1 in complex with TAB1 and TAB2. This activates the IKK complex 
(consisting of the two kinase subunits IKKα and IKKβ and the regulatory subunit NEMO) which 
phosphorylates the inhibitory IκB protein (23). Phosphorylated-IκB dissociates from the p50-p65 
complex, thus revealing the nuclear localisation signal (NLS) and allowing activated NF-κB to 
translocate to the nucleus and induce expression of pro-inflammatory cytokines (24). NF-κB is 
activated via MyD88-dependent TRAF6 signalling, but also via TRIF-dependent activation of 
TRAF6. The subsequent TAK1-TAB1-TAB2 complex propagates the TLR or IL-1β signal via two 
routes: activation of NF-κB via the IKK kinase complex and initiation of the MAPK (mitogen-
activated protein kinase) pathway. TAK1 activates the kinases p38 and JNK, which phosphorylate 
and activate the transcription factor AP1 (25). AP1, like NF-κB, translocates to the nucleus where 
it induces expression of pro-inflammatory cytokines. 
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Figure 1-2 TLR- and IL-1R-Signalling Pathways 
TLR- and IL-1R-mediated responses use the same signalling pathway mediated by MyD88. All TLRs are dependent 
on MyD88, except TLR3 which uses the TRIF-dependent pathway along with TLR4. TRAM and TIRAP are sorting 
adaptors used to determine whether MyD88 or TRIF is recruited. MyD88 recruits IRAK4, IRAK1, IRAK2 and TRAF6 
via a phosphorylation cascade. TRAF6 activates TAK1 in complex with TAB1 and TAB2 and activates the IKK 
complex (consisting of NEMO, IKKα and IKKβ) which phosphorylates the IκB protein thereby releasing NF-κB (p50-
p65 complex). NF-κB translocates to the nucleus and induces the expression of pro-inflammatory cytokines. The 
TAK1-TAB1-TAB2 complex also activates the MAPK pathway resulting in phosphorylation and activation of AP1. 
AP1 translocates to the nucleus and induces expression of pro-inflammatory cytokines. The alternative TRIF-
dependent pathway activates TRAF6, NF-κB and AP1 as described in the MyD88-dependent pathway, as well as 
TRAF3 which activates the kinases TBK1 and IKKε, which phosphorylate and activate IRF3. IRF3 induces 
expression of type I interferon (IFNβ).  
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1.1.3 Inflammatory Mediators 
Inflammation is induced by expression of interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 
(CXCL8 – neutrophil chemotactic factor) and TNF, among other cytokines. TNF is a 17 kDa 
protein whose gene is located on chromosome 6 which is released from its membrane-bound 
state by proteolytic cleavage by TNF alpha converting enzyme (TACE or ADAM17) into soluble 
TNF which trimerizes to form the active 51 kDa homotrimer (26). Its main function is a systemic 
inflammatory cytokine involved in the acute phase reaction. It induces fever, apoptosis, sepsis, 
inflammation and inhibits tumourigenesis and viral replication (27). TNF binds to its receptor 
resulting in activation of NF-κB and JNK (via the MAPK pathway) which induces pro-inflammatory 
gene expression, including CXCL8 (28); and apoptosis via activation of the caspase pathway. 
Varying levels of TNF are thought to play a role in IBD (29), though this role is controversial. The 
effective use of anti-TNF therapeutics in the treatment of both UC and CD implies that TNF is 
functional in intestinal inflammation. Reducing the amount of TNF present through the use of 
specific antibodies alleviates inflammation and promotes disease remission (30, 31). This does 
not prove whether or not TNF is causal in the development of IBD, just that it is an important 
inflammatory mediator. 
 
IL-1β is a 15kDa protein whose gene is located on chromosome 2, which is converted into its 
active form by cleavage of the IL-1β precursor by caspase-1 (previously known as IL-1β 
converting enzyme) (32). Its receptor shares a similar cytoplasmic domain and the same 
signalling pathway adaptors as the TLR-signalling pathway, thus amplifying the signalling 
cascade through increasing the activation of NF-κB. IL-1β increases expression of pro-
inflammatory cytokines and chemokines e.g. IL-6, CXCL8, type-2-cyclooxygenase (COX2) and 
nitric oxide synthase etc, whilst modulating the surface expression of IL-1R and TNF receptors 
(33).  
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IL-1R and TLRs share a number of similarities in their structure and signalling pathway 
components (34). This is mainly due to the conservation of the TIR domain between TLRs and IL-
1R and their adaptor molecules. The structure of each receptor is highly conserved across 
species with similarities between shared domains e.g. TIR. The differences in structure create a 
range of receptors with specificity to a range of different ligands. Therefore, whilst the cytosolic 
domains provide the specificity for each ligand, the shared TIR domains in the receptors and 
adaptor molecules activate the same signalling pathways. Activation of NF-κB, AP1 and IRF3 and 
the subsequent induction of gene expression is shared between the different receptors, but the 
exact profile of genes that are expressed is specific to the individual receptor. TLRs and IL-1R are 
also linked through NLRP3, a receptor which regulates caspase-1, which in turn maturates IL-1β 
(35). 
  
Both of the IL-6 and CXCL8 promoters contain NF-κB transcription factor binding sites; hence 
expression of these cytokines depends on NF-κB activation via either TLR- or IL-1R-mediated 
signalling. IL-6 is a 21 kDa pro-inflammatory cytokine located on chromosome 7. It is responsible 
for inducing fever by crossing the blood brain barrier and stimulating expression of PGE2 in the 
hypothalamus (36). IL-6 also increases respiration to increase body temperature; B cell 
maturation and neutrophil production in the bone marrow. Though IL-6 is expressed in large 
amounts by leukocytes, it is also expressed in lesser amounts by intestinal epithelial cells (37, 
38). In particular, IL-1β stimulates less IL-6 than CXCL8 in intestinal epithelial cells. 
 
CXCL8 is an 8.5 kDa chemokine located between 74,606,223 and 74,609,433 of the forward 
strand of chromosome 4. Its main function is as a granulocyte chemoattractant (primarily 
neutrophils, but also macrophages and mast cells) in order to cause neutrophils to migrate to the 
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site of inflammation (39). Once they have arrived, CXCL8 induces phagocytosis. CXCL8 also 
increases vascular permeability, necessary for neutrophil migration, through down-regulation of 
tight junction proteins (40). N-terminal processing of the CXCL8 protein results in a number of 
cleavage isoforms, whose activity or affinity relative to the complete protein is altered (41-43). 
Post-translational modification of residue Arg-27 with citrulline alters the activity of CXCL8 by 
reducing tissue inflammation and increasing leukocytosis due to the increased mobilization of 
neutrophils into the blood (44, 45). It is also a potent angiogenesis factor and a biomarker of 
senescence, particularly of oncogene-induced senescence in colon adenomas (46). CXCL8 is 
potently expressed by intestinal epithelial cells, making it an ideal indicator of inflammatory 
induction, via activation of NF-κB, by IL-1β- and P3CK-stimulated Caco-2 cells (47, 48). 
 
There are three splice variants of CXCL8, though only two produce a functional protein (Figure 
1-3) due to the third variant retaining an intron with a premature stop codon. 
 
 
Figure 1-3 CXCL8 Transcripts 
Screen shot from Ensembl showing the genomic loci and intron and exon locations of the three CXCL8 splice 
variants on chromosome 4. The transcripts are displayed graphically with introns as connecting lines between the 
exonic rectangles. Protein coding exons are distinguished from non-protein coding exons by filled rectangles.  
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There is very little known about the conditions that determine which splice variant is transcribed. 
The first splice variant is the reference gene. It is the longest transcript of 1705 bp from all 4 
exons producing a protein of 99 amino acids. In comparison, the alternative variant only has 3 
exons, the first two of which are identical to the reference transcript and the third is a slightly 
longer version using an alternative splice site, as shown in Figure 1-4. As the majority of both 
CXCL8 splice variants share the same sequence, experimental methods that detect epitopes in 
the transcribed protein, should detect all CXCL8 variants produced. 
 
 
Figure 1-4 CXCL8 Splice Variants 
Screen shot from Ensembl illustrating the genomic loci, primary protein sequences and exon locations as well as 
transcript and protein IDs of the two functional CXCL8 transcripts. There are three splice variants of CXCL8: IL8-001, 
IL8-002 and IL8-003. IL8-001 produces the reference protein and IL8-002 is the alternative variant. The primary 
protein sequences of these two proteins are listed with the different exons indicated by colour, black and blue, and 
the overlapping residues highlighted in red. 
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1.2 Intestine  
 
1.2.1 Structure and Function of the Intestine 
The intestine is the segment of the alimentary canal extending from the stomach to the anus. In 
mammals it consists of two sections, the small intestine and the large intestine, or colon. The 
main function of the small intestine is to digest and absorb nutrients from food. In light of this, the 
structure of the small intestine is designed to maximise surface area thus increasing the efficiency 
of absorption. The epithelium is a highly folded inner surface creating villi and microvilli that 
expand the surface area 30-60-fold. Three highly specialised and differentiated cell types are 
present in the epithelium (49), in addition to the columnar cells required for absorption (Figure 
1-5). Goblet cells are simple columnar cells that have differentiated further into mucin-secreting 
cells. Therefore, goblet cells play a role in innate immunity by producing mucus to maintain the 
gastrointestinal barrier against infectious microorganisms. Paneth cells in the small intestine are 
also involved in innate immunity by secreting antimicrobial products such as defensins, lysozyme 
and TNF. Due to their location in the base of the crypt next to the stem cell, it is possible that the 
function of Paneth cells is involved with the protection of stem cells that proliferate and 
regenerate the crypt. The third cell type, enteroendocrine cells, secretes hormones in response to 
various stimuli. They act as sensors for the contents of the intestine with possible roles in 
mucosal immunity including secretion of preproglucagon splice product, GLP-2, which improves 
TGF-γβ-dependent intestinal wound healing (50). 
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Figure 1-5 Organization of the Colon Crypt and the Small Intestinal Crypt–Villus 
Both the colon crypt (left) and the small intestinal crypt (right) contain a stem-cell compartment at the crypt base. 
CBCCs (crypt base columnar cells) and the +4 stem cell have been indicated to be present between and just above 
the Paneth cells, respectively. Of note, Paneth cells are not detected in the colon, yet a Paneth-like cell has been 
suggested to be present at the crypt base. All four lineages (three in the colon) — enterocytes, Paneth cells, goblet 
cells and enteroendocrine cells — appear in different, but set ratios. Paneth cells move down to the base and are 
long-lived, whereas other lineages move up and are shed (a few days later) into the lumen while undergoing 
apoptosis. Rare cell types reported to exist in crypts, such as tuft cells, are not shown. Reprinted by permission from 
Macmillan Publishers Ltd: Nature (51), copyright 2011. 
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The lamina propria is located directly beneath the epithelium. It is a loose connective tissue 
supporting the epithelium and containing many lymphatic cells, which together with the epithelium 
forms the mucosa (52). Peyer’s patches are lymphoid nodules located in the lamina propria of the 
small intestine that are enriched with immune cells (53). A large number of T-lymphocytes, 
dendritic cells (DCs) and macrophages are located in the intestinal lamina propria functioning as 
part of the innate and adaptive immune systems to protect the host from bacteria, whether 
microbiota or a potential pathogen (54, 55). Though T-lymphocytes are exposed to antigens from 
the microbiota, as well as pathogens, they do not constantly activate the immune system. This 
reduction in activity is achieved through reduced signal transduction through the T cell receptor to 
antigens and an increased sensitivity to the co-stimulatory molecule CD2, which results in 
increased production of IL-10 (56). During the pathogenesis of Crohn’s disease, the lamina 
propria is infiltrated by T-lymphocytes, which have been shown to express increased levels of the 
cytokines IL-5, IL-12 and IL-15 (57). These cytokines activate the adaptive immune system and 
contribute to the dysregulation of the immune system observed in IBD. Lymphocytes also migrate 
from the lamina propria to the epithelium when barrier integrity is compromised thus exposing the 
large population of lamina propria lymphocytes to luminal bacteria and the subsequent initiation of 
inflammation (58). 
 
The structure of the large intestine has much in common with that of the small intestine, but 
without the villi and Paneth cells. Instead its lumen is larger, goblet cells are more abundant and 
intestinal glands or invaginations of the epithelium are present. The main function of the colon is 
to absorb water from the fecal matter and vitamins such as vitamin K, vitamin B12, thiamine and 
riboflavin that are produced by the resident bacteria (59). It is also the location of many species of 
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bacteria that constitute the microbiota, whose functions in disease are the centre of intense 
investigation (see below).  
 
Because the function of the intestine is to absorb molecules, it is an ideal site for infectious 
microorganisms to target e.g. Salmonella enterica, Campylobacter jejuni, Escherichia coli, 
Salmonella typhi (typhoid fever), Vibrio cholera, Clostridium difficile, norovirus/rotavirus etc (60). 
The lumen of the intestine is topologically external to the body and it is important that the immune 
system functions appropriately. The first line of defence for organisms that have survived the low 
pH of the stomach is the layer of mucus produced by goblet cells. The increased proportion of 
goblet cells in the colon as compared with the small intestine reflects the fact that few bacteria are 
present in the small intestine, unlike the ~1014 bacteria resident in the colon (61). The colonic 
epithelium is under constant stimulation by bacteria; however the colon is not constantly inflamed, 
as one would expect the epithelium of other tissues in the body to be when interacting with 
bacteria. Therefore, the epithelium is capable of being de-sensitized or tolerized to repeated 
inflammatory stimuli. 
 
Inflammation in the intestine has several effects on the epithelium. The epithelium is the first cell-
type to come into contact with bacteria (62) and as such epithelial cells express many innate 
immune system receptors (TLRs, NLRs, NLRPs). It forms a protective barrier between sites for 
potential pathogens e.g. intestinal lumen and the rest of the organism. Barrier integrity is 
therefore a vital property and is composed of intestinal epithelial homeostasis and integrity, 
mucus production and excellent innate immune system responses. The loss of any of these 
functions can lead to inflammation and IBD pathogenesis (63). An indicator of active IBD is 
altered intestinal epithelial homeostasis with increased apoptosis, reduced differentiation and 
differences in proliferation (64). As described above, the interaction between the microbiota and 
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the intestinal epithelium is an important factor in altering the epithelial transcriptome to achieve 
the necessary functional physiological response, including the induction of inflammation. 
Therefore, investigating how healthy epithelial cells regulate their inflammatory response will 
provide insights into dysregulated conditions, such as IBD. 
 
 
1.2.2 Microbiota 
The human body contains over 100 trillion (1014) bacteria (65), ten times as many as the number 
of eukaryotic cells in the human body (3.72 x 1013 eukaryotic cells (66)), the majority of which are 
resident in the colon (65). Despite the abundance of bacteria, species diversity is relatively low 
with only 8 of the 55 known bacterial divisions present. Using rRNA sequence comparison, ~800 
different species are identified with > 7 000 unique strains (67). The commensal bacteria provide 
a range of benefits to the host, particularly in aiding digestion of nutrients. This is represented by 
the large and diverse microbiotal gemone, which contains 100-fold more unique genes than the 
human genome (61). They are also necessary to maintain the lack of immune and inflammatory 
response to the presence of the large bacterial load in the colon (68) as mice reared in a germ-
free environment show an increased susceptibility to infection and an impaired immune system. 
Human foetuses show a similar naivety to bacteria. This changes after a rapid commensal 
colonization at birth (69). Full maturation of the immune system and induction of tolerance to the 
microbiota requires the presence of the microbiota itself (70, 71). 
 
Recent studies have shown a causal link between the intestinal microbiota composition and 
improvement of symptoms in IBD (72) (73) (74) (75). Transplantation of fecal microbiota has 
shown a small amount of success in a small number of patients with severe inflammatory 
disease, resulting in improved symptoms, resolution of histological inflammation and cessation of 
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treatment (steroids, antibiotics, anti-TNF) (76). A meta-analysis performed by Colman and Rubin 
on 18 fecal microbiota transplantation as therapy for IBD studies showed that some patients did 
achieve clinical remission but the effect is variable (77). There are many inconsistencies between 
studies including the timing and frequency of transplantation, donor selection, transplantation 
delivery system and method of microbiota analysis. Further work is required to standardise fecal 
microbiota transplantation as a consistent and effective therapeutic treatment. However, it is a 
successful method for treating C. difficile (78). A recent discovery by Gerding et al found that 
recurrent C. difficile infections can be cured by using spores of nontoxigenic C. difficile to colonise 
the space occupied by the toxic C. difficile. A major benefit of this method is that it avoids the 
stool donating associated with fecal transplantation (79). 
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1.3 Tolerance 
 
Immune tolerance is a hyporesponsive state where the cell or organism becomes transiently 
unresponsive to repeated or prolonged stimulation (80). This effect is seen when macrophages 
are repeatedly stimulated with LPS (81). However, although tolerance functions as a protective 
mechanism against the potentially damaging effects of chronic inflammation, the antimicrobial 
functions of innate immunity must be retained or the host would become immunocompromised. 
The majority of existing research into tolerance has been conducted on macrophages to LPS 
(82).  Prior stimulation of macrophages and monocytes with LPS results in a tolerized phenotype 
with altered IL-1 and IL-6 production and impaired NF-κB activation (82). Evidence from Savidge 
et al. suggests that CXCL8 tolerance can be induced independently of the TLR4 signalling 
cascade (83). Considering that Caco-2 cells, which will be used for the majority of this research, 
do not express TLR4, this published research is an example of tolerance in a specific set of 
circumstances. This phenotype is also seen in patients with sepsis, which demonstrates that 
inflammation in immune cells is a self-regulating process (84). Tolerance is not only a 
phenomenon of intestinal immune cells acquired postnatally (85), but also of peripheral 
leukocytes (86).  
 
Foster et al. describe how the two classes of genes, “tolerizable” (genes not inducible in tolerant 
macrophages) and “non-tolerizable” (genes inducible in tolerant macrophages) are differentially 
regulated (87). Expression of both gene classes is similarly induced by the stimulus LPS, showing 
that neither class of genes is inherently more sensitive to stimulation nor is either class 
dependent on positive feedback of IFN-α/β or any other secreted factor. Therefore, the differential 
regulation must be gene-specific and they demonstrated that it was epigenetic in nature. Foster et 
al describe how only the histones (see 1.4.2 Histone Modifications) in non-tolerizable gene 
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promoters were re-acetylated in tolerized macrophages, though both classes of promoter were 
acetylated in naive cells. Whilst both classes of genes showed an increase in histone H3 lysine 4 
tri-methylation (H3K4me3) levels upon initial LPS stimulation, the tolerizable gene promoters lost 
the histone H3K4me3 mark and the non-tolerizable gene promoters retained it. The presence of 
histone H4 acetylation and histone H3K4me3 in non-tolerizable gene classes correlates with 
continued expression of this gene class (87). H3K9me2 has also been shown to be increased in 
tolerized immune cells (88). 
 
 
1.3.1 Regulation of Tolerance 
As previously described, down-regulation of inflammation is essential to prevent further injury. 
The mechanisms can be classified into three functional groups: the clearance of immune 
complexes and apoptotic cells (complement system); the orchestrated progression of leukocytes 
and lymphocytes through activation, amplification and apoptosis (cytokine and chemokine 
signalling pathways); and the avoidance of injury by oxidation (restrictions placed on respiration 
and removal of haem) (1). Paradoxically, many proteins that contribute to the down-regulation of 
inflammation are also instrumental in inducing inflammation e.g. NF-κB. NF-κB regulates its own 
activation via a negative feedback loop (e.g. NF-κB induces expression of IκB, its own inhibitor 
(89), thereby limiting the amount of activated NF-κB). 
 
A major regulator of IL-1β is IL-1Ra (IL-1 receptor antagonist). IL-1Ra has similar binding affinities 
to IL-1R as IL-1α and IL-1β do, but it does not initiate a signalling cascade when it binds to the 
receptor (90). Its expression is induced by LPS and TNF, themselves inducing inflammation, as a 
naturally occurring inhibitor of IL-1 limiting the degree of inflammation (91). 
 
41 
 
Another cytokine whose expression is induced by pro-inflammatory mediators, e.g. AP1 via TLR2 
signalling, is interleukin-10 (IL-10). It downregulates the expression of pro-inflammatory cytokines 
such as IFN-γ, interleukins 2 and 3 and TNF; it enhances B cell survival and antibody production; 
it blocks NF-κB activity; and regulates the JAK-STAT signalling pathway (92). IL-10 is particularly 
important in establishment of tolerance in the intestine as mice deficient in IL-10 spontaneously 
develop chronic intestinal inflammation (enterocolitis) (93). However, this can be reduced to just 
local inflammation of the proximal colon by housing the mice in a specific pathogen-free 
environment. This highlights the involvement of microbiota in the development of tolerance in a 
healthy individual and the opposing contribution to disease development in an 
immunocompromised host. Indeed, a phase I trial which treated Crohn’s Disease patients with 
recombinant IL-10-producing bacteria showed a marked decrease in the Crohn’s Disease Activity 
Index during the treatment period i.e. when IL-10 was present (94). 
 
TGF-β (transforming growth factor – β) is another essential immune regulation cytokine. It inhibits 
the differentiation of T helper type 1 (Th1) and Th2 cells and regulates tolerance via T regulatory 
(Treg) cells (95). Mice deficient in TGF-β show an increased susceptibility to colitis, as do IL-10-
deficient mice. Also, as shown by IL-10 deficiency, a decrease in TGF-β signalling increases the 
susceptibility to IBD (96) and maintains the persistence of inflammation seen in these patients 
(97). The induction of tolerance is not dependent upon the expression of the anti-inflammatory 
genes mentioned above (e.g. TGF-β, IL-10) (98). 
 
 
1.3.2 Inflammatory Bowel Disease 
While the pathology of IBD can be considered in several ways, it can be regarded as an example 
of disrupted inflammatory tolerance in the intestine. The main forms are Ulcerative Colitis (UC) 
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and Crohn’s Disease. Both are characterized by flares of acute inflammation amongst a long term 
chronic inflammatory state. Crohn’s Disease can affect the entire gastrointestinal tract, whilst UC 
only affects the colon. However, they both have an aberrant inflammatory response, possibly due 
to loss of a hyporesponsive state (99). 
 
UC is defined as idiopathic, diffuse, continuous and superficial inflammation in the large intestine, 
which relapses and remits over time. The patient is also likely to experience diarrhoea, rectal 
bleeding and inflammation in other organs with an increased long-term risk of colorectal cancer. 
UC pathogenesis is complicated and incompletely understood, but is thought to be caused by 
inappropriate immune responses. Genetically mutated genes integral to preservation of the 
epithelial barrier have also been implicated by genome-wide association studies (100). Disruption 
of the epithelial barrier allows commensal bacteria access to the underlying immune cells leading 
to a dysregulated T cell driven inflammatory response.  
 
The highest incidence rates are in the developed world for young adults with rates ranging from 
0.6 to 24.3 cases per 100 000 person-years in Europe and North America compared with 0.1 to 
6.3 cases per 100 000 person-years in Asia and Middle East (101). Approximately 500 people per 
100 000 live with UC worldwide. It can severely impact a patient’s quality of life as 67-83% will 
experience relapsing and remitting courses over the first 10 years post diagnosis (102). 
Treatments aim to heal the mucosa thereby reducing the risk of relapse or the need for a 
colectomy. 5-aminosalicylates are effective treatments for mild to moderate conditions and for 
preventing disease relapse (103). More severe cases may require glucocorticosteroids, 
thiopurines, ciclosporin and/or anti-TNF antibodies and eventually surgery (104). 
 
Crohn’s Disease is similar to UC in that it is an idiopathic inflammatory disease of the 
gastrointestinal tract, but there are several distinct differences. In Crohn’s Disease, inflammation 
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can affect any part of the gastrointestinal tract, though it is most common in the ileum (final 
section of the small intestine) and colon. Symptoms include diarrhoea, fatigue, weight loss, 
narrowing of the colon over time and the added complications of bowel obstructions, fistulae and 
abcesses, as well as an increased risk of cancer and malnutrition. Crohn’s Disease is a chronic 
inflammatory condition that is associated with several reported susceptibility genes (105). Other 
factors implicated include variations in the microbiota composition, specific food elements or 
infections and a strong correlation between smoking and worsening disease activity (106). 
Regardless of what the initiating factor is, excessive transmural inflammation (inflammation that 
spans the entire depth of the intestinal wall) is induced by T cells and further amplified and 
maintained by pro-inflammatory cytokines and other cell types (107).  
 
The incidence of Crohn’s Disease is higher in the Western world (108) with a highest annual 
incidence rate of 12.7 -20.2 cases per 100 000 person-years in Europe and North America 
compared with 5 cases per 100 000 person-years in Asia and the Middle East (101). Crohn’s 
Disease is rarer than UC in adults as shown by the worldwide prevalence of 300 – 400 per 100 
000. Disease development tends to peak in early adulthood (15 – 30 years old) and again in the 
elderly. Treatment, as for UC, involves 5-aminosalicylates, glucocorticosteroids, anti-TNF 
antibodies, thiopurines, cessation of smoking and surgery (109). Crohn’s Disease can relapse, 
even after surgery. Unlike UC, an enteral liquid diet for 6 – 8 weeks is prescribed for patients with 
Crohn’s Disease, which has similar efficacy to corticosteroids (107), though its usefulness as a 
treatment is limited by its cost and the difficulty that patients have in adhering solely to this diet 
(109). 
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As described above, IBD is characterised by chronic inflammation. It is therefore important to 
understand how both tolerance and the dysregulation of tolerance occurs; and how tolerance can 
be re-established with the aim of identifying novel therapeutic targets. 
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1.4 Epigenetics 
 
1.4.1 Chromatin 
Chromatin is composed of DNA wrapped around highly conserved histone proteins to assemble 
nucleosomes. Each nucleosome is composed of a histone octamer (2 copies each of the core 
histones H2A, H2B, H3 and H4) with 146 bp of DNA wrapped around the octamer in 1.67 left-
handed superhelical turns (110). Between each core nucleosome is 10 – 80 bp DNA and a 
histone H1 or linker histone protein (111). Many other histone variants exist and compromise a 
proportion of the core octamer nucleosomes. Under specific conditions they play a functional role, 
e.g. H2AX is phosphorylated in response to DNA double-strand breaks (112). 
 
Chromatin can be visualised with an electron microscope where the nucleosomes look like 
“beads on a string” with the string representing the rest of the DNA not wrapped around the 
histone octamer (113). Due to the linker DNA length being adjustable, chromatin is not in a fixed 
state. Relaxed, or open, chromatin, with the nucleosomes spaced apart, is called euchromatin. 
This exposes the DNA to proteins in the transcriptional machinery, including RNA polymerases, 
TFs and other DNA binding proteins. Heterochromatin is the repressed or closed state of 
chromatin where the nucleosomes are closely associated and the DNA is not easily accessed 
(114). A change from heterochromatin to euchromatin is required for gene transcription to be 
induced. 
 
Histones are positively charged proteins due to their high proportion of lysine and arginine 
residues. However, post-translational modifications (PTMs) to residues in the histone, particularly 
in the histone tail, neutralise the positive charge thus altering the histone-DNA interaction and 
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allowing the transcriptional machinery access to the DNA. Histone acetylation and methylation of 
specific residues e.g. H3K4me3 allow this to happen (115). 
 
 
Figure 1-6 Structure of the Nucleosome 
The nucleosome is an octamer of histone proteins around which is wrapped 146 bp DNA in 1.67 left-handed 
superhelical turns. Two copies each of four different histone proteins (H2A, H2B, H3 and H4) compose the histone 
octamer. The tail of each histone protein is enriched with residues that can be post-translationally modified. Figure 
adapted from (116). 
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1.4.2 Histone Modifications 
Epigenetics are defined as the heritable changes in gene expression or cellular phenotype due to 
changes above the DNA sequence hence epi- (Greek: above) genetics (study of heredity and the 
variation of inherited characteristics). There are three main types of epigenetic transcriptional 
regulation: DNA methylation, histone acetylation and histone methylation. DNA methylation in the 
gene promoter region causes gene silencing e.g. of transcription factors during embryonic stem 
cell differentiation (117), as well as X chromosome inactivation (118) and is an indicator of mitotic 
age (119); whilst histone acetylation is necessary for transcriptional activation (120, 121). 
Methylation of, in particular, lysine residues is a common PTM associated with a change in gene 
transcripition. Activated transcription is associated with e.g. H3K4me3, whilst repression of gene 
transcription is associated with e.g. H3K9me3 or H3K27me3 (122). Methylation of H3K4 has 
different roles depending on the amount of methylation. Tri-methylation of H3K4 is associated 
with active gene transcription, but mono-methylation (H3K4me1) is found to be enriched at 
enhancer regions (123). Histone methylation also maintains the boundary between transcribed 
and non-transcribed genes (124). 
 
In addition to the histone PTMs associated with gene transcriptional status, there are a variety of 
other modifications with a range of purposes. Histone phosphorylation is required for release of 
the transcriptional elongation complex (125) and activation of the DNA damage response (126); 
ubiquitination is a pre-requisite for H3K4 and H3K79 methylation (127); sumoylation mediates 
gene silencing (128); and biotinylation is involved in cell proliferation and the DNA damage 
response (129). Table 1-1 describes the range of PTMs available for the different residues in the 
histone tails, the enzymes (if known) that catalyse the histone PTM and the function of the 
epigenetic mark. PTM of residues in the body of histones also occur (Table 1-1), but are rarer 
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than PTMs to residues in the histone tail (130). These modifications are mainly believed to alter 
the strength of nucleosome binding to DNA. 
 
Chronic inflammation involves epigenetic changes to pro-inflammatory cytokines resulting in 
constitutively high gene expression. An reduction in histone acetylation at tolerizable gene 
promoters is associated with reduced gene transcription (87) and differences in DNA methylation 
is seen at multiple IBD susceptibility genes, including the IL8 receptor beta (IL8RB), between 
healthy controls and patients with IBD (131). Modification of the chromatin regulatory enzymes 
can inhibit the progression of inflammatory-diseases and small molecule inhibitors of these 
enzymes show great potential as novel therapeutics. 
 
  
49 
 
Histone Modification Site^ Enzyme Function 
H1 
Methylation K26 Ezh2 Transcriptional silencing 
Phosphorylation S27 Unknown Transcriptional activation, chromatin decondensation 
H2A 
Acetylation 
K5 Tip60, p300/CBP Transcriptional activation 
K36^ Unknown Unknown 
K119^ Unknown Unknown 
Methylation 
K74^ Unknown Unknown 
K75^ Unknown DNA binding 
R77 Unknown Inserts into minor groove 
K99 Unknown Unknown 
Phosphorylation 
S1 Unknown Mitosis & Chromatin assembly 
S1 MSK1 Transcriptional repression 
S139 
(H2A.X) 
ATR, ATM,  
DNA-PK 
DNA repair, biomarker of DNA 
double-strand breaks 
Ubiquitylation K119 Ring2 Spermatogenesis 
Biotinylation 
K9 Biotinidase Unknown 
K13 Biotinidase Unknown 
K129 Biotinidase Unknown 
H2B 
Acetylation 
K5 ATF2 Transcriptional activation 
K12 ATF2, p300/CBP Transcriptional activation 
K15 ATF2, p300/CBP Transcriptional activation 
K20 p300 Transcriptional activation 
K82^ Unknown Charge neutralization of negative helix dipole 
K105^ Unknown Unknown  
K113^ Unknown Unknown 
Methylation 
K31^ Unknown Unknown 
K40^ Unknown Indirect DNA binding 
R76^ Unknown Unknown 
R83^ Unknown DNA binding 
R89^ Unknown Unknown 
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R96^ Unknown Unknown 
Phosphorylation 
S14 Mst1, Unknown Apoptosis and DNA repair, respectively 
S33^ TAF1 DNA binding, transcriptional activation (132) 
Ubiquitylation 
K120 UbcH6 Meiosis 
K123^ Rad6 Required for methylation of H3K4 and H3K79 (133) 
H3 
Acetylation 
K9 
Unknown Histone deposition 
Gcn5, SRC-1 Transcriptional activation 
K14 
Unknown Histone deposition 
Gcn5, PCAF, 
SRC-1, Esal, 
Tip60, p300 
Transcriptional activation 
Esal, Tip60 DNA repair 
Elp3, Sas3 Transcriptional elongation 
Hpa2 Unknown 
TAF1 RNA polymerase II transcription 
hTFIIIC90 RNA polymerase III transcription 
Sas2 Euchromatin 
K18 
Gcn5, 
p300/CBP Transcriptional activation 
Gcn5 DNA repair 
p300/CBP DNA replication 
K23 
Unknown Histone deposition 
Gcn5, 
p300/CBP Transcriptional activation 
Gcn5, Sas3 DNA repair 
K27 Gcn5 Transcriptional activation 
K115^ Unknown Indirect DNA binding 
K122^ Unknown Indirect DNA binding 
Methylation 
K4 
Set7/9 Transcriptional activation (tri-Me) 
MLL, ALL-1 Transcriptional activation 
R8 PRMT5 Transcriptional repression 
K9 
Suv39h, Clr4 Transcriptional silencing (tri-Me) 
G9a Transcriptional repression, genomic imprinting 
SETDB1 Transcriptional repression (tri-Me) 
R17 CARM1 Transcriptional activation 
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K27 
Ezh2 Transcriptional silencing,  X inactivation (tri-Me) 
G9a Transcriptional silencing 
K36 Set2 Transcriptional activation (elongation) 
R52^ Unknown Indirect DNA binding (H2O-mediated) 
R53 Unknown Unknown 
K56^ Unknown Indirect DNA binding 
K79 Dot1 
Euchromatin, Transcriptional 
activation (elongation), checkpoint 
response 
K122^ Unknown Indirect DNA binding 
Phosphorylation 
T3 Haspin/Gsg2 Mitosis 
S10 
Aurora-B kinase Mitosis, meiosis 
MSK1, MSK2 Immediate-early gene activation 
IKK-α, Snf1 Transcriptional activation 
T11 Slk/Zip Mitosis 
S28 
Aurora-B kinase Mitosis 
MSk1, MSK2 Immediate-early gene activation 
T118^ Unknown DNA binding with H4R46 
Biotinylation 
K4 Biotinidase Gene expression 
K9 Biotinidase Gene expression 
K18 Biotinidase Gene expression 
H4 Acetylation 
K5 
Hat1 Histone deposition 
Esa1, Tip60, 
ATF2, p300 Transcriptional activation 
Esa1, Tip60 DNA repair 
Hpa2 Unknown 
K8 
Gcn5, PCAF, 
Esa1, Tip60, 
ATF2, p300 
Transcriptional activation 
Esa1, Tip60 DNA repair 
Elp3 Transcriptional elongation 
K12 
Hat1 Histone deposition, telomeric silencing 
Esa1, Tip60, 
p300 Transcriptional activation 
Esa1, Tip60 DNA repair 
Hpa2 Unknown 
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K16 
Gcn5, Esa1, 
Tip60, ATF2 
Esa1, Tip60 
Sas2 
Transcriptional activation 
DNA repair 
Euchromatin 
K31^ Unknown Indirect DNA binding 
K77^ Unknown Indirect DNA binding 
K91^ Unknown Forms salt bridges with H2BE63 
Biotinylation 
K8 Biotinidase DNA damage response 
K12 Biotinidase DNA damage response 
Methylation 
R3 
PRMT1 Transcriptional activation 
PRMT5 Transcriptional repression 
K20 
PR-Set7 Transcriptional silencing (mono-methylation) 
Suv4-20h Heterochromatin (tri-Me) 
K59 Unknown Forms salt bridge with H4E63, transcriptional silencing 
K79^ DOT1 DNA binding 
R92^ Unknown Unknown 
Phosphorylation 
S1 
Unknown Mitosis, chromatin assembly 
CK2 DNA repair 
S47^ Unknown Indirect DNA binding 
Table 1-1 Histone Modifications, Enzymes and Functions in Humans  
The table lists the different post-translational modifications possible at residues in the five different histone proteins 
(H1, H2A, H2B, H3 and H4), as well as the enzymes responsible for the modification and the physiological function. ^ 
denotes a residue present in the globular histone protein rather than the histone tail. Adapted from (134) (135) (136). 
 
 
1.4.3 Histone Modifications and Gene Transcription 
As previously described, gene transcriptional status is associated with specific chromatin 
modifications, usually in the gene promoter region, but also throughout the gene (H3K36me3 is 
present on the exons of the actively transcribed gene and is a marker of transcriptional elongation 
(123)). Acetylation of various lysine residues on histones H3 and H4 are associated with gene 
transcription, though the specific lysine residue is dependent upon the affinity of the histone 
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acetyltransferases (HATs) (137) (Table 1-1). Histone methylation produces a variety of effects: as 
a general rule, histone H3K4me3 is associated with activation of gene transcription whilst histone 
H3K9me3 and histone H3K27me3 are associated with transcriptional repression (122) (Table 
1-1). Not all genes require histone acetylation for transcriptional activation. Histone H3S10 
phosphorylation is sufficient, in the absence of histone acetylation, for IL-10 expression in 
macrophages, for examples (92). Therefore, regulation of H3S10 phosphorylation may play a role 
in downregulating inflammation. 
 
Individual lysine residues in a histone tail can be methylated up to three times thus changing its 
functional role accordingly (Table 1-2). However, many genes have multiple histone 
modifications, often ones that have opposing effects (Table 1-2). Depending on the combination 
of modifications present, different proteins are able to bind to the chromatin and specifically target 
certain genes for either activation or repression of gene transcription. For example, transcribed 
inflammatory gene promoters are marked with histone H3K4me3. Under non-transcribed 
conditions the gene promoters are marked with the repressive histone H3K9me3 mark. However, 
some gene promoters have both H3K4me3 and H3K9me3 marks. These marks correlate with the 
genes that have slower gene expression kinetics than the genes that only have H3K4me3 marks 
(138). The combinatorial nature of the histone code means that genes can be poised between 
activated and repressed (H3K4me2 and H3K9me2) until a stimulus causes further modification in 
one direction or the other (loss of H3K9me2 and an increase in H3K4me3 or vice versa) (139). 
Though much research has been conducted into histone modification and the subsequent effect 
on gene transcription, it is fair to say that histone methylation’s relationship with gene 
transcription has not been fully characterised and the complete epigenetic code for each gene in 
every circumstance has not been determined. Therefore, we cannot accurately state which 
changes to the epigenetic code are required to induce or repress transcription. 
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Modification 
Histone Site 
H3K4 H3K9 H3K27 H3K36 H3K79 H4K20 
Mono-
methylation Activation Activation Activation --- Activation --- 
Di-methylation --- Repression Repression --- Activation --- 
Tri-methylation Activation Repression Repression Activation Activation, Repression Repression 
Table 1-2 Histone Methylation Modifications and their Effect on Transcription 
Table 1-2 summarises the published associations between different histone methylation modifications and gene 
transcription (adapted from Table 1-1). 
 
Different cell types exhibit differences in how histone methylation modulates gene expression. For 
example, bivalent histone modifications are commonly found in stem cells. Developmental genes 
often contain both H3K4me3 and H3K27me3 before one or the other mark is removed and the 
cell fate is determined (140). Very little is understood about genes displaying opposing epigenetic 
signatures. Though bivalent modifications may be found in one cell type under certain 
experimental conditions, it does not necessarily hold true that these relationships exist in all cell 
types in all environmental conditions. 
 
 
1.4.4 Regulation of Histone Modifications 
The post-translational modification of histones is catalyzed by a variety of enzymes with different 
affinities and specificities (141). These include histone acetyltransferases (HATs), histone 
deacetylases (HDACs), DNA methyltransferases (DNMTs), histone/lysine methyltransferases 
(HMTs/KMTs), histone/lysine demethylases (HDM/KDM) as well as the histone phosphorylases 
required for activation of the transcriptional initiation complex. Modifying the degree of acetylation 
55 
 
through use of butyrate, a known histone deacetylase inhibitor, thereby increases the amount of 
histone acetylation present and exacerbates the inflammatory response to IL-1β and LPS (121). 
 
Until the discovery of histone demethylases in 2004, histone methylation was thought to be a 
permanent modification (142). A variety of small molecule inhibitors of histone deacetylases, 
methyltransferases and demethylases have been developed as novel therapeutic agents. The 
majority have an application in cancer (143) (144), though trials for inflammatory diseases are 
also underway (145). One example in particular that shows promise in inflammatory disorders is 
Lysine specific demethylase 1 (LSD1). LSD1 only demethylates H3K4me2 and H3K9me2, the 
latter when in complex with the androgen receptor (146), thus modulating the transcriptional state 
of the gene. Janzer et al. describes how LSD1 alters the methylation state of several pro-
inflammatory cytokine promoters including IL-1β and CXCL8 (139). 
 
 
1.4.5 Epigenetics and Inflammatory Bowel Disease 
Epigenetics is a relatively new area of research so the understanding of epigenetics in IBD is 
limited. However, many complex diseases, including IBD, are beginning to be researched for the 
epigenetic mechanisms underlying a proportion of the disease. Genetic loci discovered to 
promote susceptibility to IBD pathogenesis only account for a small proportion of the disease 
variance, 13.6% for Crohn’s Disease and 7.5% for UC (147). Environmental factors, including 
smoking, account for much of the remaining disease variance. These factors cause an alteration 
in gene expression and lead to development of IBD. As gene expression is also known to be 
regulated by epigenetics, it is logical to assume that a small percentage of the disease variance is 
due to epigenetics. Further evidence is provided by the mechanism of action of some of the 
known drugs used to treat patients with IBD (148).  
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Glucocorticoids are steroid hormones which are used in IBD to suppress the immune response. 
Expression of anti-inflammatory genes is increased due to increased histone acetylation. 
However, glucocorticoids can also suppress gene expression via specific histone deacetylation of 
pro-inflammatory cytokines (149). Methotrexate, an immunosuppressant, is used to maintain 
remission of Crohn’s disease. It has the effect of reducing the amount of folic acid by inhibiting 
dihydrofolate reductase. Folic acid is known to be involved in the DNA methylation pathway. A 
reduction in folic acid by methotrexate has been associated with an increase in DNA methylation 
levels in patients suffering from arthritis (150), though the before and after effects of methotrexate 
in patients with IBD has not yet been investigated.  
 
Analysis of the differences in intestinal microbiotal composition between healthy controls and 
patients with IBD indicate an underrepresentation of butyrate-producing bacterial species (151). 
Butyrate and other short chain fatty acids have been implicated in the regulation of gene 
transcription via inhibition of histone deacteylase activity (121). Therefore, the use of butyrate as 
a treatment for IBD should increase the level of histone acetylation and promote gene 
transcription. This is associated with an alleviation of symptoms and a statistically significant 
decrease in endoscopic and histological inflammation (152). Therefore, there is strong evidence 
for an epigenetic component to regulation of inflammation and IBD pathogenesis. 
 
Other evidence for the involvement of epigenetics in the development of IBD comes from parent-
of-origin studies. Analysis of IBD inheritance from parent to child showed that disease 
transmission from mother to child was statistically far more likely than from father to child 
(P=0.00001) (153) and that this is likely due to genomic imprinting. Genomic imprinting is the 
heritable DNA methylation of a particular gene to prevent its transcription. Therefore, the 
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conditions required for the development of IBD in the parent can be programmed epigenetically 
for inheritance in the child. Evidence for the involvement of epigenetics in IBD pathogenesis is 
described by the relatively low concordance rate for IBD in monozygotic twins (148), indicating 
that the environment plays a large role. Epigenetics can be considered to be at the boundary 
between the environment and the DNA. Epigenetic permutations between genetically identical 
twins are an interpretation of the environmental effect on the DNA and gene expression and can 
be very different between two individuals with the same genetic background.  
 
Petronis describes the association between epigenetics and differences in the DNA sequence of 
candidate susceptibility genes (148). SNPs (single nucleotide polymorphisms) are variations at 
the same position in the DNA that occur in at least 1% of the population. Some SNPs e.g. G(-
308)A in the AP2 TF binding site, are sensitive to DNA methylation and can thus control whether 
the gene can be epigenetically modified leading to a change in gene transcription. The C(-511)T 
SNP in the IL-1β promoter, depending on the study, has shown a conflicting association with IBD 
(148).  
 
Diet is another environmental factor, along with smoking, whose effect on gene expression can 
be seen epigenetically. As previously mentioned, butyrate and other short chain fatty acids have 
an effect on both gene transcription and IBD. Diets rich in methyl-donor metabolites, such as 
choline, methionine and folate can increase the amount of DNA methylation and the presence of 
dietary pholyphenols, such as curcumin and catechins found in tea, inhibit DNMTs and HATs 
(154, 155). It has previously been shown that diet has a clinical benefit in IBD e.g. an elemental 
diet for children suffering from Crohn’s disease is as effective as high dose steroids (156) and 
curcumin, a component of tumeric, enhances anti-inflammatory gene expression in patients with 
IBD (157). However, much more research is required before we fully understand the effects of 
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diet in epigenetics and disease and before diet can become a therapeutic tool in the treatment of 
IBD, based on epigenetic predictions.  
 
In conclusion, there is an increasing amount of evidence for the role of epigenetics in IBD 
pathogenesis. Epigenetics acts as a central mediator for several IBD susceptibility and risk 
factors (158).  The effects of diet, environment, microbiota and susceptibility genes on the 
immune system and gene transcription are mediated through epigenetics and as such, modifying 
the epigenetic signature may, in time, allow us to develop treatments that will reverse IBD 
pathogenesis. 
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2 Aims and Hypotheses 
 
The aims of this research project are: 
 
 To establish the induction of tolerance in intestinal epithelial cells to pro-inflammatory 
agents. Intestinal epithelial cell-lines Caco-2 and NCM460 will be first stimulated with 
P3CK and/or IL-1β to produce an inflammatory response then tolerized by pre-stimulating 
the cells followed by another pro-inflammatory stimulation. 
 To study the epigenetic mechanisms involved in the regulation of tolerance. This will be 
achieved by the use of a range of small molecule epigenetic inhibitors to alter the 
methylation level of particular histone H3 lysine residues associated with a role in gene 
transcription. These inhibitors will then be incubated with tolerized cells and the effect on 
inflammatory gene expression measured. 
 
I hypothesise that the inflammatory gene expression profile of intestinal epithelial cells is tolerized 
to pro-inflammatory agents following pre-stimulation with said agents. I also hypothesise that 
modifying the epigenetic signature of intestinal epithelial cells, via modification of the relative 
levels of histone methylation, will alter the expression level of inflammatory genes. 
 
 
 
  
60 
 
3 Materials and Methods 
 
3.1 Cell Culture 
 
Reagent Supplier Address 
Caco-2 cell line ECACC Salisbury, UK 
HT29 cell line ECACC Salisbury, UK 
NCM460 cell line INCELL Corporation LCC San Antonio, USA 
THP-1 cell line ECACC Salisbury, UK 
Dulbecco’s modified Eagle medium (DMEM) Invitrogen Paisley, UK 
M3 base medium INCELL Corporation LCC San Antonio, USA 
Fetal Calf Serum (FCS) Gibco Paisley, UK 
Non-Essential Amino Acids (NEAA) Gibco Paisley, UK 
Hepes Buffer Gibco Paisley, UK 
Penicillin/Streptomycin (Pen/Strep) Gibco Paisley, UK 
Dulbecco’s Phosphate-Buffered Saline (PBS) Invitrogen Paisley, UK 
Insulin-Transferrin-Selenium (ITS) Invitrogen Paisley, UK 
Interleukin-1β (IL-1β) Gibco Paisley, UK 
N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-
(R)-cysteinyl-(S)-seryl-(S)-lysyl-(S)-lysyl-(S)-lysyl-
(S)-lysine Pam3CysK4 (P3CK) 
EMC Tuebingen, Germany 
Roswell Park Memorial Institute (RPMI) medium Invitrogen Paisley, UK 
Table 3-1 Reagents used in Tissue Culture  
 
3.1.1 Caco-2 and HT29 Cell Lines 
All experiments were performed on the human cell lines Caco-2 and HT29, as relevant to the 
study of inflammatory bowel disease and its potential treatment in humans. Both Caco-2 and 
HT29 cells have been used extensively to model intestinal epithelial function in vitro for over 25 
years as they are derived from human colorectal adenocarcinomas. Whilst the two cell lines have 
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similar phenotypes, there are some critical differences. Both cell lines are immortalised and 
differentiate spontaneously in long-term culture to form a monolayer. However, Caco-2 cells 
dedifferentiate and acquire some characteristics of mature small intestinal enterocytes including 
apical microvilli and intercellular tight junctions. They also express small intestinal hydrolases 
including sucrose-isomaltase and lactase which are transiently expressed in the human foetal 
colon but not the adult colon. HT29 cells do not acquire enterocytic characteristics and remain as 
exclusive colonocytes. 
 
As the number of passages increases, the function, metabolism and rate of differentiation of 
Caco-2 cells changes, as shown by the increasing expression of enterocyte differentiation 
markers such as the glucose transporter (GLUT)-5 (159) (160). We address this potentially 
confounding factor by performing all experiments on Caco-2 cells between passages 47 and 60 
(supplied from ECACC at passage 45). We were able to achieve reproducibility of results using 
cell lines of relative uniformity and ready availability and minimised other influencing factors such 
as seeding density, culture conditions and media composition by strictly standardising them to 
achieve robust reproducibility of results. 
 
Whilst Caco-2 and HT29 cell lines are derived from adenocarcinomas and therefore contain 
multiple mutations that are not present in the normal, non-malignant colon, they are still a suitable 
model. Cancer cells have already become immortalised escaping cellular senescence and thus 
able to proliferate indefinitely. This is necessary for a cell line as it ensures that there is a 
continuous supply of genetically identical cells. However, in order to confirm that the results are 
not due to cancerous mutations, we performed repeat experiments in a non-malignant cell line. 
Caco-2 and HT29 cell lines also grow and proliferate much more quickly than normal cell lines, 
making them an appropriate research model. 
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Caco-2  and HT29 cells (both human colon epithelial cell lines) were grown in DMEM 
supplemented with 10% heat inactivated-FCS (HI-FCS), 1% NEAA, 10 mM Hepes Buffer, 10000 
U/ml / 10000 µg/ml Pen/Strep (+FCS media) at 37 °C and 5% CO2. When the cells reached 80-
95% confluency, they were seeded at 0.5 x 104 cells per ml (Caco-2) or 2.5 x 104 cells per ml 
(HT29) into either 6-well or 12-well plates, or if not required for an experiment subcultured at 
~1:10. 6-well plates were used originally whilst optimising the experimental conditions of IL-1β 
stimulation. 12-well plates were used for the majority of experiments as they require smaller 
volumes of media than 6-well plates and as such are more economical. 
 
After seeding, the cells were grown for a total of 7 days before sample collection. The cells were 
pre-stimulated 48 hours prior to sample collection, stimulated again (for the tolerized cells or 
stimulated for the first time for the stimulated cells) 24 hours prior to sample collection and the 
samples were collected ater 7 days. 24 hours prior to the first stimulation with P3CK or IL-1β or 
the first epigenetic inhibitor incubation, the +FCS media is discarded, the cells washed with PBS 
and the media replaced with +ITS media (DMEM supplemented with 1% NEAA, 10mM Hepes 
Buffer, 10000 U/ml / 10000 µg/ml Pen/Strep and 1000 mg/L Insulin, 550 mg/L Transferrin and 
0.67 mg/L sodium selenite). Cells in the control condition had their +FCS media replaced by +ITS 
media 48 hours before sample collection. In the tolerization experiments, the cells in the control 
and stimulation conditions, as well as the cells that received the tolerizing pre-stimulation of P3CK 
or IL-1β were all given fresh media 48 hours prior to sample collection. The control cells also 
received fresh media 24 hours prior to sample collection when the other cells were stimulated for 
the first (stimulated) and second (tolerized) time. Therefore, substances secreted by the cells into 
the media only accumulated for 24 hours before the cells were washed with PBS and the media 
replaced. 
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When using media free from FCS, as described in 4.1.3 and Figure 4-14 onwards, DMEM was 
supplemented with insulin, transferrin and selenium as these are obligatory nutrients for optimal 
performance in the absece of FCS. Whilst serum contains the required growth factors, transport 
proteins, minerals, trace elements, lipids, extracellular matrix components, protease inhibitors and 
detoxifying factors necessary for cell proliferation and growth, it is possible to replace FCS with 
just insulin, transferrin and selenium. This reduces the inherent variability in the amount of 
endotoxin, haemoglobin, microbial contaminants and other adverse factors present in serum 
(161). 
 
 
3.1.2 NCM460 Cell Line 
NCM460 cells are a non-malignant epithelial cell line derived from the colon mucosa of a 68-year 
old Hispanic male Moyer et al., 1996. This cell line has been used in a number of studies 
investigating the function of normal colonic epithelial cells in infectious disease, cell signalling, 
cytokine production, gene regulation, protein expression and phosphorylation in multiple growth 
regulatory pathways. Like Caco-2 and HT29 cell lines, NCM460 cells form a mixed 
monolayer/suspension culture and express colonic epithelial cell associated antigens, such as 
cytokeratins and villin. Some cells are also positive for mucin synthesis. Though the cells show 
normal growth characteristics and are not tumourigenic, they have acquired some transformation-
associated properties due to being in culture for a long time.   
 
NCM460 cells were cultured in M3 medium supplemented with 10% HI-FCS (+FCS), or 1000 
mg/L Insulin, 550 mg/L Transferrin and 0.67 mg/L sodium selenite (+ITS), and 10000 U/ml / 
10000 µg/ml Pen/Strep at 37 °C and 5% CO2. When the cells reached 80-95% confluency, they 
were seeded at 8 x 104 cells per ml into 12-well plates, or if not required for an experiment 
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subcultured at ~1:10. As for Caco-2 cells, after seeding the NCM460 cells were grown for a total 
of 7 days before sample collection. The cells were pre-stimulated 48 hours prior to sample 
collection, stimulated again (for the tolerized cells or stimulated for the first time for the stimulated 
cells (Figure 3-2)) 24 hours prior to sample collection and the samples were collected ater 7 days. 
+FCS medium was replaced by +ITS medium 24 hours prior to the first stimulation with P3CK or 
IL-1β or 48 hours before sample collection for the control cells. In the tolerization experiments, the 
cells in the control and stimulation conditions as well as the cells that received the tolerizing pre-
stimulation of P3CK were all given fresh media 48 hours prior to sample collection. The control 
cells also received fresh media 24 hours prior to sample collection when the other cells were 
stimulated for the first (stimulated) and second (tolerized) time. Therefore, substances secreted 
by the cells into the media only accumulated for 24 hours before the cells were washed with PBS 
and the media replaced. 
 
In this project, the NCM460 cell line was therefore used to show that IL-1β-induced tolerance is 
not just a consequence of malignancy in the Caco-2 and HT29 cell lines and is instead a property 
of epithelial cells. 
 
 
3.1.3 THP-1 Cell Line 
THP-1 cells are a peripheral blood monocyte cell line derived from a one-year old male with acute 
monocytic leukemia. After stimulation with phorbol esters THP-1 monocytes differentiate into 
macrophages closely mimicking native monocyte-derived macrophages (162). This cell line has a 
substantially different transcriptome to the previously described intestinal epithelial cell lines. 
However, as the THP-1 cell line was only used an IL-1 receptor positive control to ensure that the 
IL-1β was active in vivo, the difference in transcriptomes was not relevant. 
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THP-1 cells were cultured in RPMI-1640 medium supplemented with 10% HI-FCS, 2 mM L-
Glutamine and 10000 U/ml / 10000 µg/ml Pen/Strep at 37 °C and 5% CO2. 
 
 
3.1.4 Experimental Protocols 
The optimum concentration of stimulant was determined by producing a dose-response curve. 
Caco-2 and NCM460 cell-lines were stimulated with a range of concentrations of Interleukin-1β 
(IL-1β) or Pam3CysK4 (P3CK) for 24 hours (Figure 3-1) before the conditioned media is collected 
and the cells harvested with CelLytic™ M solution. 
 
 
 
 
Figure 3-1 Experimental Protocol for the P3CK and IL-1β Dose-Response Curves  
Dose-Response curve experimental protocols are described diagramatically. +FCS media was replaced with +ITS 
media 48 hours before sample collection. Caco-2 and NCM460 cell lines were stimulated with a two-fold serial 
dilution of P3CK (100 – 3.125 µg/ml) or IL-1β (4 – 0.0625 ng/ml) for 24 hours. CXCL8 was measured by ELISA and 
normalized to cellular protein content (measured by BCA protein assay). 
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Tolerance of CXCL8 protein levels was induced by stimulating Caco-2 and NCM460 (P3CK only) 
cells twice with either 1 ng/ml IL-1β or 25 µg/ml P3CK for 24 hours each (Figure 3-2). Cross-
tolerization, the induction of a hyporesponsive state of gene expression following repeated 
stimulations of different pro-inflammatory stimuli, was induced by pre-stimulating Caco-2 cells 
with 25 µg/ml P3CK for 24 hours followed by stimulation with 1 ng/ml IL-1β for 24 hours. In 
between the two stimulations, the media was discarded, the cells washed with PBS and the next 
stimulation added prepared in fresh +ITS media. Samples of conditioned media were collected for 
measurement of CXCL8 (or IL-6) production by ELISA and the cells harvested with CelLytic™ M 
solution. Total cellular protein content was measured by BCA protein assay. CXCL8 (or IL-6) 
production was normalized to total cellular protein content (pg/mg protein). Multiple experiments 
were combined by converting each CXCL8 production value to a percentage of the mean 
production by the stimulated samples.  
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Figure 3-2 Experimental Protocol for Inducing Tolerance 
Tolerance and cross-tolerance experimental protocols are described diagramatically. +FCS media was replaced with 
+ITS media 72 hours before sample collection. Caco-2 and NCM460 (P3CK only) cells were stimulated with either 1 
ng/ml IL-1β or 25 µg/ml P3CK for 24 hours and tolerized by a prior stimulation of either 1 ng/ml IL-1β or 25 μg/ml 
P3CK 24 hours earlier. Caco-2 cells were cross-tolerized by pre-stimulating the cells with 25 µg/ml P3CK for 24 
hours followed by stimulation with 1 ng/ml IL-1β for 24 hours. Conditioned media was discarded and the cells washed 
with PBS between the two stimulations for tolerized and cross-tolerized cells. IL-6 and CXCL8 were measured by 
ELISA and normalized to cellular protein content (measured by BCA protein assay). 
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In order to address the concern that the reduced levels of CXCL8 in “tolerized” cells was due to 
the tail-off in expression from the pre-stimulation and not from the re-induction of the second 
stimulation, an additional control condition was incorporated into the experimental protocol shown 
in Figure 3-2. CXCL8 expression in tolerized Caco-2 cells was compared to stimulated and pre-
stimulated cells (Figure 3-3). Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours, pre-
stimulated with 1 ng/ml IL-1β for 24 hours followed by 24 hours incubation with unconditioned 
media, and tolerization induced by pre-stimulation with 1 ng/ml IL-1β for 24 hours followed by 
stimulation with 1 ng/ml IL-1β for another 24 hours. After the first stimulation for 24 hours, the 
media was discarded, the cells washed with PBS and the next stimulation added prepared in 
fresh +ITS media. Samples of conditioned media were collected for measurement of CXCL8 
production by ELISA and the cells harvested with CelLytic™ M solution. Total cellular protein 
content was measured by BCA protein assay. CXCL8 production was normalized to total cellular 
protein content (pg/mg protein). Multiple experiments were combined by converting each CXCL8 
production value to a percentage of the mean production by the stimulated samples.  
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Figure 3-3 Experimental Protocol for Inducing Tolerance in Comparison to Pre-Stimulation 
Tolerance experimental protocols are described diagramatically. +FCS media was replaced with +ITS media 72 
hours before sample collection. Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours, pre-stimulated with 1 
ng/ml IL-1β for 24 hours followed by 24 hours incubation with unconditioned medium and tolerized by a prior 
stimulation of either 1 ng/ml IL-1β 24 hours followed by an additional stimulation of 1 ng/ml IL-1β for 24 hours. 
Conditioned media was discarded and the cells washed with PBS after each 24 hour incubation period. CXCL8 was 
measured by ELISA and normalized to cellular protein content (measured by BCA protein assay). 
 
 
The optimum stimulation length for mRNA analysis was determined by stimulating the cells with 1 
ng/ml IL-1β for 0 – 4 hours before harvesting with TRIzol® (Figure 3-4). Total RNA was extracted 
from the cells using TRIzol®, as described below in 3.2.1. The amount of RNA extracted was 
quantified using a NanoDrop spectrophotometer, which calculates the amount of nucleic acid 
present according to the level of UV absorbance. Equal amounts of RNA were used in cDNA 
synthesis. CXCL8 mRNA transcribed by Caco-2 cells in response to IL-1β stimulation was 
measured by RT-PCR and normalized to the amount of β-Actin. 
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Figure 3-4 Experimental Protocol for the Time-Course of IL-1β-Stimulated Caco-2 Cells 
Experimental protocol for obtaining RNA from IL-1β-stimulated Caco-2 cells is described diagramatically. +FCS 
media was replaced with +ITS media 24 hours before stimulation with 1 ng/ml IL-1β. All Caco-2 cells were stimulated 
with 1 ng/ml IL-1β at time point 0h. Samples were collected using TRIzol® 0, 1, 2 and 4 hours after stimulation with 
IL-1β. Conditioned media was discarded and the cells collected with TRIzol®. Total RNA was extracted from the 
TRIzol® samples, converted to cDNA and the amount of CXCL8 measured by RT-PCR and normalized to the 
amount of β-Actin. 
 
 
Tolerance experiments were performed by pre-stimulating the Caco-2 cells with 1 ng/ml IL-1β for 
24 hours followed by stimulation for 2 hours (Figure 3-5). The +FCS media was replaced with 
+ITS media 24 hours prior to pre-stimulation by IL-1β. Total RNA was extracted from the cells 
using TRIzol®. The amount of RNA extracted was measured by nanodrop and equal amounts of 
RNA were used in cDNA synthesis. CXCL8 mRNA transcribed by Caco-2 cells in response to IL-
1β stimulation was measured by RT-PCR and normalized to the amount of β-Actin. CXCL8 
mRNA transcribed by stimulated cells was compared to the CXCL8 mRNA produced by tolerized 
cells and analysed using ImageJ software (see 3.10 Statistics). 
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Figure 3-5 Experimental Protocol for the Induction of Tolerance as Measured by Transcription 
Experimental protocol for inducing tolerance as measured by transcription in Caco-2 cells is described 
diagramatically. +FCS media was replaced with +ITS media 50 hours before sample collection. Tolerance in Caco-2 
cells was induced by a prior stimulation of 1 ng/ml IL-1β for 24 hours followed by stimulation with 1 ng/ml IL-1β for 2 
hours. Between the two stimulation of IL-1β, the conditioned media is discarded and the cells washed with PBS. 
Stimulated cells were stimulated with 1 ng/ml IL-1β for 2 hours only. Conditioned media was discarded and the cells 
collected with TRIzol®. Total RNA was extracted from the TRIzol® samples, converted to cDNA and the amount of 
CXCL8 measured by RT-PCR and normalized to the amount of β-Actin). 
 
 
To support the data collected in Figure 3-3, mRNA expression was measured over 48 hours of IL-
1β-stimulation. Caco-2 cells were pre-stimulated with 1 ng/ml IL-1β for 24 hours followed by 
another stimulation with 1 ng/ml IL-1β stimulation for a further 24 hours. Samples were collected 
at the time points illustrated in Figure 3-3. Samples collected during the first 24 hours (0, 1, 2, 4, 8 
and 24 hours) after IL-1β-stimulation are from stimulated Caco-2 cells, whilst the samples 
collected from the second 24 hours (24, 25, 26, 28, 32 and 48 hours) are from tolerized cells. 
Total RNA was extracted from the cells using TRIzol®. The amount of RNA extracted was 
measured by nanodrop and equal amounts of RNA were used in cDNA synthesis. The amount of 
72 
 
cDNA present was measured by qPCR. A number of genes were measured (IL-6, CXCL8, IL-10, 
CCL2, BD-2, TNF) and normalized to the amount of β-Actin. 
 
 
 
 
Figure 3-6 Experimental Protocol for the Expression of Tolerizable and Non-Tolerizable Genes Over 
48 Hours in IL-1β-Stimulated Caco-2 Cells  
Experimental protocol for measuring the expression of tolerizable and non-tolerizable genes over 48 hours in IL-1β-
stimulated Caco-2 cells. +FCS media was replaced with +ITS media 24 hours before the first sample collection. 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours, the conditioned media was discarded and the cells 
washed with PBS, followed by a further stimulation with 1 ng/ml IL-1β for another 24 hours. At each time point (0, 1, 
2, 4, 8, 24, 25, 26, 28, 32 and 48 hours) conditioned media was discarded and the cells collected with TRIzol®. Total 
RNA was extracted from the TRIzol® samples, converted to cDNA and the amount of IL6, CXCL8, IL-10, CCL2, BD-
2, TNF and ACTB measured by qPCR. The expression of each gene was normalized to the amount of β-Actin). 
 
 
The involvement of epigenetics in the regulation of tolerance was investigated by incubating small 
molecule epigenetic inhibitors with tolerized cells and measuring the production of CXCL8. If the 
production of CXCL8 increases by a statistically significant level above that of tolerized only cells, 
tolerance is said to be broken. The experimental protocol for breaking tolerance with epigenetic 
inhibitors is pictured in Figure 3-7. Both SAH and 2,4-PDCA are incubated with tolerized Caco-2 
cells for a total of 72 hours. 24 hours prior to pre-stimulation with 1 ng/ml IL-1β 100 µM SAH or 5 
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mM 2,4-PDCA is incubated with the cells. IL-1β is diluted in fresh preparations of 100 µM SAH or 
5 mM 2,4-PDCA to 1 ng/ml for the pre-stimulation and stimulation stages, 24 hours apart.  
 
Chaetocin and pargyline were incubated with the tolerized cells in two separate treatments. 
Based on a comparable experiment on macrophages by Foster et al. (87), pargyline and 
Chaetocin are incubated with the tolerized cells for 1 hour prior to the second stimulation with IL-
1β. This was found to not be a sufficient length of time to break tolerance (see Figure 5-26) and a 
number of other incubation lengths were investigated, as described in Figure 5-24. Therefore, 3 
mM pargyline hydrochloride was incubated with tolerized Caco-2 cells for 1 hour prior to the 
second stimulation with IL-1β and again for 18 hours prior to sample collection i.e. added to the 
IL-1β-conditioned media 6 hours after the second stimulation. Chaetocin was incubated with 
tolerized Caco-2 cells in a similar manner to the pargyline incubation. However, two different time 
periods for the second Chaetocin incubation were used, 8 hours and 18 hours (Figure 3-7). The 
conditioned media is only discarded and the cells washed with PBS before the first and second 
stimulations with IL-1β, not when Chaetocin and pargyline are added to the cells. The conditioned 
media samples were collected and the cells harvested with CelLytic™ M solution (as described 
below in 3.2.2). The production of CXCL8 is measured by ELISA and normalised to the total 
cellular protein content (as measured by BCA assay). Multiple experiments were combined by 
converting each CXCL8 production value to a percentage of the mean CXCL8 expression 
produced by the stimulated samples. 
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Figure 3-7 Experimental Protocol for Breaking Tolerance with Epigenetic Inhibitors 
Experimental protocols for breaking tolerance through the use of epigenetic inhibitors are described diagramatically. +FCS media was replaced 
with +ITS media 72 hours before sample collection (96 hours before sample collection for Tolerized + SAH and Tolerized + 2,4-PDCA). Caco-2 
cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 hours earlier. Conditioned media was 
discarded and the cells washed with PBD between the two IL-1β stimulations. Tolerized cells were incubated with a variety of small molecule 
epigenetic inhibitors: SAH, Chaetocin, pargyline and 2,4-PDCA. 100 µM SAH and 5 mM 2,4-PDCA were incubated with the tolerized cells for a 
total of 72 hours (24 hours prior to stimulation with IL-1β). 100 nM Chaetocin and 3 mM pargyline were incubated witih the tolerized cells for an 
hour at the end of the pre-stimulation with IL-1β and again for the final 8 (Chaetocin) or 18 (Chaetocin and pargyline) hours before sample 
collection. CXCL8 production was measured by ELISA and normalized to cellular protein content (measured by BCA protein assay. 
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3.2 Cell Harvesting Methods 
 
Reagent Supplier Address 
CelLytic™ M Sigma-Aldrich Gillingham, UK 
TRIzol® and TRI Reagent® Invitrogen Paisley, UK 
Chloroform Sigma-Aldrich Gillingham, UK 
Isopropanol Sigma-Aldrich Gillingham, UK 
Ethanol VWR Lutterworth, UK 
RNase-free H2O Qiagen Manchester, UK 
Trypsin-EDTA PAA Yeovil, UK 
Triton™ X-100 Sigma-Aldrich Gillingham, UK 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich Gillingham, UK 
Sodium Azide (NaN3) Sigma-Aldrich Gillingham, UK 
Hydrochloric Acid (HCl) Sigma-Aldrich Gillingham, UK 
Sodium Hydroxide (NaOH) Sigma-Aldrich Gillingham, UK 
Table 3-2 Reagents used to Harvest Cells 
 
3.2.1 RNA 
Growth medium was aspirated and discarded. After washing the cells with PBS, 1 ml TRIzol® 
was added to each well and the cells lysed from the plate by pipetting up and down. This solution 
was stored at -70 °C until ready to extract the RNA. All samples were brought to room 
temperature and incubated for a further 5 minutes before adding 200 µl chloroform per 1 ml 
TRIzol® and inverting vigorously for 15 seconds. The samples were incubated at room 
temperature for 2-3 minutes and centrifuged at 12 000 rpm for 15 minutes at 4 °C. The aqueous 
layer was carefully aspirated and placed in a new tube, ensuring that none of the interphase or 
organic layers was disturbed. RNA is always lost at this step as some of the aqueous layer must 
remain behind in order that it is not contaminated by the organic layer. 500 µl ice-cold 100% 
isopropanol was added to each sample and incubated on ice for 10 minutes before centrifuging at 
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12 000 rpm for 12 minutes at 4 °C. The supernatant was carefully aspirated and discarded 
leaving ~50 µl behind so as not to disturb the pellet. The pellet was washed with 1 ml ice-cold 
75% ethanol, vortexed briefly and centrifuged at 8 000 rpm for 8 minutes at 4 °C. The 
supernatant was carefully aspirated and discarded, ensuring that the pellet remained undisturbed, 
and was left to air-dry for ~20 minutes. It is important not to over-dry the pellet or it will degrade, 
as shown by an A260/280 ratio of <1.6. The air-dried pellet was resuspended in 40 µl RNase-free 
H2O and incubated at 58 °C for 10 minutes so that any remaining alcohol could evaporate. 
 
Although RNA extraction using TRIzol® is prone to DNA and protein contamination, the RNA is 
protected by the reagent during the extraction procedure (and should be performed on ice to limit 
degradation) and is cheaper than using spin columns. Spin columns also have a lower maximum 
yield and do not collect very small RNAs (<200 nt), unlike TRIzol®.  
 
RNA is inherently less stable than DNA and more difficult to work with than either DNA or protein. 
RNA, unlike DNA, is a single strand molecule and contains ribose not deoxyribose. Because of 
this difference there is an additional hydroxyl group present at the 2’ position of the sugar ring 
moiety making RNA more susceptible to alkaline hydrolysis than DNA and therefore less stable 
(163). It is essential that RNA work is always carried out on a surface that has been treated with 
an RNase inhibitor e.g. RNaseZap® (Invitrogen), on ice and stored at -70 °C to minimise 
degradation.  
 
 
3.2.2 Protein 
Growth medium was removed from the Caco-2 and HT29 cells and stored at -20 °C for further 
analysis. After washing the cells with PBS, 200 µl CelLytic™ M reagent was added and incubated 
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for 15 minutes at 37 °C. Cells were collected, assisted by scraping, and centrifuged for 15 
minutes at 4 °C at 18 000 x g to pellet the cellular debris. The supernatant was removed into a 
pre-chilled tube and stored at -20 °C or -70 °C for long-term storage. When harvesting the THP-1 
cells, which grow in suspension, the cells must first be centrifuged to pellet the cells and the 
supernatant stored at -20 °C. After resuspending the cell pellet in PBS and centrifuging again, the 
new cell pellet was resuspended in 200 µl CelLytic™ M reagent and preceded as above. 
 
CelLytic™ M reagent is a rapid, non-denaturing method of lysing cultured mammalian cells and is 
up to 50% more efficient than other products and methods of cell lysis e.g. sonication. It does not 
interfere with many downstream processes, such as Western blotting and BCA protein assay, 
which make it particularly suitable for this procedure (164). 
 
 
3.2.3 Histones 
Cells for histone analysis by Western Blotting or Histone H3 PTM Multiplex assay were grown in 
T75 flasks at a seeding density of 1.2 - 1.7 x10^4. Histone modifying enzyme inhibitors were 
diluted to the appropriate concentrations to produce a dose-response curve and added to the 
cells in fresh medium for the time required. An aliquot of growth medium was removed and stored 
at -20 °C for future analysis whilst the rest was discarded. After washing the cells twice with ice-
cold PBS, cells were scraped into Triton Extraction Buffer (TEB: PBS containing 0.5% Triton X-
100 (v/v), 2 mM PMSF, 0.02% (w/v) NaN3) at a cell density of approximately 107 cells per ml. 
Scraping the cells directly into the extraction buffer preserves the histone post-translational 
modifications and interactions with DNA, as using trypsin to lyse the cells from the flask can 
digest the histone tails. PMSF, a protease inhibitor, prevents histone degradation by proteases in 
the cells. 
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The cells were left to lyse on ice for 10 minutes with regular inversion to gently mix then 
centrifuged at 2 000 rpm for 10 minutes at 4 °C. The supernatant was discarded and the pellet 
resuspended in half the volume of TEB and centrifuged as before. The supernatant was 
discarded and the pellet resuspended in 0.2 N HCl at a cell density of approximately 4 x 107 cells 
per ml. The histones were acid extracted overnight at 4 °C and centrifuged at 2 000 rpm for 10 
minutes at 4 °C. The supernatant was aspirated and the pH neutralized by addition of 1/5th 
volume 1 M NaOH. The extracted and pH-neutralized histones were stored at -20 °C and the 
protein concentration determined by BCA protein assay. 
 
It is critical that the pH of the extracted histones is neutralized or the histones will degrade, even 
whilst frozen and the epitopes to be detected by antibody-binding and Western blot will be 
destroyed.  
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3.3 Reverse Transcriptase – Polymerase Chain Reaction (RT-PCR) 
 
Reagent Supplier Address 
RQ1 RNase-free DNase Promega Southampton, UK 
High Capacity cDNA Reverse Transcription Kit Invitrogen Paisley, UK 
GoTaq® Flexi DNA Polymerase Promega Southampton, UK 
PCR Tubes StarLab Milton Keynes, UK 
dNTP mix Bioline London, UK 
Primers Sigma-Aldrich Gillingham, UK 
GelRed™ Nucleic Acid Gel Stain VWR Lutterworth, UK 
Table 3-3 Reagents used in RT-PCR 
 
PCR is a technique used to specifically amplify DNA. The discovery of thermostable DNA 
polymerases enabled the reaction to proceed efficiently at high temperatures without destruction 
of neither the polymerase nor the requirement for additional enzymes such as DNA helicase. The 
double-stranded DNA helix is denatured by heating it to 95 °C. This separates the two strands so 
that the DNA polymerase can access the DNA. The temperature is lowered to ~60 °C so that 
primers, short oligonucleotides ~20 nt long whose sequence is complementary to the 3’ ends of 
the DNA to be amplified, anneal to the single-stranded DNA. DNA polymerase can only bind to 
double-stranded DNA, hence the requirement for primers. This annealing temperature varies 
depending on the primers used. It is typically ~5 °C lower than the Tm of the primers 
(temperature at which half of the primers will be denatured). As the annealing temperature 
increases, primers that contain mismatches to the desired sequence will dissociate thus resulting 
in a more specific product. As the annealing temperature decreases, the primers are able to bind 
to sequences that are not 100% complementary to their sequence and incorrect products will be 
formed. Therefore, the annealing temperature must be a compromise between being low enough 
to allow the primers to bind securely to the DNA, but high enough to get specific binding. The 
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temperature is then increased to 72 °C for the elongation phase. 72 °C is the optimum 
temperature for the DNA polymerase isolated from the bacterium Thermus aquaticus, though it is 
stable at the higher temperatures required to denature the double-stranded DNA. As in semi-
conservative replication that occurs in every cell, the DNA polymerase synthesizes a new 
complementary strand of DNA thus creating two identical double-stranded DNA molecules 
identical to the original molecule. Each new molecule contains one strand of the original molecule 
and one new strand. The whole process is then repeated with the newly synthesized molecules 
being denatured, the primers annealing and DNA polymerase synthesizing a new DNA strand, 
except that this time there are twice as many single strands of DNA. The steps are repeated 30-
40 times resulting in an exponential increase in the number of identical DNA molecules. 
 
PCR is a very sensitive and accurate technique, with widespread applications. A single DNA 
molecule can be specifically amplified millions of times to create a genetic fingerprint used in 
forensic science, as well as uses in DNA cloning for sequencing, phylogeny, functional gene 
analysis, medical diagnoses and paternity testing. 
 
The discovery of reverse transcriptase in bacteria revolutionised RNA analysis as it allowed 
amplification using PCR and development of quantitative PCR (qPCR), which is much more 
sensitive, efficient and precise than Northern Blotting. It also extended the range of applications 
of PCR to gene expression analysis; forensic detection of RNA not just DNA; identification of 
introns, exons and transcriptional start sites; disease diagnosis; and more precise genetic 
engineering e.g. insertion of the gene after the introns have been spliced out into bacteria for 
recombinant protein production. 
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Total RNA was extracted with TRIzol® as described in 3.2.1 and quantified using a NanoDrop 
Spectrophotometer. Equal concentrations of RNA were DNase-treated to remove any 
contaminating DNA. Though TRIzol® extraction includes a separation of DNA and RNA stage; it is 
easy to accidentally aspirate part of the DNA-containing interphase layer when aspirating the 
RNA-containing aqueous layer from the centrifuged tube. The DNase-treated RNA is used to 
synthesize complementary DNA (cDNA) using reverse transcriptase (RT) enzyme. It is important 
to dilute the DNase-treated RNA before cDNA synthesis as the inhibitors of the DNase interfere 
with the subsequent PCR. Also, a –RT reaction should be included, where no reverse 
transcriptase enzyme is added, as a control in the subsequent PCR for genomic DNA (gDNA). 
Only if there is DNA contamination in the RNA sample will there be a product formed in the PCR 
in the – RT as no cDNA synthesis has occurred. A negative control (-ve), water instead of cDNA, 
should be included in the PCR to determine whether there was any contamination present setting 
up the PCR as no product can be formed unless there is DNA present. 
 
The PCR is performed using primers specific to the gene of interest and a constitutively 
expressed gene or house-keeping gene (HKG). As the expression of the HKG is constant, it acts 
as a loading control to ensure that the same quantity of cDNA is added to each reaction. We used 
ACTB as the HKG, as it has been shown to be a good normalizing gene in Caco-2 cells (165) and 
is highly expressed thus acting as a positive control for the PCR. CXCL8 primers were designed 
using Primer-BLAST and specified to span an exon-exon junction, thereby reducing the possibility 
that any contaminating gDNA present will be amplified. The β-Actin primer sequences were taken 
from (166) (Table 3-4). The optimum primer annealing temperature was determined by 
performing a temperature gradient reaction with 58 °C resulting in the cleanest and highest 
yielding product. The PCR reactions were performed using the conditions as described in Table 
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3-5. The PCR products were separated by gel electrophoresis in a 2% agarose gel stained with 
GelRed (1:10 000 v/v) and visualised with a UV transilluminator. 
 
 
 
Gene 
ACTB CXCL8 
Accession 
Number NM_001101 NM_000584 
Pr
im
er
 
Se
qu
en
ce
s Forward CTGGAACGGTGAAGGTGACA CTCTGTGTGAAGGTGCAGTT 
Reverse AAGGGACTTCCTGTAACAACGCA ACTTCTCCACAACCCTCTGC 
Product Size (bp) 140 222 
Table 3-4 Primer Sequences 
Table illustrating the primer sequences and product sizes of the genes analysed by RT-PCR. 
 
Step Temperature (°C) Time (mins) Reason 
1 95 5 Initial denaturation 
2 95 1 Denaturation 
3 58 1 Annealing 
4 72 1 Extension 
5 Repeat steps 2 – 4 x35 
6 72 5 Final extension 
7 4 ∞ Prevent degradation 
Table 3-5 RT-PCR Reaction Conditions 
Table illustrating the temperatures and incubation lengths of the RT-PCR reaction.  
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3.4 Quantitative Polymerase Chain Reaction (qPCR) 
 
Reagent Supplier Address 
High Capacity cDNA Reverse Transcription Kit Invitrogen Paisley, UK 
Power SYBR® Green PCR Master Mix Thermo Fisher Scientific Paisley, UK 
MicroAmp® Optical 96-well Reaction Plate Thermo Fisher Scientific Paisley, UK 
MicroAmp® Optical Adhesive Film Thermo Fisher Scientific Paisley, UK 
Primers Thermo Fisher Scientific Paisley, UK 
Table 3-6 Reagents used in qPCR 
 
Quantitative or real-time PCR (qPCR) is a variation of PCR that measures the amplification of 
DNA in real time, unlike conventional PCR which only measures the relative amount at the end of 
the reaction. qPCR is quantitative thereby allowing statistical analysis of the data. DNA 
amplification is measured in one of two ways, non-specific DNA-intercalating fluorescent dyes or 
sequence-specific probes labelled with a fluorescent reporter which enables detection after 
hybridzation with its complementary sequence.  
 
Fluorescent dyes such as SYBR Green, intercalate with double-stranded (ds) DNA thus as the 
amount of dsDNA increases with each PCR cycle, so does the fluorescence intensity. 
Theoretically, the fluorescence intensity is directly proportional to the amount of dsDNA present. 
However, as SYBR Green is a non-specific dye and binds to all DNA regardless of the sequence, 
the fluorescence intensity can be misleading as it includes all PCR product as well as primer 
dimers and PCR products from non-specific binding. The advantages of this method include the 
relatively cheap cost and only requiring one pair of primers per target. Unfortunately, multiplex 
reactions are not possible as the detection method is not sequence specific. 
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Sequence-specific probes with attached fluorescence reporters, known as Taqman probes, only 
fluoresce when bound to the complementary DNA sequence. The probe, which has sequence-
specificity complementary to the target, has reporter and quencher molecules attached at either 
end. When the probe is bound to the target, the close proximity of the reporter and quencher 
prevents fluorescence. However, as the DNA is amplified, the probe is destroyed by the 
exonuclease activity of the Taq polymerase, thus enabling fluorescence detection proportional to 
the amount of target DNA. This method greatly increases the specificity of the qPCR technique as 
other dsDNA e.g. non-specific PCR products do not affect the fluorescent intensity. Primer 
dimers, however, can reduce the amplification of the desired target. Also, by using different 
fluorescent reporters for different target probes, it is possible to multiplex several targets into one 
reaction. A limitation is the increased difficulty of designing both primers and a probe that meet 
the specificity requirements. 
 
Analysis of qPCR data, whether it is obtained from the fluorescent dye or sequence-specific 
probe method, is dependent upon the cycle threshold or CT value. It is a relative value taken from 
the exponential part of the amplification curve. Amplification curves plot the amount of 
fluorescence against the PCR cycle number. A threshold level is chosen for the fluorescence 
level of all samples is being produced in the exponential phase, though it may be at different 
points in the PCR reaction. Conversely, the higher the CT value, the smaller the amount of the 
target present in the sample as it takes more PCR cycles for it to reach the same fluorescence 
level as targets present in greater amounts.  
 
The Power SYBR Green master mix from Invitrogen was used with primers designed using 
Primer-BLAST (for sequences of each gene see Table 3-7). In order to accurately measure the 
amount of cDNA present, the target is referenced to an internal control or HKG. As in RT-PCR, 
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ACTB was used as the HKG in qPCR. The comparative CT or 2−ΔΔCT method was used to analyse 
the qPCR results (167). The first comparison or ΔCT is the subtraction of the HKG CT from the CT 
of the target gene. The second comparison or ΔΔCT is the subtraction of an internal control from 
the target ΔCT. Two raised to the negative power of the second comparison, or 2-ΔΔCT, gives the 
fold change in expression of the target gene. The mean of the fold changes for each condition 
was calculated and plotted. 
 
 
Gene 
Accessio
n 
Number 
Forward Reverse 
Produ
ct size 
(bp) 
IL-6 NM_000600 GGCACTGGCAGAAAACAACC GCTCTGGCTTGTTCCTCACT 177 
CXCL8 NM_000584 CTCTGTGTGAAGGTGCAGTT ACTTCTCCACAACCCTCTGC 222 
IL-10 NM_000572 TACGGCGCTGTCATCGATTT TAGAGTCGCCACCCTGATGT 191 
DEFB4A NM_004942 CTCGTTCCTCTTCATATTCCTGA CTAGGGCAAAAGACTGGATGAC 111 
CCL2 NM_002982 GATCTCAGTGCAGAGGCTCG TTTGCTTGTCCAGGTGGTCC 155 
TNF NM_000594 AGCCCATGTTGTAGCAAACC TGAGGTACAGGCCCTCTGAT 134 
ACTB NM_001101 CTGGAACGGTGAAGGTGACA AAGGGACTTCCTGTAACAACGCA 140 
Table 3-7 qPCR primer sequences 
Table illustrating the primer sequences and product sizes of the genes analysed by qPCR. 
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3.5 Protein Concentration Determination – BCA Assay 
 
Reagent Supplier Address 
Bovine serum albumin (BSA) Standard Sigma-Aldrich Gillingham, UK 
Bicinchoninic Acid (BCA) Sigma-Aldrich Gillingham, UK 
Copper Sulphate Sigma-Aldrich Gillingham, UK 
96-well plate VWR Southampton, UK 
Table 3-8 Reagents used for Determination of Protein Concentration  
 
The protein concentration of the CelLytic™ M extractions was calculated by BCA protein assay. 
Each sample was tested in duplicate and the concentration calculated by comparison to a BSA 
protein standard curve. Results were analysed and presented using Microsoft Excel software. 
 
The CelLytic™ M protein extractions were thawed on ice and diluted 1:5 and 1:10 in PBS. A 6-
point standard curve starting at 1 mg/ml was prepared by serially diluting BSA in PBS by a factor 
of two. 5 µl standard/sample was added per well in duplicate to a 96-well plate. 200 µl BCA 
solution (50:1 ratio of BCA to CuSO4) was added per well. The plate was sealed and incubated 
for 30 minutes at 37 °C. The optical density of each well was determined using a microplate 
reader set to 570 nm and used to calculate the protein concentration.  
 
It is important that the BSA and the samples use the same diluent in order to achieve an accurate 
standard curve and that the samples are sufficiently diluted so that their optical density reading 
lies within the linear part of the standard curve. Errors are usually caused by pipetting error hence 
the need for duplicates of each sample. Any samples where the optical densities are greater than 
±10% from the mean should be repeated. 
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3.6 Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Reagent Supplier Address 
Human CXCL8/IL-8 DuoSet R&D Systems Abingdon, UK 
Human IL-6 DuoSet R&D Systems Abingdon, UK 
BSA (≥96%) Sigma-Aldrich Gillingham, UK 
TWEEN® 20 Sigma-Aldrich Gillingham, UK 
Trizma base Sigma-Aldrich Gillingham, UK 
Sodium Chloride (NaCl) Sigma-Aldrich Gillingham, UK 
TMB Substrate Solution R&D Systems Abingdon, UK 
TMB Substrate Solution Cambridge Bioscience Cambridge, UK 
TMB Substrate Solution Biolegend London, UK 
Sulphuric Acid (H2SO4) Sigma-Aldrich Gillingham, UK 
Human IL-8 ELISA MAX™ Standard Biolegend London, UK 
CXCL8 Recombinant Protein R&D Systems Abingdon, UK 
Table 3-9 Reagents used in ELISA 
 
The immunological response of Caco-2 and HT29 cells to stimulation by IL-1β and P3CK was 
determined by measuring the quantity of CXCL8 and IL-6 secreted into the growth media. Each 
sample was tested in duplicate and the concentration calculated by comparison to the appropriate 
standard curve. Results were analysed and presented and statistical tests performed using 
Microsoft Excel and GraphPad Prism software. 
 
ELISA is a quantifiable immunological technique used to detect the amount of antigen in a 
sample. This type of ELISA, where two antibodies are used to bind and detect the antigen, is 
known as a sandwich ELISA. Therefore, the measured antigen or protein must be multivalent with 
at least two antigenic sites, one each for the capture and the detection antibodies. As it is an 
antibody-based technique, it is highly specific and can detect very low concentrations of the 
antigen, even when the sample is not pure, as long as the antibody does not have cross-
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reactivity. It has found many applications ranging from diagnostics (e.g. measurement of HCG in 
pregnancy tests), toxicology (drug screening) and the food industry for seeking traces of potential 
allergens. 
 
Two different manufacturers of ELISA antibody kits, R&D Systems and Biolegend, were used to 
measure the production of CXCL8. The protocols are similar, with a couple of differences in the 
compositions of the blocking and reagent diluents and the recommended use of a plate shaker by 
Biolegend. However, despite the Biolegend kit being significantly cheaper than R&D Systems, I 
would recommend the use of the R&D Systems DuoSet as its CXCL8 protein produces a more 
reliable standard curve compared to the one from Biolegend, which is not supplied at its stated 
concentration and increases its absorbance readings for the same concentration in successive 
experiments. 
 
The capture antibody is diluted to the specified concentration (using PBS: R&D Systems; 
carbonate-bicarbonate buffer: Biolegend) and left to coat the 96-well plate overnight. The excess 
is then washed off using PBST (PBS + 0.05% Tween-20) a minimum of 3 times (preferably 5 
times) and the plate blotted against clean paper towels each time. The washing steps are critical 
to ensure low background levels and reproducibility of results. The antigen-binding sites in the 
capture antibody are then blocked with BSA (1% BSA in PBS with 0.05% NaN3: R&D Systems 
CXCL8; 1% BSA in PBS: R&D Systems IL-6 and Biolegend CXCL8) for a minimum of 1 hour to 
reduce non-specific binding to the antibody. The plate is washed, as described above, and the 
sample solutions and standards are applied in duplicate. These should both be diluted in the 
reagent diluent (0.1% BSA, 0.05% Tween-20 in Tris-buffered Saline (20mM Trizma base, 150 
mM NaCl) pH 7.2-7.4, 0.2 µm filtered: R&D Systems CXCL8; 1% BSA in PBS: R&D Systems IL-6 
and Biolegend) so that the standard curve is as accurate as possible.  
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It is important to perform duplicate measurements to minimise pipetting errors. After sufficient 
time has been left to allow the antibody-antigen complex to form, the diluted (in reagent diluent) 
detection antibody is added. This antibody is conjugated to biotin, which binds specifically to 
streptavidin in the streptavidin-conjugated horseradish peroxidise (HRP) enzyme applied in the 
next step. A substrate solution of equal parts H2O2 and tetramethylbenzidine (TMB) is added and 
left to develop in the dark. The HRP enzyme uses hydrogen peroxide to oxidize TMB into the blue 
oxidation product and the reaction is stopped using 0.2 N H2SO4, which produces the yellow 
diimine product (168). A schematic of the ELISA reaction is shown in Figure 3-8. The intensity of 
the yellow coloured product, as read by a microplate reader at 450 nm wavelength, is directly 
correlated with the amount of antigen present. The optical density is converted into a 
concentration through comparison with the known standard curve generated in the same 
experiment. It is important to read the colour intensity promptly so that the signal does not 
degrade. The microplate reader is set to dual wavelength (450 nm - 570 nm) in order to correct 
for any signal originating from the plate itself at 570 nm. If the values calculated from the 
duplicates had a variation greater than ±10%, the experiment was repeated. 
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Figure 3-8 Schematic of the CXCL8 ELISA Reaction 
A diagram representing the CXCL8 ELISA reaction from both R&D Systems and Biolegend. The capture antibody 
adheres to the 96-well reaction plate (one well illustrated here) in all orientations. CXCL8 binds to the capture 
antibody and the biotinylated detection antibody binds to the CXCL8 to form a sandwich complex. Streptavidin 
conjugated horseradish peroxidase (SA-HRP) binds to the biotinylated complex and catalyses the oxidation of TMB 
substrate with hydrogen peroxide (H2O2) to the blue diimine product. The reaction is stopped by addition of sulphuric 
acid (H2SO4) which causes the reaction product to turn yellow. This has a maximum absorbance at 450 nm and can 
be measured with a microplate reader. The colour intensity is proportional to the amount of CXCL8-antibody 
sandwich complex. 
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3.7 Protein Immunoblot (Western Blot) 
 
Reagent Supplier Address 
SDS Sigma-Aldrich Gillingham, UK 
Glycerol Sigma-Aldrich Gillingham, UK 
Bromophenol blue Sigma-Aldrich Gillingham, UK 
NuPAGE® Novex® 4-12% Bis-Tris Gel 1.0 mm, 15 well Invitrogen Paisley, UK 
NuPAGE® Novex® 12% Bis-Tris Gel 1.0 mm, 15 well Invitrogen Paisley, UK 
NuPAGE® MOPS SDS Running Buffer Invitrogen Paisley, UK 
NuPAGE® Transfer Buffer Invitrogen Paisley, UK 
Methanol VWR Lutterworth, UK 
PVDF Membranes Invitrogen Paisley, UK 
Non-Fat Dry Milk Supermarket London, UK 
Anti-Histone H3 Antibody (ab1791) Abcam Cambridge, UK 
Anti-Histone H3 (tri-methyl K4) Antibody (ab12209) Abcam Cambridge, UK 
Anti-Histone H3 (tri-methyl K9) Antibody (ab8898) Abcam Cambridge, UK 
Goat anti-Rabbit (HRP) Secondary Antibody (ab97051) Abcam Cambridge, UK 
Anti-Histone H3 tri-methyl Lysine4 Antibody Merck Millipore Watford, UK 
Anti-Histone H3 tri-methyl Lysine9 Antibody Merck Millipore Watford, UK 
Anti-Histone H3 tri-methyl Lysine27 Antibody Merck Millipore Watford, UK 
ECL Detection Reagent Promega Southampton, UK 
Amersham ECL Detection Reagent GE Healthcare 
Life Sciences Little Chalfont, UK Amersham Hyperfilm ECL 
Table 3-10  Reagents used in Western Blotting 
 
Histones were extracted as described in 3.2.3 and the protein concentration determined by BCA 
assay as described in 3.4. Samples were normalized to the sample with the lowest protein 
concentration then loaded onto 4-12% or 12% gels before being resolved by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) run in MOPS buffer. They were 
transferred onto PVDF (Polyvinylidene difluoride) membranes, blocked with 5% milk/BSA in 0.1% 
TBST and probed overnight with primary antibodies to Anti-Histone H3 loading control (molecular 
weight 17 kDa), histone H3 (tri-methyl K4) (molecular weight 17 kDa), histone H3 (tri-methyl K9) 
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(molecular weight 17 kDa) and histone H3 (tri-methyl K27) (molecular weight 17 kDa) (all diluted 
in 5% milk/BSA in 0.1% TBST). Membranes were washed in 0.1% TBST for 1 hour, changing the 
wash buffer every 10 minutes. The membranes were re-probed with HRP-conjugated rabbit anti-
mouse/ goat anti-rabbit secondary antibodies (raised against the primary antibody host) and the 
wash step repeated. It is essential that the membranes are thoroughly washed to reduce non-
specific binding and background luminescence. A chemiluminescent substrate is applied and the 
western blot visualised by hyperfilm development.  
 
Western blotting is a highly specific though only semi-quantitative, technique. It can detect the 
protein of interest amongst a complex mixture of other biological components. Therefore, 
evaluation of the primary antibody specificity to the target protein is essential to ensure that it is 
not binding non-specifically to another protein and producing false negative results. Accurate 
determination of sample concentration is important to ensure that the samples are loaded equally 
and that any differences in signal intensity are truly due to differences in the protein expression. A 
control antibody should always be included against a protein whose expression does not vary in 
the experimental conditions used. We were measuring the difference in histone H3 methyl 
signatures so histone H3 is a good control as it has to be present in order to measure the methyl 
signature. 
 
Proteins migrate through a polyacrylamide gel at a rate proportional to their size. The higher the 
polyacrylamide percentage is, the smaller the pore size in the gel is and the smaller the size of 
protein that can fit through. It is essential that the protein samples are properly denatured by 
heating to 95 °C in a reducing buffer to break any disulphide bonds as protein tertiary structure 
retards the rate of migration. SDS is also added to the reducing buffer in order to help denature 
the proteins and give them a uniformly negative charge so that they migrate towards the positive 
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anode. A ladder consisting of proteins of known molecular weight is always run alongside the 
samples of interest so that the target proteins can be identified by their size. The membrane is 
able to bind any and all proteins so must be blocked before the primary antibody is applied. 
 
The secondary antibody is conjugated to the enzyme HRP so that the protein-antibody complex 
can be visualised. A chemiluminescent substrate is used, instead of TMB like in an ELISA, which 
produces light. This can be captured on film and developed photographically. The intensity of the 
signal correlates with the abundance of the antigen. This can be measured quantitatively if using 
fluorescent antibodies, but chemiluminescence will only indicate whether one sample is more or 
less than another rather than giving a numerical value.  
 
We chose this technique as we needed to verify that the histone methyltransferase 
inhibitor/histone demethylase inhibitor was having an effect on the cells, but quantification of the 
effect was not required. It requires careful optimisation as it contains multiple critical steps, each 
of which can affect the final outcome. Troubleshooting was systematic and comprehensive, as 
well as challenging and gave experience in correlating specific sub-optimal results with likely 
problems and causes. 
 
 
3.7.1 Antibody Stripping for Restaining of Protein Immunoblots 
Stripping and restaining western blots is a cost-effective and efficient method of probing for 
multiple primary antibodies from the same sample. This is particularly useful when the two or 
more proteins of interest cannot be sufficiently resolved by SDS-PAGE or when looking at 
different modifications of the same protein e.g. Histone H3 and H3K4me3. PVDF membranes are 
recommended for blots that are to be reprobed as they bind protein with a higher capacity than 
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nitrocellulose membranes and are also more resistant to mechanical and chemical damage. 
Chemiluminescent developing substrates are also recommended as colourimetric/chromogenic 
substrates can stick to the membrane and interfere with subsequent antibody binding. An acidic 
buffer (200 mM Glycine, 3.5 mM SDS, 1% TWEEN® 20 in H2O, pH 2.2), is used to denature the 
antibody-protein complex so that the antibody can be washed away whilst the protein sample 
remains bound to the membrane. The blot is incubated with enough stripping buffer to cover the 
membrane at RT for 5-10 mins and repeated with fresh buffer. It is then washed with PBS for 10 
mins twice and with 0.1% TBST for 5 mins twice. Thorough washing is required to ensure that the 
stripping buffer is completely removed from the blot otherwise it can prevent the antibody from 
binding. The blot is then ready for blocking with 5% milk in 0.1% TBST and incubation with the 
second primary antibody. Blocking the blot again is not always necessary, depending on the 
quality of the primary antibody used for restaining, but it can help to keep the background level 
low, as this tends to rise as the membrane is repeatedly stripped. 
 
A small amount of protein is lost from the sample with each round of stripping and restaining so 
ideally, quantitative comparisons should not be made before and after stripping. However, by 
comparing the signal intensity patterns using the same primary antibody before and after stripping 
blots assuming that they are similar means that it can be used for quantitative analysis. 
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3.8 Histone H3 PTM (Post-Translational Modifications) Multiplex Assay 
 
Reagent Supplier Address 
Histone H3 PTM Multiplex Assay Active Motif La Hulpe, Belgium 
Histone H3 Total Antibody-conjugated Beads Active Motif La Hulpe, Belgium 
Histone H3K4me3 Antibody-conjugated Beads Active Motif La Hulpe, Belgium 
Histone H3K9me3 Antibody-conjugated Beads Active Motif La Hulpe, Belgium 
Histone H3K27me3 Antibody-conjugated Beads Active Motif La Hulpe, Belgium 
MAGPIXTM Luminex ‘s-Hertogenbosch,  The Netherlands 
Table 3-11  Reagents used in Histone H3 PTM Multiplex Assay 
 
The histone H3 post-translational modifications multiplex assay is a novel antibody-based bead 
method that can simultaneously measure the levels of multiple modifications at once using 
Luminex technology. It is a high-throughput ELISA technique producing quantitative results as an 
alternative to qualitative Western Blotting results. The sample binds to the histone H3 post-
translationally modified (PTM) antibody conjugated to magnetic Luminex beads. The secondary 
biotinylated Histone H3 antibody then binds to the sample and provides the internal control for 
normalization across multiple samples. Streptavidin-phycoerythrin binds to the biotinylated 
histone H3 antibody and produces fluorescence proportional to the amount of modified histone 
H3 present. The median fluorescence intensity (MFI) is measured with a MAGPIXTM instrument 
and xPONENT software. These steps are illustrated in Figure 3-9. 
 
The Active Motif Histone H3 PTM Multiplex assay is based upon Luminex technology. Luminex 
technology involves the production of supramagnetic beads containing a range of dye ratios that 
produce distinctive fluorescent signals capable of identifying the bead. Active Motif developed the 
Luminex technology for use with histone H3 PTM antibodies. Each PTM antibody is associated 
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with a unique fluorescent signal thereby allowing later identification of each bead in the 
multiplexed system. As the beads pass through the MAGPIXTM instrument, the beads are excited 
by two wavelengths; the first to excite the fluorescent dye in the bead and identify the PTM 
antibody, and the second to measure the magnitude of the streptavidin-phycoerythrin signal. The 
streptavidin-phycoerythrin signal is directly proportional to the amount of sample bound to that 
particular PTM antibody-conjugated bead. A major advantage of this assay over Western blotting 
is that multiple PTMs can be interrogated in the same sample, a smaller sample size is required 
than for immunoblotting and the results area quantitative and subject to statistical analysis.  
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Figure 3-9 Schematic of the Histone H3 PTM Multiplex Bead-based Sandwich Assay 
A diagram representing the Active Motif Histone H3 PTM Multiplex Assay: circle – PTM antibody-conjugated 
magnetic bead; triangle – PTM methyl group; pentagon – histone H3 protein sample; lightning bolt – biotinylated 
histone H3 antibody; star – streptavidin-phycoerythrin (SA-PE). The histone sample (pentagon with attached triangle 
modification) binds to the PTM antibody-conjugated magnetic bead. This forms a sandwich complex with a 
biotinylated Histone H3 antibody. SA-PE bindsto the histone-antibody sandwich complex and fluoresces in proportion 
to the amount of histone H3 sample bound to the PTM antibody. The fluorescence is measured using MAGPIXTM and 
xPONENT software. 
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3.9 Chromatin Immunoprecipitation (ChIP) 
 
Reagent Supplier Address 
37% Formaldehyde Sigma-Aldrich Gillingham, UK 
Glycine Sigma-Aldrich Gillingham, UK 
IGEPAL® CA-630 Sigma-Aldrich Gillingham, UK 
Triton-X 100 Sigma-Aldrich Gillingham, UK 
NaCl Sigma-Aldrich Gillingham, UK 
EDTA Sigma-Aldrich Gillingham, UK 
EGTA Sigma-Aldrich Gillingham, UK 
PMSF Sigma-Aldrich Gillingham, UK 
SDS Sigma-Aldrich Gillingham, UK 
Tris-HCl, pH 8.0 Sigma-Aldrich Gillingham, UK 
cOmplete, EDTA-free Protease Inhibitor Cocktail Roche Burgess Hill, UK 
Magna ChIP™ Protein A/G Magnetic Beads Merck Millipore Watford, UK 
Anti-Histone H3 Antibody Abcam Cambridge, UK 
Anti-trimethyl-Histone H3 (Lys4) Antibody Merck Millipore Watford, UK 
Anti-trimethyl-Histone H3 (Lys9) Antibody Merck Millipore Watford, UK 
Anti-trimethyl-Histone H3 (Lys27) Antibody Merck Millipore Watford, UK 
Primers Sigma-Aldrich Gillingham, UK 
Table 3-12 Reagents used in ChIP 
 
Chromatin immunoprecipitation (ChIP) is a method used to determine the nature of protein-DNA 
interactions. It can be used to profile the binding pattern of transcription factors and proteins that 
interact with DNA, as well as determining the positions that histone modifications are associated 
with. DNA is fixed to the proteins that are bound to it using formaldehyde and sheared into small 
pieces by sonication or micrococcal nuclease. Antibodies against the protein of interest 
precipitate the specific protein-DNA immune complex thereby isolating the specific regions of 
DNA that are boiund to the protein. Degradation of the protein with proteinase K is followed by 
purification of the DNA which is analysed by PCR. The precipitated DNA is analysed either by 
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sequencing (ChIP-seq) to identifiy the specific regions, or primers against specific areas are used 
in qPCR to measure the fold change difference at certain specific loci. 
 
There are a number of limitations to consider when performing ChIP. The main limitation is that 
ChIP is an antibody-based technique, which is inherently inefficient. Non-specific binding is a 
major issue and although some antibodies work perfectly well for other techniques e.g. ELISA 
and Western blotting, they do not work well in ChIP. It is recommended to use a ChIP-validated 
antibody and empirically determine the optimum concentration and incubation time for maximum 
binidng.  
 
Fragmentation is another limitation. There are two methods of fragmentation, sonication and 
micrococcal nuclease digestion. Sonication uses sound waves to agitate particles, or as in this 
situation, break chromatin into small pieces. The samples need to be sonicated enough to 
produce fragment sizes of 200 – 1000 bp, which is small enough to easily analyse but large 
enough to include at least one whole nucleosome and not just the linker DNA (Figure 1-6). 
Sonication produces a range of fragment sizes but by using a Bioruptor® (sonication device using 
a water bath), the fragmentation is more reproducible. A further complication is that sonication 
causes an increase in temperature which can degrade the chromatin, reverse fixation and cause 
the SDS in the buffer to precipitate. Therefore, it is necessary to keep the samples cool and, if 
possible, on ice. An alternative method of fragmentation is enzymatic digestion using micrococcal 
nuclease (MNase). MNase is an endo-exonuclease that cleaves DNA. As formaldehyde 
crosslinks prevent MNase access to the DNA, this technique is restricted to native ChIP and the 
analysis of proteins that are naturally bound to DNA (169). 
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SDS is a detergent which is used in several of the ChIP buffers to facilitate lysis and increase 
sonication efficiency. However, it can interfere with antibody-antigen binding by preventing the 
antibody associating with its epitope. Therefore, although it is required for efficient sonication, it 
needs to be diluted out after fragmentation in order to maximise antibody binding (170). 
. 
Chromatin was extracted for histone methylation analysis by ChIP. Intestinal epithelial (Caco-2) 
cells were grown in T75 flasks at a seeding density of 1.2 – 1.7 x 10^4 cells/ml and were 
incubated with IL-1β and epigenetic inhibitors as described in Figure 3-7. An aliquot of growth 
medium was removed for analysis by ELISA, in order to confirm both tolerance and the breaking 
of tolerance by the epigenetic inhibitor. The chromatin was fixed by adding formaldehyde to the 
cells to a final concentration of 1%. The flasks were gently agitated for 10 mins to ensure 
thorough fixation, followed by 5 mins incubation with 125 mM glycine to quench the reaction. The 
cells were washed twice with ice-cold PBS, placed on ice and scraped into cold lysis buffer with 
added protease inhibitor cocktail (PIC). After 10 mins incubation on ice with gentle agitation, the 
samples were centrifuged at 500 x g for 5 mins at 4 °C. The supernatant was discarded and the 
pellet resuspended in cold post-lysis buffer with added PIC. After 10 mins incubation with gentle 
agitation, the samples were centrifuged at 500 x g for 5 mins at 4 °C. The supernatant was 
discarded and the pellet resuspended in 1.8 ml sonication buffer with added PIC. Each sample 
was aliquoted into 6 volumes of 300 ml. The chromatin was sheared by sonication using a 
Bioruptor for 15 mins in 30 sec pulses in ice-cold water. The samples were centrifuged at 12 000 
x g for 10 mins at 4 °C to pellet any debris. The resulting supernatant containing the sheared 
chromatin was then stored at -70 °C until ready for ChIP analysis. 
 
Using the EZ-Magna ChIP A/G kit from Merck Millipore, protease inhibitor cocktail was added to 
dilution buffer, which was used to dilute the ChIP samples in half. (The kit recommends a 1 in 10 
101 
 
dilution, but to maximise the amount of chromatin available to the antibody, a 1 in 2 dilution was 
used.) 5 µl of the diluted sample was removed as the “input” and stored at 4 °C until the elution 
step. 20 µl of fully resuspended protein A/G magnetic beads with the appropriate antibody of 
interest or control IgG antibody, at the amount listed in Table 3-13, were added to each sample 
and incubated overnight with rotation at 4 °C. Although the antinobdy incubation time can be 
reduced to as little as 1 hour, overnight incubation was used to maximise antibody binding and 
precipitate the maximal amount of chromatin. 
 
Antibody Amount (µg) 
Anti-Histone H3  2 
Anti-trimethyl-Histone H3 (Lys4)  1 
Anti-trimethyl-Histone H3 (Lys9)  4 
Anti-trimethyl-Histone H3 (Lys27) 4 
Table 3-13 Table Describing the Amount of Each Antibody used in ChIP 
 
The immunoprecipitated chromatin binds to the magnetic beads. A magnetic rack is used to 
separate the beads from the buffer and the supernatant is discarded. A series of wash buffers 
including low salt, high salt, LiCl and TE are used to wash the immunoprecipitated chromatin. 
After the final wash, the chromatin is resuspended in ChIP elution buffer and incubated with 
Proteinase K for 2 hours with shaking at 65 °C. The reaction is stopped by incubation at 95 °C for 
10 mins. Proteinase K degrades any protein fixed to the DNA, leaving just the sheared DNA 
pieces, which are cooled down to room temperature before being purified for PCR analysis. 
Purification is necessary to remove salts and degraded proteins which may interfere with or inhibit 
PCR. This is achieved by using spin columns and centrifuging with a succession of buffers, the 
first of which is a wash buffer, followed by a binding buffer which binds the DNA to the spin 
column. Finally, the DNA is eluted and is analysed immediately by qPCR or stored at -20 °C for 
future analysis using the primer pairs in Table 3-14. 
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CXCL8 
Primers Forward Reverse 
Product 
size 
(bp) 
5’ GGTGCTAGTCTCTGCTCATCAA AGAGCAAAGTGGGGTACAAAGT 172 
Promoter AACTGAGGTCAAGGGCTAGGAG TCTTTAGCACTCCTTGGCAAAAC 188 
Gene Body AGGAAGTGTGATGACTCAGG GTCCTAGAAGCTTGTGTGCT 189 
Table 3-14 CXCL8 qPCR Primers used in ChIP Analysis 
 
 
 
  
103 
 
3.10 Statistics 
 
CXCL8 production was normalized to the amount of protein per well, as as measured by BCA 
assay (pg/mg protein) and different experiments standardized to each other by expressing the 
CXCL8 pg/mg protein values as a percentage of the mean singly stimulated CXCL8 production 
values (performed in Microsoft Excel 2007).  
 
The pooled data from each experiment was tested for Gaussian distribution i.e. that the scatter of 
multiple data points around the mean resembles a bell-shaped curve with a continuous probability 
distribution approaching zero on either side. This was tested for using the D’Agostino and 
Pearson omnibus normality test, which tests the null hypothesis that the data has Gaussian 
distribution. Therefore it tests how closely the data resembles the Gaussian ideal, but does not 
say what distribution the data is if it is not Gaussian. As it is almost impossible to actually have a 
data set with ideal Gaussian distribution, many statistical tests work well with data sets that 
closely resemble normal distribution.  
 
Data was plotted as mean ± SEM (standard error of the mean), using SEM to show how precise 
the mean is. As the data set increases in size the SEM tends to decrease as the data values tend 
not to vary far from the mean thus reinforcing the authenticity of the mean. The student’s t-test 
and the Mann-Whitney U test were used to test the null hypothesis that the mean of the two data 
sets is equal. The student’s t test was used for data sets that conformed to Gaussian distribution 
whereas the non-parametric Mann-Whitney U test was used for non-Gaussian distributed data. 
Both of these statistical tests test the quality of the mean between two groups whereas ANOVA 
tests the equality between three or more data sets. As the Mann-Whitney U test compares the 
sum of ranks, it is less likely than the student’s t test to produce an incorrect significant result, 
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especially for non-normally distributed data containing outliers. ANOVA, or analysis of variance, is 
particularly appropriate for testing the equality of means in three or more groups as it avoids 
producing a false positive result and rejecting the null hypothesis when it should not be, as often 
occurs when performing multiple two-group statistical tests. Two-tailed P values were calculated 
as they are more stringent than one-tailed tests and account for deviation from the null hypothesis 
in either direction happening by chance. Results were considered significant where P<0.05 
(according to convention). Data were analysed and presented after normalization and 
standardization using GraphPad Prism 5 statistical and graphical software. 
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4 Immune Tolerance in Intestinal Epithelial Cells 
 
4.1 Establishment of Immune Tolerance in Intestinal Epithelial Cells to Bacterial 
Lipoprotein 
 
4.1.1 Optimization of Bacterial Lipoprotein-Stimulation 
Bacterial lipoprotein is found naturally in the small intestine and colon where, being a component 
of bacteria, it is shed by the microbiota. It is a highly recognisable PAMP common to many 
bacteria and as such activates the innate immune system. Bacterial lipoprotein is an agonist of 
TLR2 and causes expression of pro-inflammatory cytokines e.g. CXCL8. Although there is a large 
range of different natural bacterial lipoproteins, a synthetic bacterial lipoprotein has been 
developed, Pam3CysK4 (P3CK), which is regularly used as a TLR2 agonist (Figure 4-1). CXCL8 is 
expressed in low amounts in the healthy intestine, but in large amounts in patients with UC, 
correlating with disease severity (171). Epithelial cell chemokine expression results in extensive 
neutrophil recruitment (172) in to the lamina propria. As epithelial cells respond to TLR 
stimulation, we compared the effect on CXCL8 production of repeatedly stimulating intestinal 
epithelial cells to cells with a single stimulation. 
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Figure 4-1 Structure of P3CK 
The chemical structure of P3CK, taken as a screenshot from (173). 
 
The optimum concentration of P3CK required to both stimulate the intestinal epithelial cell lines 
was determined by establishing a dose-response curve. As described in Figure 3-1, Caco-2 cells 
were stimulated by serial dilutions of P3CK (0 – 100 µg/ml) for 24 hours. The conditioned media 
samples were collected for analysis by CXCL8 ELISA and the cells harvested and measured for 
total protein content. As can be seen in Figure 4-2, the production of CXCL8 increased as the 
concentration of P3CK increased, with statistically significant production of CXCL8 as compared 
to unstimulated cells. Caco-2 cells stimulated with 6.25 µg/ml P3CK produced a statistically 
significant greater expression of CXCL8 than cells stimulated with 3.125 µg/ml P3CK (P<0.001). 
Cells stimulated with 12.5 µg/ml P3CK also produced a statistically significant greater secretion 
of CXCL8 than the preceding concentration (6.25 µg/ml) (P<0.05). Each further concentration of 
P3CK (25, 50 and 100 µg/ml) produced a greater, though non-significant, quantity of CXCL8. 
However, as it was not economical to use 100 µg/ml P3CK for subsequent tolerization 
experiments, 25 µg/ml was chosen as it induces a large and statistically significant CXCL8 
response. 
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Figure 4-2  Dose-Response Curve of Bacterial Lipoprotein-Stimulated Intestinal Epithelial (Caco-2) 
Cells 
P3CK was serially diluted by a factor of two (0-100 µg/ml) and used to stimulate Caco-2 cells for 24 hours, as 
described in Figure 3-1. CXCL8 production was measured by ELISA and normalized to cellular protein content 
(measured by BCA protein assay). Bars represent mean ± SEM, n = 2. Statistical analysis was performed using the 
Student’s t-test (for normally distributed data) or the Mann-Whitney U test (for non-normally distributed data). * and 
*** signify P<0.05 and <0.001.  
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P3CK stimulation of NCM460 cells, non-malignant intestinal epithelial cells, also showed a dose-
dependent increase in CXCL8 production. Two-fold serial dilutions of P3CK (0-100 µg/ml) were 
used to stimulate NCM460 cells. As was seen in Caco-2 cells, the optimum P3CK concentration 
for NCM460 cell CXCL8 production was 25 µg/ml, as higher P3CK concentrations did not 
produce a statistically significantly greater production of CXCL8 (Figure 4-3). Both cell types 
produce a similar dose-response curve and although the optimum concentration is the same for 
both Caco-2 and NCM460 cells, NCM460 cells stimulated by 25 µg/ml P3CK produced more 
CXCL8 than Caco-2 cells when expressed as cytokine per cell weight (533.2 pg/mg protein vs. 
249.4 pg/mg protein, p<0.05). Therefore, both types of intestinal epithelial cell express TLR2. It 
can be deduced and is logical to assume that both cell types initiate signalling cascades that 
result in similar levels of CXCL8 expression. 
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Figure 4-3 Dose-Response Curve of Bacterial Lipoprotein-Stimulated Intestinal Epithelial (NCM460) 
Cells 
P3CK was serially diluted by a factor of two (0-100 µg/ml) and used to stimulate NCM460 cells for 24 hours, as 
described in Figure 3-1. CXCL8 production was measured by ELISA and normalized to cellular protein content 
(measured by BCA protein assay). Bars represent mean ± SEM, n = 4. Statistical analysis was performed using the 
Student’s t-test (for normally distributed data) or the Mann-Whitney U test (for non-normally distributed data). *, ** 
and *** signify P<0.05, <0.01 and <0.001, respectively.  
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4.1.2 Tolerance to Bacterial Lipoprotein 
We were interested in determining whether cells with a prior stimulation of P3CK could become 
hyporesponsive (tolerized) following further P3CK stimulation, because this represents a natural 
bacterial product present in the intestinal lumen. This was established by comparing the CXCL8 
production of cells that were stimulated with 25 µg/ml P3CK for 24 hours with similarly stimulated 
cells that had been stimulated with 25 µg/ml P3CK 24 hours previously (as described in Figure 
3-2). Conditioned media samples were collected and CXCL8 expression measured by ELISA and 
normalized to the cellular protein content, as measured by BCA protein assay. These 
experimental conditions reflect the physiological situation of the intestinal epithelium which is 
responding to the presence of the gut microbiota. Constant stimulation by the millions of bacteria 
found in the gut would result in a massive, chronic, deleterious inflammatory response, if cytokine 
expression were left unchecked and not tightly controlled. A reduced ability to induce CXCL8 by 
small concentrations of lipoprotein could help to prevent excessive inflammatory cascade 
initiating a lower response (tolerance).  
 
As shown in Figure 4-4, the production of CXCL8 was greatest in the cells that have only been 
stimulated once with P3CK and was decreased, but still greater than the unstimulated control 
cells, in the cells that were stimulated 24 hours earlier. This was a statistically significant 
reduction (P<0.001), as calculated by Student’s t test and was 37.3% of the stimulated 
production. 
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Figure 4-4  Tolerization of Intestinal Epithelial (Caco-2) Cells by Bacterial Lipoprotein 
Caco-2 cells were stimulated with 25 µg/ml P3CK for 24 hours and tolerized by a prior stimulation of 25 µg/ml P3CK 
24 hours earlier, as described in Figure 3-2. CXCL8 production was measured by ELISA, normalized to cellular 
protein content (measured by BCA protein assay) and represented as a percentage of the mean stimulated amount. 
Bars represent mean ± SEM, n = 4 Statistical analysis was performed using the Student’s t-test. *** signifies 
P<0.001. 
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Figure 4-5  Tolerization of Intestinal Epithelial (NCM460) Cells by Bacterial Lipoprotein 
NCM460 cells were stimulated with 25 µg/ml P3CK for 24 hours and tolerized by a prior stimulation of 25 µg/ml P3CK 
24 hours earlier, as described in Figure 3-2. CXCL8 production was measured by ELISA, normalized to cellular 
protein content (measured by BCA protein assay) and represented as a percentage of the mean stimulated amount 
Bars represent mean ± SEM, n = 4 . Statistical analysis was performed using the Student’s t-test.  *** signifies 
P<0.001. 
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Tolerance was also established in NCM460 cells, as described in Figure 3-2. Tolerized cells were 
stimulated twice with 25 µg/ml P3CK for 24 hours each and CXCL8 expression was compared to 
CXCL8 expression by NCM460 cells that had only been stimulated once with P3CK (Figure 4-5). 
As seen with Caco-2 cells in Figure 4-4, the reduction in CXCL8 production by tolerized NCM460 
cells compared to stimulated NCM460 cells is statistically significant (P<0.001) (Figure 4-5). 
 
In summary, tolerance, a hyporesponsive state, was established in both Caco-2 and NCM460 
cells, as measured by the decrease in CXCL8 expression following TLR pre-stimulation thereby 
demonstrating that tolerance is a phenomenon in epithelial cell lines. Furthermore, it is not one 
that is confined to malignant cell lines. 
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4.1.3 Optimization of IL-1β Stimulation  
As demonstrated above, P3CK produces a tolerized immune response in intestinal epithelial 
cells. P3CK represents the presence of microbiota in the intestine and their effect on the 
inflammatory immune response of epithelial cells. The effect of IL-1β on intestinal epithelial cells 
was also investigated, as IL-1β is a major inflammatory mediator, particularly in IBD (174). IL-1β 
represents the effect of active inflammation on the intestinal epithelium, regardless of whether the 
inflammation is a result of an infection, stress or a disease. Therefore, the effect of IL-1β on 
intestinal epithelial cells was investigated. 
 
The optimum concentration of IL-1β required to stimulate the Caco-2 cells was determined by 
production of a dose-response curve. As described in Figure 3-1, Caco-2 cells were stimulated by 
a two-fold serial dilution of IL-1β (4 – 0 ng/ml) for 24 hours. The conditioned media samples were 
collected for analysis by CXCL8 ELISA and the cells harvested and measured for protein content. 
As can be seen in Figure 4-6  a significant increase in the expression of CXCL8 was seen each 
time the IL-1β concentration doubled (except between 0.0625 ng/ml and 0.125 ng/ml) up to 1 
ng/ml. Although both 2 ng/ml and 4 ng/ml IL-1β stimulated a greater production of CXCL8 than 
the amount produced by 1 ng/ml IL-1β, it is not a statistically significant increase. 1 ng/ml IL-1β 
was, therefore, the most efficient stimulant and therefore the optimum concentration for CXCL8 
stimulation.   
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Figure 4-6 Dose-Response Curve of IL-1β-Stimulated Intestinal Epithelial (Caco-2) Cells 
IL-1β was serially diluted by a factor of two (0-4 ng/ml) and used to stimulate Caco-2 cells for 24 hours, as described 
in Figure 3-1. CXCL8 production was measured by ELISA and normalized to cellular protein content (measured by 
BCA protein assay). Bars represent mean ± SEM, n = 4. Statistical analysis was performed using the Student’s t-test 
or the Mann-Whitney U test. ** and *** signify P<0.01 and <0.001.  
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The effect of IL-1β on NCM460 cells was different from that observed on Caco-2 cells. NCM460 
cells stimulated with a two-fold serial dilution (4 – 0 ng/ml) of IL-1β did not produce a statistically 
significant increase in CXCL8 secretion (Figure 4-7). NCM460 cells stimulated with 1 ng/ml IL-1β, 
the standard IL-1β concentration used to stimulate Caco-2 cells, produced similar levels of 
CXCL8 as unstimulated cells (Figure 4-7). A small, but statistically significant (P<0.05), increase 
in CXCL8 production by NCM460 cells resulted from stimulation with 10 ng/ml IL-1β (Figure 4-7). 
However, this production of CXCL8 (41.8 pg/mg protein vs. 25.3 pg/mg protein, P<0.05), was not 
even a two-fold increase above background production levels. Though 10 mg/ml IL-1β stimulated 
a statistically greater production of CXCL8 than 1 ng/ml IL-1β did (P<0.05, Figure 4-7), 10 ng/ml 
is a disproportionate concentration that produces an insufficient production of CXCL8. 
Background levels of CXCL8 production were higher in NCM460 cells than Caco-2 cells, making 
a statistically significant induction of CXCL8 expression harder to achieve in the NCM460 cell-
line. IL-1β was not a potent enough stimulant in NCM460 cells, as insufficient CXCL8 was 
produced to observe a statistically significant difference in CXCL8 expression between control, 
unstimulated and tolerized cells. We concluded that this cell line did not express CXCL8 in 
response to IL-1β. Therefore, further experiments investigating the effect of tolerance to IL-1β in 
intestinal epithelial cells were conducted only on Caco-2 cells. 
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Figure 4-7 Dose-Response Curve of IL-1β-Stimulated Intestinal Epithelial (NCM460) Cells 
IL-1β was serially diluted by a factor of two (0-4, 5, 10 ng/ml) and used to stimulate NCM460 cells for 24 hours, as 
described in Figure 3-1. CXCL8 production was measured by ELISA and normalized to cellular protein content 
(measured by BCA protein assay). Bars represent mean ± SEM, n = 5. Statistical analysis was performed using the 
Student’s t-test. * signifies P<0.05.  
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4.1.4 Technical Difficulties in Establishing Tolerance to IL-1β 
Technical difficulties had to be overcome during the course of the investigation when attempting 
to induce tolerance. There was a period in which the Caco-2 cells stopped responding to IL-1β 
stimulation and could not be either stimulated or tolerized. HT29 cells at this time, in comparison, 
produced large, but not non-significant, differences in the production of CXCL8, regardless of 
whether or not the cells were stimulated with IL-1β. Before describing the successful results, I will 
outline the difficulties encountered. 
 
Tolerance was induced as described in Figure 3-2. Caco-2 cells were stimulated with 1 ng/ml IL-
1β for 24 hours. Tolerized cells were pre-stimulated with 1 ng/ml IL-1β for 24 hours followed by 
another 24 hour stimulation of 1 ng/ml IL-1β. However, the production of CXCL8 was not 
significantly different between the control, stimulated and tolerized cells (Figure 4-8), as 
measured by ANOVA (P=0.4504). 
 
After repeating the initial stimulation experiment a number of times with a consistent failure of 
stimulation, the protocol was tested on HT29 cells, in case the Caco-2 cells, through multiple 
passages, had lost the ability to produce CXCL8. I hypothesized that this may have been due to a 
number of reasons such as epigenetic silencing, expulsion of chromosome 4, presence of small 
molecule inhibitors e.g. in FCS etc. However, whilst the Caco-2 cells did not produce CXCL8, 
both the control and the stimulated HT29 cells produced large amounts of CXCL8 with a non-
significant difference (Figure 4-9). Our suspicions that problems had occurred, in these particular 
experiments, were confirmed as the stimulated Caco-2 cells produced a lower expression of 
CXCL8 than the control. Therefore, neither intestinal epithelial cell line responded to IL-1β.  
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Figure 4-8 Failure of Intestinal Epithelial (Caco-2) Cells to Respond to IL-1β 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. CXCL8 production was measured by ELISA and normalized to cellular 
protein content (measured by BCA protein assay). Bars represent mean ± SEM, n = 1. ANOVA P=0.4504 
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Figure 4-9 Failure of Intestinal Epithelial (Caco-2 and HT29) Cells to Respond to IL-1β 
Caco-2 and HT29 cells were stimulated with 1 ng/ml IL-1β for 24 hours. CXCL8 production was measured by ELISA 
and normalized to cellular protein content (measured by BCA protein assay). Bars represent mean ± SEM, n = 2. 
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Interleukin-6 (IL-6) is another pro-inflammatory cytokine that is produced by intestinal epithelial 
cells in response to IL-1β stimulation (37). This has been shown to be an indicator of tolerance in 
macrophages (87), as CXCL8 was shown to be in response to tolerization by P3CK in Caco-2 
and NCM460 cells (Figure 4-4 and Figure 4-5, respectively). We investigated whether expression 
of IL-6 was differentially regulated in epithelial cells as well as in macrophages. This would also 
show if the lack of CXCL8 response (sometimes seen in response to IL-1β stimulation) was in the 
IL-1β receptor and signal transduction, or in CXCL8 activation. Foster et al used LPS to induce 
tolerance as measured by IL-6. However as Caco-2 cells are hyporesponsive to LPS (175) due to 
an absence of TLR4, IL-1β was used to investigate the effect on IL-6 expression (as described in 
Figure 3-2).  
 
Caco-2 cells were not successfully stimulated or tolerized with IL-1β according to the expression 
of IL-6 produced per mg protein (Figure 4-10 a)). However, when IL-6 production was 
represented as a percentage of the mean stimulated amount, the reduction in IL-6 expression by 
tolerized cells became statistically significant (P<0.001) (Figure 4-10 b)). Figure 4-10 highlights 
the importance of not just relying on one method of results presentation. Epithelial cells have 
been shown to produce less IL-6 than CXCL8 in response to IL-1β (38). Epithelial cells in these 
experiments, unlike leukocytes in (87), did not produce a sufficient expression of IL-6 (mean 
production of 4 pg/mg protein by stimulated cells), as shown in Figure 4-10 a). IL-6 was therefore 
not a suitable alternative to CXCL8 for measuring the induction of tolerance, as the effect of IL-
1β-stimulation was not readily observable. 
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Figure 4-10 Tolerization of IL-6 Expression in Intestinal Epithelial (Caco-2) Cells by IL-1β 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. IL-6 production was measured by ELISA and normalized to cellular protein 
content (measured by BCA protein assay) (a). Multiple experiments were combined by calculating IL-6 production as 
a percentage of the mean IL-6 production per single stimulation of IL-1β (b). Bars represent mean ± SEM, n = 2. 
Statistical analysis was performed using the Student’s t-test. *** signifies P<0.001. 
123 
 
Following the failure of IL-1β to induce significant quantities of IL-6 (4 pg/mg protein) or CXCL8 
proteins, silencing of transcription was tested for. Silencing of transcription would result in a lack 
of mRNA translation e.g. by epigenetic silencing via DNA methylation of the CXCL8 gene. Caco-2 
cells were stimulated with IL-1β and the total RNA extracted for analysis of CXCL8 production. 
The optimum concentration of IL-1β required to stimulate CXCL8 mRNA production was therefore 
determined by production of a dose-response curve similar to the protocol described in Figure 
3-1. However, the Caco-2 cells were stimulated with IL-1β for 2 hours not 24 hours. Caco-2 cells 
were stimulated by serial dilutions of IL-1β (4 – 0 ng/ml) for 2 hours. CXCL8 and β-Actin mRNA 
production was measured by RT-PCR, as shown in Figure 4-11. Increasing concentrations of IL-
1β resulted in increasing amounts of CXCL8 mRNA produced. CXCL8 production plateaued at 1 
– 4 ng/ml IL-1β so 1 ng/ml IL-1β, the same concentration as required for optimum CXCL8 protein 
production, was used for subsequent experiments.  
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Figure 4-11 Dose-Response Curve of CXCL8 mRNA Production by IL-1β-Stimulated Intestinal 
Epithelial (Caco-2) Cells 
IL-1β was serially diluted by a factor of two (0-4 ng/ml) and used to stimulate Caco-2 cells for 2 hours. CXCL8 mRNA 
production was measured using RT-PCR with β-Actin as a loading control. –ve and –RT signify negative and “no 
Reverse Transcriptase” controls, respectively. 
 
 
 
 
By measuring the production of CXCL8 over time (0 – 4 hours), as described in Figure 3-4, 2 
hours was determined as the optimum stimulation time for maximum CXCL8 production (Figure 
4-12). 
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Figure 4-12 Time-Course of CXCL8 mRNA Production by IL-1β-Stimulated Intestinal Epithelial (Caco-2) 
Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 0 – 4 hours, as described in Figure 3-4. CXCL8 mRNA production 
was measured by RT-PCR with β-Actin as the loading control. –ve and –RT signify negative and “no Reverse 
Transcriptase” controls, respectively. 
 
 
 
 
 
126 
 
As previously shown in Figure 4-11 and Figure 4-12, IL-1β was capable of stimulating production 
of CXCL8 mRNA, even if no CXCL8 protein was produced at that time. Therefore, a positive 
control to examine IL-1β activity was required. The THP1 cell-line is a monocytic cell-line derived 
from an acute monocytic leukemia. THP1 responds to inflammatory stimulation and produces 
inflammatory cytokines, such as CXCL8. This cell-line was used as a good model for CXCL8 
expression.  
 
We also decided to investigate whether the preparation and storage of IL-1β affected its activity. 
According to the Gibco manual supplied with recombinant human IL-1β (176), freeze-thaw cycles 
should be kept to a minimum. However, the advice supplied by Abcam with their human IL1 beta 
product (ab9617) is to avoid repeated freeze-thaw cycles (177). Therefore, we decided to 
compare the ability of repeatedly freeze-thawed IL-1β and freshly prepared (no freeze-thaw 
cycles) IL-1β to stimulate the production of CXCL8 in the THP1 cell-line. As shown in Figure 4-13, 
repeatedly freeze-thawed IL-1β was unable to stimulate THP1 cells to produce CXCL8, whereas 
the freshly prepared IL-1β stimulated a statistically significant production of CXCL8. Therefore, all 
subsequent preparations of IL-1β were aliquoted into small working volumes, frozen only once 
and any excess discarded.  
 
CXCL8 mRNA was produced, as demonstrated in Figure 4-11 and Figure 4-12 due to an 
inadvertant fresh preparation of IL-1β 
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Figure 4-13  IL-1β-Stimulated THP1 Cells 
Thp1 cells were stimulated with 1 ng/ml IL-1β for 24 hours prepared from two different sources, one that had been 
repeatedly freeze-thawed (freeze-thawed IL-1β) and one that had been freshly prepared with no freeze-thaw cycles 
(fresh IL-1β). CXCL8 production was measured by ELISA and normalized to cellular protein content (measured by 
BCA protein assay). Bars represent mean ± SEM, n = 2. 
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4.1.5 Induction of Tolerance to IL-1β 
Once the effect of thawing had been identified (Figure 4-13), a fresh IL-1β preparation in each 
experiment was used to stimulate Caco-2 cells and compared against the absence of stimulation 
with freeze-thawed stimulant. As shown in Figure 4-14, the use of a fresh IL-1β preparation 
resulted in a statistically significant increase in the production of CXCL8 (P<0.001).  
 
CXCL8 production was also analysed when using different growth medium supplements (178), as 
described in 3.1.4 and Figure 3-2. Though the CXCL8 production amounts are greater when 
using +FCS media (medium supplemented with fetal calf serum), the variation in CXCL8 results 
was less when using the +ITS media (medium supplemented with insulin, transferrin and 
selenium), thereby giving the statistical significance calculations more confidence.  
 
Upon repetition of the stimulation experiment in both Caco-2 and HT29 cells, the same level of 
statistical significance was found as before, but the individual values varied between different 
preparations (Figure 4-14 and Figure 4-15). Therefore, it was decided that the CXCL8 production 
amount should be standardized between similar experiments by converting each CXCL8 
production value into a percentage of the mean IL-1β-stimulated production (Figure 4-16). 
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Figure 4-14  Comparison of Different IL -1β Preparations and Media Supplements on CXCL8 
Production by Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours, diluted in +FCS media or +ITS media (as described in 
3.1.1). CXCL8 production was measured by ELISA and normalized to cellular protein content (measured by BCA 
protein assay). Bars represent mean ± SEM, n = 2. Statistical analysis was performed using the Student’s t-test. *** 
signifies P<0.001.  
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Figure 4-15 IL-1β-Stimulated Intestinal Epithelial (Caco-2 and HT29) Cells 
Caco-2 and HT29 cells were stimulated with 1 ng/ml IL-1β for 24 hours. CXCL8 production was measured by ELISA 
and normalized to cellular protein content (measured by BCA protein assay). Bars represent mean ± SEM, n = 1. 
Statistical analysis was performed using the Student’s t-test. *** signifies P<0.001. 
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Tolerance was established by stimulating one set of Caco-2 cells with 1 ng/ml IL-1β for 24 hours, 
and pre-stimulating another set of cells twice with 1 ng/ml IL-1β for 24 hours followed by another 
stimulation with 1 ng/ml IL-1β for 24 hours (as described in Figure 3-2). The conditioned media 
was collected and the amount of CXCL8 produced measured by ELISA. This was normalized to 
the total cellular protein content, as measured by BCA protein assay. As mentioned previously, 
the CXCL8 production results were converted into a percentage of the mean IL-1β-stimulated 
CXCL8 production (Figure 4-16), in order to combine multiple experiments. Caco-2 cells 
stimulated once by IL-1β express the greatest production of CXCL8 whilst the tolerized cells 
express a reduced production of CXCL8, ~50% of the stimulated expression level. The reduction 
in CXCL8 production by tolerized cells compared to stimulated cells was statistically significant 
(P<0.001), as calculated by Student’s t test. Therefore, tolerance induction is a statistically 
significant and reproducible effect. 
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Figure 4-16 Tolerization of Intestinal Epithelial (Caco-2) Cells by IL-1β 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. CXCL8 production was measured by ELISA and normalized to cellular 
protein content (measured by BCA protein assay). Multiple experiments were combined by calculating CXCL8 
production as a percentage of the mean CXCL8 production per single stimulation of IL-1β. Bars represent mean ± 
SEM, n = 8. Statistical analysis was performed using the Student’s t-test. *** signifies P<0.001. 
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To address criticism that CXCL8 mRNA may still be present from IL-1β-pre-stimulation when the 
second stimulation was given, another condition was added to the tolerization experiments, that 
of pre-stimulated only cells. Pre-stimulated cells were stimulated with 1 ng/ml IL-1β for 24 hours 
48 hours prior to sample collection (as described in Figure 3-3). The conditioned media was 
washed out with PBS to remove all traces of IL-1β and fresh unstimulated media was added to 
the cells for the final 24 hours before sample collection. Stimulated and tolerized cells were 
stimulated as previously described in Figure 3-2. The conditioned media was collected and the 
amount of CXCL8 produced measured by ELISA. This was normalized to the total cellular protein 
content, as measured by BCA protein assay. Figure 4-17 displays the production of CXCL8 in two 
forms, as the normalized values in pg/mg protein (top graph) and as percentages of the mean 
stimulated amount (bottom graph). The production of CXCL8 in stimulated and tolerized cells was 
similar in both Figure 4-16 and Figure 4-17, both figures showing a statistically signficant ~50% 
reduction in CXCL8 expression in tolerized cells as compared to stimulated cells (P<0.001). As 
shown in Figure 4-17, the amount of CXCL8 expressed by pre-stimulated cells was extremely low 
and though greater than in control cells, this was not statistically significant. Therefore the 
changes induced by pre-stimulating the cells were not due to CXCL8 still being produced by the 
first IL-1β-stimulation. 
 
A comparison of the top and bottom graphs of Figure 4-17 shows that expressing the values as 
percentages does not alter the trend of CXCL8 production. The range and variance of the values 
in each condition is reduced, as illustrated by the smaller error bars in the bottom graph of Figure 
4-17. As the production of CXCL8 in pre-stimulated cells is not statistically greater than that of the 
control cells, it indicates that CXCL8 production has ceased by the time that the tolerized cells 
receive their second IL-1β-stimulation. Tolerance is therefore a true effect and the reduction in 
CXCL8 production is not the tail-end of the original stimulation. 
134 
 
 
Figure 4-17 Tolerization of Intestinal Epithelial (Caco-2) Cells by IL-1β 
Caco-2 cells were pre-stimulated with 1 ng/ml IL-1β for 24 hours before the cells were washed with PBS and the 
conditioned media replaced with fresh media. Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and 
tolerized by a prior stimulation of 1 ng/ml IL-1β 24 hours earlier, as described in Figure 3-3. CXCL8 production was 
measured by ELISA and normalized to cellular protein content (measured by BCA protein assay). The top graph is of 
the normalized CXCL8 values in pg/mg protein whilst the bottom graph represents the values as percentages. 
Multiple experiments were combined by calculating CXCL8 production as a percentage of the mean CXCL8 
production per single stimulation of IL-1β. Bars represent mean ± SEM, n = 4. Statistical analysis was performed 
using the Student’s t-test. *** signifies P<0.001. 
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Tolerance was also established at transcription by stimulating Caco-2 cells with 1 ng/ml IL-1β for 
24 hours followed by a second stimulation by IL-1β for 2 hours before extracting total RNA and 
measuring CXCL8 and β-Actin mRNA production by RT-PCR (Figure 3-5). CXCL8 mRNA was 
produced by Caco-2 cells with both single and double stimulations of IL-1β. However, although 
production of CXCL8 appears to be lower in the double IL-1β-stimulated cells (Figure 4-18), the 
exact difference was not possible to determine as RT-PCR is a qualitative technique. Thus, the 
production of CXCL8 cannot be proven to be statistically different between single and double 
stimulations of IL-1β.  
 
Quantitative PCR (qPCR) produces quantitative numerical results that can be statistically 
analysed and hence verify that repeated stimulation of Caco-2 cells with IL-1β induces tolerization 
of CXCL8 at the level of mRNA as well as protein, but because we had quantitative protein 
assays that showed statistical differences, we did not undertake the qPCR experiments. 
 
136 
 
 
Figure 4-18 Tolerization of Intestinal Epithelial (Caco-2) Cells by IL-1β as shown by mRNA Production 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 2 hours (stimulated) and tolerized by a prior stimulation of IL-1β, 
24 hours earlier, as described in Figure 3-5. CXCL8 mRNA production was measured by RT-PCR with β-Actin as the 
loading control. –ve and –RT signify negative and “no Reverse Transcriptase” controls, respectively. 
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To further address a criticism that the effects of a pre-stimulation of intestinal epithelial cells are 
not finished by the second stimulation and is therefore responsible for the reduction in CXCL8 
expression in tolerized cells; the expression of several inflammatory and intestine-specific genes 
was monitored over 48 hours by qPCR. Total RNA was extracted from IL-1β-stimulated Caco-2 
cells using TRIzol®, incubated with DNase I to remove any residual DNA and cDNA synthesized. 
The amount of cDNA present in each sample was measured using qPCR and the primers 
described in Table 3-7. Each target was normalized to β-Actin and again to the mean 0 hour 
value for each respective gene. As shown in Figure 4-19, the expression profiles of IL-6, CXCL8, 
IL-10, CCL2 (or MCP-1, monocyte chemoattractant protein 1), DEFB4A (or BD-2, human β-
defensin 2) and TNF are plotted as fold changes in expression over the 48 hours of IL-1β-
stimulation. IL-6 and CXCL8 both show maximal expression at 2 – 4 hours after IL-1β-stimulation, 
with a subsequent decrease back to levels similar to that at 0 hours by 24 hours, which is before 
the second stimulation is given. There is a second peak in expression of CXCL8 2 – 4 hours after 
the second IL-1β-stimulation (26 – 28 hours), though this is smaller than the first stimulation, in 
agreement with the tolerizing effect of the first stimulation observed in the experiments measuring 
protein expression (Figure 4-17). Expression decreases back to background levels again 24 
hours after the stimulus is applied. These results are consistent with the protein data shown in 
Figure 4-16 and Figure 4-17. TNF shows similar activity to IL-6 and CXCL8, though the peaks in 
expression are of similar magnitude. The amounts of TNF cDNA measured were often below the 
detection limit with only one value being obtained for the 1 and 2 hour time points and none at all 
for 0 hours. TNF fold changes are therefore normalized to the mean 24 hour value. IL-10 
expression shows a small increase at 1 hour, followed by a decrease to almost background levels 
and a subsequent increase again at 8 hours. A decrease back to background levels occurs again 
with a smaller peak at 28 hours. As IL-10 is an anti-inflammatory cytokine, it is not unexpected 
that it shows a different expression profile to the pro-inflammatory cytokines IL-8, CXCL8 and 
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TNF. Neither CCL2 nor DEFB4A show signs of being tolerized, as the second IL-1β-stimulation 
causes a peak in expression that is larger than the peak after the first stimulation. 
 
 
Figure 4-19 Time-Course of Tolerizable and Non-Tolerizable Gene Expression in Intesinal Epithelial 
(Caco-2) Cells 
Caco-2 cells were stimulated twice with 1 ng/ml IL-1β for 24 hours each, as described in Figure 3-6, and illustrated 
with dashed grey arrows. Cell samples were collected at 0, 1, 2, 4, 8, 24, 25, 26, 28, 32 and 48 hours using TRIzol®. 
Total RNA was extracted, cDNA synthesized and measured by qPCR. The amounts of IL-6, CXCL8, IL-10, CCL2, 
DEFB4A and TNF were normalized to ACTB and analysed using the ΔΔCT method. The expression levels of each 
gene were plotted as fold changes normalized to the fold change value at 0 hours against time. Error bars are 
omitted for clarity. n = 4  
139 
 
4.2 Establishment of Cross-Tolerance 
 
We have demonstrated that intestinal epithelial cells can be tolerized to the TLR2 agonist P3CK 
and to the pro-inflammatory cytokine IL-1β. P3CK is representative of a physiological stimulant 
(lipoprotein component of the microbiotal or pathogenic bacterial cell wall) and IL-1β is a cytokine 
overexpressed during inflammation in general, and in IBD patients in particular. As both 
stimulants are present in the inflamed intestinal lumen we decided to investigate the effect on 
CXCL8 expression of pre-stimulating the intestinal epithelial cells with a different agent to the 
second stimulation. In particular, we wished to ascertain if constant stimulation by a bacterial 
product reduced the effect of IL-1β stimulation. This represents a reductionist model of the 
luminal bacteria on the response of the epithelium to inflammatory stimuli. Caco-2 cells were pre-
stimulated with P3CK rather than IL-1β as commensal bacteria are constantly present in the 
intestine from shortly after birth, whereas IL-1β expression is dependent upon the circumstances 
e.g. pathogens, injury, disease state etc. The microbiota, which contains products such as 
bacterial lipoprotein, is required for the correct development of tolerance. This has been shown by 
the susceptibility to IBD of germ-free mice. Additionally, these mice exhibit intestinal 
immunological defects and immunomodulatory deficiencies e.g. altered T cell development 
particularly of Treg cells (179), a lack of bacterially-generated ATP resulting in a lack of anti-
inflammatory IL-17 (180), a lack of commensal bacterial DNA which cannot induce protective 
signalling through TLR9 (181). Therefore, as bacteria are required for the correct development of 
tolerance, we used P3CK to pre-stimulate the Caco-2 cells, simulating the microbiota’s ability to 
tolerize the epithelium. We recognize that other mechanisms are possible in a multi-cell intestine. 
 
The experimental method for inducing tolerance described in Figure 3-2 in Caco-2 cells was 
modified to investigate whether epithelial cells can be cross-tolerized to different pro-inflammatory 
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stimuli. This modification was to pre-stimulate the Caco-2 cells with P3CK before the stimulation 
with IL-1β (Figure 3-2). This model is a simple representation of the microbiota tolerizing the 
intestinal epithelial cells to subsequent stimulations by pro-inflammatory cytokines e.g. IL-1β. 48 
hours prior to sample collection, the tolerized and cross-tolerized cells were pre-stimulated with 1 
ng/ml IL-1β and 25 μg/ml P3CK, respectively for 24 hours. 24 hours prior to sample collection, 
both tolerized and cross-tolerized cells, in addition to the stimulated cells, were further stimulated 
with 1 ng/ml IL-1β for another 24 hours. All CXCL8 production values were converted to a 
percentage of the mean IL-1β-stimulated production of CXCL8.  
 
The production of CXCL8 was greatest by the cells that were stimulated once by IL-1β and was 
decreased to 50% by the IL-1β-only-tolerized cells (Figure 4-20). The cross-tolerized cells (cells 
pre-stimulated with P3CK) expressed a statistically significant increase in CXCL8 production than 
the cells tolerized with IL-1β alone (P<0.001), but less than the cells that were only stimulated 
once with IL-1β (78%) (Figure 4-20). This was a statistically significant reduction, as calculated by 
Student’s t-test (P<0.001), thus bacterial products can cause intestinal epithelial cells to be 
hyporesponsive to IL-1β stimulation.  
 
The CXCL8 values normalized to the total protein content are plotted in Figure 4-21. CXCL8 
production is greatest in stimulated cells, reduced to approximately half the amount in tolerized 
cells and reduced in cross-tolerized cells, but to about three-quarters of the amount of stimulated 
cells. This is the same effect seen in Figure 4-20, but the range of values is larger, as shown by 
the larger error bars and the reduction in statistical significance between tolerized and cross-
tolerized cells from P<0.001 to P<0.01. 
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Figure 4-20 Cross-Tolerization of Intestinal Epithelial (Caco-2) Cells to IL-1β by P3CK 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. Cross-tolerance was established by pre-stimulating Caco-2 cells with 25 
µg/ml P3CK for 24 hours before stimulating them with 1 ng/ml IL-1β for another 24 hours. CXCL8 production was 
measured by ELISA and normalized to cellular protein content (measured by BCA protein assay). Multiple 
experiments were combined by calculating CXCL8 production as a percentage of the mean CXCL8 production per 
single stimulation of IL-1β. Bars represent mean ± SEM, n = 5. Statistical analysis was performed using the Student’s 
t-test. *** signifies P<0.001. 
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Figure 4-21 Cross-Tolerization of Intestinal Epithelial (Caco-2) Cells to IL-1β by P3CK 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. Cross-tolerance was established by pre-stimulating Caco-2 cells with 25 
µg/ml P3CK for 24 hours before stimulating them with 1 ng/ml IL-1β for another 24 hours. CXCL8 production was 
measured by ELISA and normalized to cellular protein content (measured by BCA protein assay). Bars represent 
mean ± SEM, n = 5. Statistical analysis was performed using the Student’s t-test. ** and *** signifies P<0.01 and 
<0.001, respectively. 
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4.3 Conclusions 
 
In conclusion, both P3CK and IL-1β stimulate and tolerize Caco-2 cells. NCM460 cells are 
tolerized by P3CK, but are unresponsive to stimulation by IL-1β. Tolerance is therefore a true and 
reproducible effect in intestinal epithelial cells. Tolerance to P3CK in NCM460 cells demonstrates 
that tolerance is not a phenomenon seen only in malignant cells. Due to the greater stimulation of 
Caco-2 cells by IL-1β than NCM460 cells by P3CK, all further experiments examining the 
underlying mechanisms of tolerance regulation were designed using Caco-2 cells and IL-1β. This 
is because the greater the CXCL8 production, the easier it is to induce tolerance and achieve a 
statistically significant difference. It was also more economical to use IL-1β than P3CK as it is a 
more potent agonist (1 ng/ml IL-1β produces more CXCL8 than 25 µg/ml P3CK). The ability of 
P3CK to cross-tolerize Caco-2 cells to IL-1β represents an ability of the microbiota to tolerize the 
epithelium to a pro-inflammatory stimulus. 
 
The combination of ELISA data from pre-stimulated only Caco-2 cells and the qPCR data show 
that the induction of CXCL8 is finished before the second IL-1β-stimulation and therefore the 
reduction in CXCL8 expression seen in tolerized cells is due to tolerance and not the end of a 
previous stimulation.  
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5 Histone Methylation and its Effect on Tolerance in Intestinal 
Epithelial Cells 
 
Epigenetic involvement in tolerance in macrophages has been proposed by several groups (81, 
87), but has not been investigated in epithelial cells. This can be examined by modifying the 
existing epigenetic features and measuring their effect on tolerance. For example, a histone 
lysine methyltransferase inhibitor will decrease the level of methylation present at a particular 
epigenetic locus. If this then causes a change in the level of CXCL8 produced when the cells are 
stimulated the second time with IL-1β, as compared to when the inhibitor is not present, 
epigenetics has an involvement in tolerance 
 
The effect of epigenetic modifying enzyme inhibitors, in this work, was focussed on three specific 
epigenetic markers: H3K4me3, H3K9me3 and H3K27me3. Tri-methylated residues rather than 
mono- or di-methylated residues are most likely to be affected by epigenetic inhibitors, as they 
have the greatest number of methyl groups. A methyltransferase inhibitor should prevent the 
formation of tri-methylated residues as a residue needs to be mono- and then di-methylated first 
before it can be tri-methylated. Conversely, demethylase inhibitors will prevent the conversion of 
tri-methylated residues to di-methylated residues. However, inhibition of the other demethylases 
should increase the substrates available for the tri-methyl-methyltransferases thus promoting the 
formation of tri-methylated residues. If a study of epigenetic inhibition were to focus on mono- or 
di-methylated residues, it is possible that no change would be seen as an increase in di-
methylation would act as a substrate for di-methyl-demethylases and tri-methyl-
methyltransferases.  
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H3K4me3, H3K9me3 and H3K27me3 affect transcription and are therefore likely to be involved in 
regulation of tolerance that is based on gene regulation. In most cell-types under the majority of 
circumstances, H3K4me3 is associated with transcriptional activation whilst both H3K9me3 and 
H3K27me3 are associated with transcriptional repression (122). Although other epigenetic 
markers may be involved in tolerance and the inhibitors chosen may affect multiple markers, it is 
the most efficient use of time and resources to concentrate on these three, as they were used to 
examine the principle that histone methylation might affect tolerance. It was not our aim to 
examine every aspect of the molecular mechanisms underlying tolerance, but to establish the 
principle that histone methylation is an integral part of the regulatory system. 
 
 
5.1 Inhibition of Histone Methyltransferases 
 
Evidence for the involvement of epigenetics can be determined by altering the activity of 
epigenetic enzymes using small molecule inhibitors. A range of histone methyltransferase and 
histone demethylase inhibitors was used to alter the methylation level of particular Histone H3 
lysine residues. Table 5-1 lists the epigenetic inhibitors used for this research with the enzyme 
specificity and the predicted effect on particular Histone H3 lysine residues. As inhibitor specificity 
is determined in vitro using purified enzymes and synthetic histone proteins, it is possible that the 
expected effect on relative histone methylation amounts will not be produced in vivo in intestinal 
epithelial cells.  
 
Two inhibitors were chosen for activity against histone methyltransferases and histone 
demethylases. One of the inhibitors for each class of enzymes had a broad range of activity, 
whilst the other inhibitor had specific activity against one enzyme or range of enzymes for one 
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particular histone H3 residue. Though SAH, for example, was predicted to affect many histone 
methyltransferases, its main effect was predicted to be on Histone H3K27me3. Chaetocin, as a 
specific inhibitor of SU(VAR)3-9, which is a K9-specific histone methyltransferase, is predicted to 
effect the methylation level of H3K9me3 most. Both demethylase inhibitors, 2,4-PDCA and 
pargyline hydrochloride, are predicted to affect the levels of H3K4me3, though pargyline 
hydrochloride should also alter the level of H3K9me3.  
 
Inhibitor Enzyme Enzyme Specificity Potential Histone Residue Affected 
S-adenosyl-L-
homocysteine (SAH) Methyltransferase Broad 
H3K27me3 ↓, 
(H3K9me3 ↓, 
H3K4me3 ↓) 
Chaetocin Methyltransferase H3K9-specific H3K9me3 ↓ 
Pargyline 
hydrochloride Demethylase 
Monoamine oxidase-specific, 
broad demethylase range 
H3K4me3 ↑, 
H3K9me3 ↑ 
2,4-
pyridinedicarboxylic 
acid (2,4-PDCA) 
Demethylase H3K4-specific H3K4me3 ↑ 
Table 5-1 Table of Epigenetic Inhibitors and Their Predicted Effect on Histone H3 Lysine Residues 
A table listing the small molecule inhibitors of histone methyltransferases and histone demethylases used in this 
research with their enzyme specificity and predicted effect on Histone H3 lysine residues from a variety of cell lines.   
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5.1.1 S-adenosyl-L-homocysteine (SAH) 
A literature search was performed to find existing histone methyltransferase inhibitors. This was 
achieved by performing a web-search for commercially available inhibitors, as well as searching 
PubMed for published data on histone methyltransferases. Non-specific inhibitors were prioritised 
as the particular enzymes, as well as the specific histone methylation marks themselves, are 
unknown. S-adenosyl-L-homocysteine (SAH) (Figure 5-1) was chosen as it is a non-specific 
inhibitor of multiple histone methyltransferases. It is also the product of S-adenosyl-methionine 
(SAM)-dependent methylation of DNA, RNA and proteins and therefore acts as a natural 
competitor and competitive inhibitor of methyltransferases (182).  
 
 
Figure 5-1 Structure of S-adenosyl-L-homocysteine (SAH) 
The 3D chemical structure of S-adenosyl-L-homocysteine (taken as a screenshot from the Cayman Chemical 
website (182)).  
 
Intestinal epithelial cells were incubated with 0, 1 or 100 µM SAH for 72 hours and the histones 
extracted for Western Blot analysis of methylation levels. As shown in Figure 5-2, both H3K9me3 
and H3K27me3 increased in methylation levels as the concentration of SAH increases. H3K9me3 
increased by 2.2 fold and H3K27me3 by 1.6 fold. This was contrary to expectation as SAH is a 
histone methyltransferase inhibitor so it would be expected that as the level of SAH increases, the 
amount of histone methylation decreases. Whilst this was surprising, it was reproducible (Figure 
5-3) and we have a possible explanation: SAH may degrade in vivo to adenosine and 
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homocysteine and increase the SAM/SAH ratio. SAM acts as a substrate for histone 
methyltransferases and promotes histone methylation (183) therefore the amount of histone 
methylation would increase as the concentration of SAH increases, thus explaining the effect 
seen once in Figure 5-2 and reproducibly in Figure 5-3. 
 
The fold changes in methylation resulting from SAH were plotted as shown in Figure 5-3. 
H3K9me3 (shown in purple) did not significantly vary as the concentration of SAH increased. 
Whilst both H3K4me3 (blue) and H3K27me3 (brown) showed a ~1.5-fold increase in methylation 
at 1 µM, only the increase in H3K27me3 showed a statistically significant increase (P<0.05). 
However, in parallel with previous experiments that investigated the effect of SAH on histone 
methylation levels (184) all further experiments with SAH used 100 µM to test its effect on 
modifying tolerance.  
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Figure 5-2 Dose-Response Effect of SAH on Histone Methylation 
Caco-2 cells were incubated with 0, 1 or 100 µM SAH for 72 hours. Histones were extracted according to the Histone 
Acid Extraction Protocol from Abcam and the amount measured by BCA assay. Equal amounts of histone protein 
were loaded onto 12% agarose gels and separated by gel electrophoresis before being transferred to PVDF 
membranes. Membranes were blocked in 5% milk in 0.1% TBST, incubated with the primary antibody (Histone H3, 
H3K4me3, H3K9me3 or H3K27me3) at 4 °C overnight and detected with an anti-rabbit secondary antibody. Bands 
were visualised using ECL detection reagent and hyperfilm developer. ImageJ software was used to normalise the 
histone H3 bands to each other and calculate the adjusted density values for each histone methylation marker. 
Representative of n=5 experiments – see Figure 5-3. 
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Figure 5-3 Dose-Response Effect of SAH on Methylation Levels at Specific Histone H3 Lysine 
Positions  
Western blots were performed on histone samples extracted from Caco-2 cells incubated with a ten-fold serial 
dilution of SAH ranging from 100 µM to 0.01 µM for 24 hours. ImageJ software was used to normalise the histone 
H3 bands to each other and calculate the adjusted density values for each histone methylation marker. The fold-
changes in adjusted density of all SAH Western Blots were compiled and the adjusted densitometry plotted against 
the concentration of SAH used for each of the three epigenetic marks H3K4me3, H3K9me3 and H3K27me3. 
Statistical analysis was performed using the Student’s t-test. n = 5. * represents P<0.05. 
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Western blotting produces qualitative results, which can be analysed statistically. However, a 
technique which produces quantitative results enables statistical analysis to be performed. 
Therefore, histone samples that were extracted from Caco-2 cells that had been incubated with 0 
and 100 µM SAH were interrogated using the Histone H3 PTM Multiplex assay from Active Motif 
(Methods 3.8). This technique uses a smaller amount of protein than Western blotting to measure 
the level of methylation present at multiple histone H3 lysine residues. The sample binds to the 
PTM antibody-conjugated magnetic bead and forms a sandwich complex with a biotinylated 
histone H3 antibody. This histone-antibody sandwich binds proportionally to streptavidin-
phycoerythrin, according to the amount of PTM histone present. The fluorescence emitted by the 
streptavidin-phycoerythrin is measured using Luminex technology and converted into quantitative 
median fluorescence intensity (MFI) value. This is normalised to the total histone H3 protein 
present.  
 
Figure 5-4 represents the MFI of H3K4me3, H3K9me3 and H3K27me3 in Caco-2 cells incubated 
with 100 µM SAH as a percentage of the methylation level of each residue in Caco-2 cells that 
have not been incubated with SAH. H3K4me3 and H3K9me3 levels were unaltered by SAH, 
comparable to the Western blotting results. However, H3K27me3 levels were shown to decrease, 
by a statistically significant amount (P<0.01), when Caco-2 cells are incubated with 100 µM SAH 
(Figure 5-4). This is the opposite effect to what is seen in Western blotting, though the expected 
effect of a histone methyltransferase inhibitor. This could be due to the increased sensitivity of the 
multiplex assay in comparison to Western blotting or interactions between the multiple antibodies 
preventing the H3K27me3 antibody in the multiplex solution from binding to its epitope resulting in 
an artificial decrease in H3K27me3 levels. 
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Figure 5-4 Effect of 100 µM SAH on Methylation Levels at Specific Histone H3 Lysine Positions 
Caco-2 cells were incubated with 0 and 100 µM SAH for 24 hours. Histones were extracted according to the Histone 
Acid Extraction Protocol from Abcam and the amount measured by BCA assay. Equal amounts of histone protein 
were analysed for methylation levels of H3K4me3, H3K9me3 and H3K27me3 using the Histone H3 PTM Multiplex kit 
from Active Motif. Histone proteins were incubated with H3K4me3, H3K9me3 and H3K27me3 antibody conjugated 
magnetic beads. Biotinylated Histone H3 antibody and streptavidin-phycoerythrin were added and the resulting 
fluorescent complex was read by a MAGPIX™ instrument with xPONENT® software. The amount of fluorescence 
(MFI) for each methylated residue was normalized to total Histone H3. Multiple experiments were combined by 
plotting the MFI of each methylated residue at 100 µM SAH as a percentage of the MFI of each methylated residue 
at 0 µM SAH (control). Statistical analysis was performed using the Student’s t-test. n = 3. ** represents P<0.01. 
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5.1.2 Chaetocin 
Though SAH is a non-specific histone methyltransferase inhibitor, it has been demonstrated here 
by Western Blotting and use of multiplexed antibodies on Luminex beads that SAH only 
significantly affects H3K27me3 levels. Therefore, an alternative methyltransferase inhibitor was 
chosen with specific activity against a different histone lysine residue. Chaetocin is a 3,6-
epidithio-diketopiperazine (ETP) metabolite from the fungus Chaetomium minutum. It is a cis 
fused dimer of two five-membered rings, as shown in Figure 5-5. Inhibition studies by Cherblanc 
et al have shown that only the unique ETP core of Chaetocin is required for inhibition of histone 
methyltransferases by forming a covalent bond between Chaetocin and the enzyme (185). As 
well as being a specific inhibitor of the histone lysine methyltransferase SUV39H1 (IC50 = 0.8 µM) 
(186), Chaetocin has also been shown to have antimicrobial  (187), antitumour (188) and 
cytotoxic (189) activity. SUV39H1 is responsible for methylating lysine9 on Histone H3, a 
repressive epigenetic marker. Therefore, inhibiting H3K9 methylation with Chaetocin will 
determine whether epigenetic repression is involved in the regulation of immune tolerance in 
intestinal epithelial cells. 
 
  
Figure 5-5 Structure of Chaetocin 
The 3D chemical structure of Chaetocin (taken as a screenshot from the Tocris website (190)). 
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Caco-2 cells were incubated with a 10-fold serially diluted range of Chaetocin concentrations 
beginning at 5000 nM for 18 hours. Based on the data in Tran et al. (191), and the IC50 data, 
5000 nM was chosen as the maximum concentration for the dose-response curve. It is almost 10-
fold more concentrated than required to inhibit the enzyme activity to 50%. 100 – 200 nM 
Chaetocin reduced the level of methylation at H3K9. The histones were extracted using the acid 
extraction protocol from Abcam and the methylation status investigated by Western Blotting. As 
shown in Figure 5-6, although the methylation status of the three lysine residues tested varied 
across the range of Chaetocin concentrations used, only H3K9me3 showed a two-fold increase in 
methylation in cells incubated with 500 nM Chaetocin compared to cells incubated without 
Chaetocin. Chaetocin is an inhibitor of a methyltransferase and as such the degree of methylation 
would be expected to decrease as the concentration of Chaetocin increases. The data (Figure 
5-6) showed the opposite effect to that which was predicted. Though the results with a Chaetocin 
concentration of 5000 nM are included, the Caco-2 cells showed significant toxicity to Chaetocin 
at this concentration.  
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Figure 5-6 Dose-Response Effect of Chaetocin on Histone Methylation 
Caco-2 cells were incubated with a ten-fold serial dilution of Chaetocin starting at 5000 nM for 18 hours, with an 
additional condition at 100 nM. Histones were extracted according to the Histone Acid Extraction Protocol from 
Abcam and the amount measured by BCA assay. Equal amounts of histone protein were loaded onto 12% agarose 
gels and separated by gel electrophoresis before being transferred to PVDF membranes. Membranes were blocked 
in 5% milk in 0.1% TBST, incubated with the primary antibody (Histone H3, H3K4me3, H3K9me3 or H3K27me3) at 4 
°C overnight and detected with an anti-rabbit secondary antibody. Bands were visualised using ECL detection 
reagent and hyperfilm developer. ImageJ software was used to normalise the histone H3 bands to each other and 
calculate the adjusted density values for each histone methylation marker. Representative of n=5 experiments – see 
Figure 5-7. 
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The fold changes in methylation resulting from Chaetocin were plotted as shown in Figure 5-7. 
The amount of H3K4me3 was reduced by ~0.5-fold at both 100 nM and 500 nM Chaetocin 
(P<0.05). H3K27me3 levels were reduced by ~0.6-fold and ~0.4-fold at 50 nM and 100 nM 
Chaetocin, respectively (P<0.05). When multiple experiments were combined, H3K9me3 levels 
were reduced by ~0.7-fold at both 50 nM and 100 nM Chaetocin (P<0.05). 500 nM and 5000 nM 
Chaetocin produced an increase in the amount of H3K9me3 and H3K27me3, which was contrary 
to expectation. This was likely due to the high amount of cell death present at these higher 
concentrations and therefore 100 nM Chaetocin was used for all further experiments. 
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Figure 5-7 Effect of Chaetocin on Methylation Levels at Specific Histone H3 Lysine Positions 
Western blots were performed on histone samples extracted from Caco-2 cells incubated with ten-fold serial dilutions 
of Chaetocin ranging from 5000 nM to 0.5 nM for 18 hours. ImageJ software was used to normalise the histone H3 
bands to each other and calculate the adjusted density values for each histone methylation marker. The fold-changes 
in adjusted density of all Chaetocin Western Blots were compiled and the adjusted densitometry plotted against the 
concentration of Chaetocin used for each of the three epigenetic marks H3K4me3, H3K9me3 and H3K27me3. 
Statistical analysis was performed using the Student’s t-test. n = 5. * represents P<0.05. 
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5.2 Effect of Histone Methyltransferase Inhibition on Immune Tolerance in 
Intestinal Epithelial Cells 
 
5.2.1 S-adenosyl-L-homocysteine (SAH) 
We examined if altering histone methylation affected CXCL8 production and therefore had an 
impact on tolerance. This was established by comparing the CXCL8 production of cells that were 
stimulated with 1 ng/ml IL-1β for 24 hours and cells that were stimulated with 1 ng/ml IL-1β twice 
for 24 hours each with cells that had been incubated with different concentrations of SAH as well 
as being tolerized by 1 ng/ml IL-1β (Figure 3-7). Conditioned media were collected and the 
amount of CXCL8 produced measured by ELISA and normalized to the cellular protein content, 
as measured by BCA assay.  
 
As shown in Figure 5-8, the production of CXCL8 is greatest in the cells that have only been 
stimulated once with IL-1β and is decreased, but still greater than the unstimulated control cells, 
in the cells that have been tolerized, as described in Chapter 4, Figure 4-16. This decrease is a 
statistically significant difference (P<0.001), as calculated by Student’s t test. The addition of SAH 
to the tolerized cells did not significantly alter CXCL8 production compared to CXCL8 produced 
by tolerized cells alone, except when SAH is at 100 µM. The addition of 100 µM SAH to Caco-2 
cells tolerized with IL-1β resulted in an increase in CXCL8 production that was statistically 
significantly greater than that of tolerized cells alone but is less than that of stimulated cells 
(P<0.05, in each case). The results of the statistical tests (P<0.05) showing a significant 
difference between each of the 50 – 90 µM SAH concentrations and stimulated cells are omitted 
for clarity. Therefore, 72 hours incubation with 100 µM SAH causes cells that have been 
stimulated twice with IL-1β to break tolerance.  
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Figure 5-8 Incubation of SAH with Intestinal Epithelial (Caco-2) Cells to Break Tolerance 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-7. SAH was diluted to the required concentrations (50-100 µM) and incubated 
with Caco-2 cells for 72 hours in total, as described for 100 µM SAH in Figure 3-7. Caco-2 cells were tolerized by a 
prior stimulation with 1 ng/ml IL-1β for 24 hours followed by stimulation with 1 ng/ml IL-1β for 24 hours, as well as 
being incubated with fresh preparations of SAH (if required). CXCL8 production was measured by ELISA and 
normalized to cellular protein content (measured by BCA protein assay). Multiple experiments were combined by 
calculating CXCL8 production as a percentage of the mean CXCL8 production per single stimulation of IL-1β. Bars 
represent mean ± SEM, n = 3. Statistical analysis was performed using the Student’s t-test and Mann-Whitney U 
test. n = 5. * and *** represent P<0.05 and <0.001, respectively. 
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After confirming that SAH had an effect on tolerance, the time period necessary to cause that 
effect was investigated. Tolerized cells were incubated with 100 µM SAH at different time points 
and for different periods of time: 24 (prior to IL-1β stimulation, with the first IL-1β stimulation and 
with the second IL-1β stimulation), 48 (not including the second IL-1β stimulation and not 
including the 24 hours before IL-1β stimulation) and 72 hours. Only 72 hours incubation with 100 
µM SAH resulted in a statistically significantly increased production of CXCL8 (Figure 5-9). All of 
the tolerized + SAH conditions produced a statistically significant reduction of CXCL8 compared 
to stimulated cells, though the results of the statistical tests (P<0.05) are omitted from Figure 5-9 
for clarity. Figure 5-9 emphasises the importance of inhibitor incubation time on the ability to 
break tolerance. 
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Figure 5-9 Effect of SAH Given at Different Time Points on Tolerization of Intestinal Epithelial (Caco-
2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. SAH was diluted to 100 µM and incubated with Caco-2 cells for 24, 48 or 72 
hours prior to sample collection. Fresh preparations of SAH (if required) and two stimulations of 1 ng/ml IL-1β 24 
hours apart were added to the cells. CXCL8 production was measured by ELISA and normalized to cellular protein 
content (measured by BCA protein assay). Multiple experiments were combined by calculating CXCL8 production as 
a percentage of the mean CXCL8 production per single stimulation of IL-1β. Bars represent mean ± SEM, n = 3. 
Statistical analysis was performed using the Student’s t-test and Mann-Whitney U test. n = 4. * and *** represent 
P<0.05 and <0.001, respectively. 
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The effect of SAH on tolerized cells was confirmed. The effect on unstimulated and stimulated 
cells was also tested for by incubating Caco-2 cells with 100 µM SAH for 72 hours and IL-1β if 
required. Though the sample variation is greater in the cells treated with SAH than in the cells not 
treated with SAH, it is not a statistically significant difference. It is only for tolerized cells that 
treatment with SAH affects the production of CXCL8 to a statistically significant level (p<0.05) 
(Figure 5-10). Therefore, SAH breaks tolerance, thus showing that using an agent capable of 
modifying histone methylation has an effect on tolerance. 
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Figure 5-10 Effect of SAH on Control, Stimulated and Tolerized Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-7. SAH was diluted to 100 µM and incubated with control, stimulated and 
tolerized Caco-2 cells for 72 hours (48 hours for stimulated cells) prior to sample collection. Fresh preparations of 
SAH (if no IL-1β was required) and two stimulations of 1 ng/ml IL-1β 24 hours apart were added to the cells. CXCL8 
production was measured by ELISA and normalized to cellular protein content (measured by BCA protein assay). 
Multiple experiments were combined by calculating CXCL8 production as a percentage of the mean CXCL8 
production per single stimulation of IL-1β. Bars represent mean ± SEM, n = 3. Statistical analysis was performed 
using the Student’s t-test and Mann-Whitney U test. n = 4. * and *** represent P<0.05 and <0.001, respectively. 
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The effect of SAH on tolerized cells is also shown in Figure 5-11, but the normalized CXCL8 
values in pg/mg protein are plotted instead of percentages of the mean stimulated amount. Like 
the same conditions in Figure 5-10, Figure 5-11 shows that the tolerized cells express ~50% the 
amount of CXCL8 as stimulated cells (P<0.001). The tolerized cells that are incubated with 100 
µM SAH express a statistically significant greater amount of CXCL8 than tolerized cells alone do 
(P<0.05). However, even though it is a statistically significant difference, it is only a small 
increase in CXCL8 production. Plotting the original normalized values highlights the range of 
values produced each time the experiment is repeated. Though the effect is the same for each 
repetition, the actual values vary. By representing the values as a percentage of the mean 
stimulated amount the values are brought closer together as shown by the tighter error bars in 
Figure 5-10. 
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Figure 5-11 Effect of SAH on Tolerization of Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-7. SAH was diluted to 100 µM and incubated with tolerized Caco-2 cells for 72 
hours prior to sample collection. Fresh preparations of SAH and two stimulations of 1 ng/ml IL-1β 24 hours apart 
were added to the cells. CXCL8 production was measured by ELISA and normalized to cellular protein content 
(measured by BCA protein assay). Bars represent mean ± SEM, n = 4. Statistical analysis was performed using the 
Mann-Whitney U test. * and *** represent P<0.05 and <0.001, respectively. 
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5.2.2 Chaetocin 
Chaetocin was also investigated for its effect on tolerance in intestinal epithelial cells. SAH is a 
broad spectrum histone methyltransferase inhibitor, so a more specific inhibitor with an effect on 
a different epigenetic marker was investigated to see if the same effect on tolerance was seen. 
As determined by Western blotting of a range of Chaetocin concentrations, 100 nM Chaetocin 
was incubated with Caco-2 cells for 1 hour prior to stimulation by IL-1β (or at that time point in the 
unstimulated cells) and was added directly into the media for 8 or 18 hours prior to sample 
collection. In data not shown, cells incubated with 100 nM Chaetocin for greater than 12 hours 
died (data not shown). One hour incubation was not enough to alter the methylation level of 
epigenetic markers but if incubated for too long the cells did not survive, so the incubation period 
was separated into two periods of short duration, as described in Figure 3-7.  
 
Unstimulated Caco-2 cells incubated with Chaetocin had a small increase in CXCL8 production 
(P<0.05). Stimulated (1+8 hrs) cells showed no difference in CXCL8 production but stimulated 
(1+18 hrs) showed a large increase in the production of CXCL8 (P<0.001) (Figure 5-12). The 
variation is much larger in all of the Chaetocin incubated samples compared to the non-Chaetocin 
counterparts, due to cell death creating artificially increased values thus enhancing the p value. 
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Figure 5-12 Effect of Chaetocin on Control and Stimulated Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. Chaetocin was diluted to 100 nM and incubated with control and stimulated 
Caco-2 cells for 1 hour followed by fresh media/ 1ng/ml IL-1β for 18 hours then 100 nM Chaetocin added directly to 
the cells for 8 hours. CXCL8 production was measured by ELISA and normalized to cellular protein content 
(measured by BCA protein assay). Multiple experiments were combined by calculating CXCL8 production as a 
percentage of the mean CXCL8 production per single stimulation of IL-1β. Bars represent mean ± SEM, n = 3. 
Statistical analysis was performed using the Student’s t-test and Mann-Whitney U test. *, ** and *** represent P<0.05, 
<0.01 and <0.001, respectively. 
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The effect of Chaetocin on tolerance was investigated by incubating Caco-2 cells with 100 nM 
Chaetocin for one hour prior to the second IL-1β stimulation and again 8 or 18 hours before 
sample collection (Figure 3-7). As seen in Figure 5-13, both incubation times result in an 
increased level of CXCL8 production compared to tolerized only cells (P<0.001) showing that 
incubation with Chaetocin breaks tolerance. CXCL8 produced by 1 + 8 hours incubation is 
statistically significantly lower than stimulated cells (P<0.001) but there is no statistical difference 
between tolerized + 100 nM Chaetocin (1 + 18 hours) cells and stimulated only cells (P>0.05). 
Although 1 + 8 hours incubation is sufficient to break tolerance, an increase in the incubation 
length of the epigenetic inhibitor Chaetocin is associated with an increase in CXCL8 production. 
 
In summary, whilst both SAH and Chaetocin increase histone methylation levels at H3K9 and 
H3K27, as measured by Western blotting, SAH causes a decrease in H3K27me3 levels when 
measured using the Histone H3 PTM Multiplex Luminex technology. Tolerance is broken 
following incubation with either inhibitor, thereby proving that tolerance is regulated, at least in 
part, by epigenetics. 
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Figure 5-13 Effect of Chaetocin on Tolerization of Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-7. Chaetocin was added directly to pre-stimulated Caco-2 cells at a 
concentration of 100 nM for 1 hour. The second stimulation with IL-1β was followed by another incubation with 100 
nM Chaetocin for 8 or 18 hours prior to sample collection, as described in Figure 3-7. CXCL8 production was 
measured by ELISA and normalized to cellular protein content (measured by BCA protein assay). Multiple 
experiments were combined by calculating CXCL8 production as a percentage of the mean CXCL8 production per 
single stimulation of IL-1β. Bars represent mean ± SEM, n = 5. Statistical analysis was performed using the Student’s 
t-test and Mann-Whitney U test. *** represents P<0.001. 
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The effect of Chaetocin on tolerized cells is also shown in Figure 5-14, but the normalized CXCL8 
values in pg/mg protein are plotted instead of percentages of the mean stimulated amount. Like 
the same conditions in Figure 5-13, Figure 5-14 shows that the tolerized cells express ~25% of 
the amount of CXCL8 as stimulated cells (P<0.001). The tolerized cells that are incubated with 
100 nM Chaetocin express a statistically significant greater amount of CXCL8 than tolerized cells 
alone do (P<0.01 for 1 + 8 hours and P<0.001 for 1 + 18 hours). Due to the greater range of 
values in each condition, the statistical significance of some tests in Figure 5-13 and Figure 5-14 
are different. Though in Figure 5-13 tolerized + Chaetocin for 1 + 18 hours cells do not produce a 
statistically significant reduction in CXCL8 in comparison to stimulated cells, the original 
normalized values in Figure 5-14 show that there is a reduction. Incubating tolerized cells with 
Chaetocin for 1 + 8 hours produces a statistically significant increase in CXCL8 compared to 
tolerized cells only. This has a P value of <0.01 in Figure 5-14 but <0.001 in Figure 5-13. This is 
due to the smaller spread of the values in Figure 5-13 compared to Figure 5-14. 
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Figure 5-14 Effect of Chaetocin on Tolerization of Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-7. Chaetocin was added directly to pre-stimulated Caco-2 cells at a 
concentration of 100 nM for 1 hour. The second stimulation with IL-1β was followed by another incubation with 100 
nM Chaetocin for 8 or 18 hours prior to sample collection, as described in Figure 3-7. CXCL8 production was 
measured by ELISA and normalized to cellular protein content (measured by BCA protein assay). Bars represent 
mean ± SEM, n = 5. Statistical analysis was performed using the Student’s t-test and Mann-Whitney U test. ** and 
*** represent P<0.01 and <0.001, respectively. 
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5.3 Inhibition of Histone Demethylases 
 
Histone lysine demethylases have the opposite function to histone methyltransferases as they 
catalyse the removal of a methyl group from the lysine residue in histone proteins, rather than 
catalyse methylation. Histone lysine demethylases were not discovered until 2004 (192) thereby 
proving that histone methylation is not an irreversible process as previously thought (193).  
 
 
5.3.1 Pargyline 
Pargyline was first developed as a non-selective monoamine oxidase inhibitor with 
antihypertensive and antidepressive properties (194). It was marketed under the name Eutonyl 
until its discontinuation in 2007 due to its interaction with other non-prescribed compounds (195). 
Pargyline and other monoamine oxidase inhibitors prevent the metabolism of tyramine, commonly 
found in certain foods and drinks including anchovies, sherry, salami, bananas, soy sauce etc, 
resulting in severe headaches and cerebral haemorrhages, hence the discontinuation of pargyline 
as a therapeutic drug. Pargyline inhibits monoamine oxidases by covalently binding to the FAD 
cofactor in the enzyme’s active site, as shown by the crystal structure produced by Binda et al 
(196). The alkyne moiety in the pargyline structure (Figure 5-15) reacts with the flavin-dependent 
enzyme cofactor, creating a covalent adduct and inhibiting FAD-dependent enzymes. 
 
The structural similarity of monoamine oxidases to other FAD-dependent enzymes, including 
LSD1 (lysine specific demethylase 1), implies that pargyline will bind to and inhibit histone 
demethylases as well (197). LSD1 catalyses the demethylation of mono- and di-methylated 
173 
 
lysines 4 and 9 in Histone H3 (H3K4 and H3K9). As the concentration of pargyline increases, the 
relative amount of H3K4me2 also increases (198).  
 
 
Figure 5-15 Chemical Structure of Pargyline Hydrochloride 
Chemical structure of Pargyline hydrochloride taken as a screenshot from the Cayman Chemical  website (199). 
 
Caco-2 cells were incubated for 1 hour with a range of pargyline concentrations starting at 3 mM 
and diluted ten-fold each time until 0.3 µM was reached. As pargyline is an inhibitor of histone 
demethylases, the amount of methylation should increase as the concentration of pargyline 
increases. As shown in Figure 5-16, the amount of H3K4me3 and H3K9me3 increases as the 
concentration of pargyline increases. H3K4me3 increases 1.6-fold whilst a much smaller effect is 
had on H3K9me3. Figure 5-16 is representative of n=5 experiments, which are combined in 
Figure 5-17. LSD1 is an H3K4me2 and H3K9me2 specific demethylase. Therefore as the 
concentration of pargyline increases, the amount of H3K4me2/H3K9me2 increases thus 
increasing the amount of substrate for the H3K4me3/H3K9me3 methyltransferase resulting in an 
increased amount of H3K4me3/H3K9me3. H3K9me2 is only a specific substrate for LSD1 when it 
is coupled to the androgen receptor, therefore its inhibition by pargyline will have a greater effect 
on H3K4me3 than H3K9me3, as shown in Figure 5-16. 
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Figure 5-16 Dose-Response Effect of Pargyline on Histone Methylation 
Caco-2 cells were incubated with a ten-fold serial dilution of Pargyline hydrochloride starting at 3 mM for 1 hour. 
Histones were extracted according to the Histone Acid Extraction Protocol from Abcam and the amount measured by 
BCA assay. Equal amounts of histone protein were loaded onto 12% agarose gels and separated by gel 
electrophoresis before being transferred to PVDF membranes. Membranes were blocked in 5% milk in 0.1% TBST, 
incubated with the primary antibody (Histone H3, H3K4me3, H3K9me3 or H3K27me3) at 4 °C overnight and 
detected with an anti-rabbit secondary antibody. Bands were visualised using ECL detection reagent and hyperfilm 
developer. ImageJ software was used to normalise the histone H3 bands to each other and calculate the adjusted 
density values for each histone methylation marker. Representative of n=5 experiments – see Figure 5-17. 
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The fold changes in methylation resulting from pargyline were plotted as shown in Figure 5-17. 
H3K27me3 (shown in brown) does not significantly vary as the concentration of pargyline 
increases. This is as expected as pargyline is not known to have activity against any H3K27 
specific demethylases. A subtle, but statistically significant (ANOVA P=0.0163) increase in the 
amount of H3K9me3 (shown in purple) across all concentrations of pargyline was found, though 
the only concentrations to produce a statistically significant increase were 0.003 and 0.3 mM. 
Pargyline mainly affects the level of H3K4me3, as shown in blue in Figure 5-17. A statistically 
significant increase in the amount of H3K4me3 across all concentrations was found (ANOVA 
P=0.0012). Each concentration of pargyline between 3 mM and 0.003 mM causes a maximal two-
fold increase in the amount of H3K4me3 (P<0.05). 3 mM pargyline hydrochloride was used for all 
subsequent experiments to ensure maximal inhibition. 
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Figure 5-17 Effect of Pargyline on Methylation Levels at Specific Histone H3 Lysine Positions 
Western blots were performed on histone samples extracted from Caco-2 cells incubated with a ten-fold serial 
dilution of pargyline hydrochloride ranging from 3 mM to 3 µM for 24 hours. ImageJ software was used to normalise 
the histone H3 bands to each other and calculate the adjusted density values for each histone methylation marker. 
The fold-changes in adjusted density of all pargyline Western blots were compiled and the adjusted densitometry 
plotted against the concentration of pargyline used for each of the three epigenetic marks H3K4me3, H3K9me3 and 
H3K27me3. Statistical analysis was performed using the Student’s t-test. n = 5. * represents P<0.05. 
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In experiments on macrophages undertaken by Foster et al, pargyline was incubated with the 
cells for 1 hour only. In our experiments, the effect of incubation length on histone methylation 
levels was investigated by incubating the intestinal epithelial cells with 3 mM pargyline 
hydrochloride for 1, 2, 3, 6 and 24 hours. All of the fold-changes were accumulated and plotted 
against incubation time (Figure 5-18). An ANOVA performed on each histone methylation mark 
showed that only H3K4me3 showed a statistically significant increase in the amount of 
methylation over time (P<0.0001). At least 6 hours of incubation is required to produce a 
statistically significant increase in H3K4me3 (P<0.05 for both 6 and 24 hours incubation). 
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Figure 5-18 Effect of Pargyline over Time on Methylation Levels at Specific Histone H3 Lysine 
Positions 
Western blots were performed on histone samples extracted from Caco-2 cells incubated with 3 mM Pargyline 
hydrochloride for a range of time periods from 1 hour to 24 hours. ImageJ software was used to normalise the 
histone H3 bands to each other and calculate the adjusted density values for each histone methylation marker. The 
fold-changes in adjusted density of all pargyline Western blots were compiled and the adjusted densitometry plotted 
against the concentration of pargyline used for each of the three epigenetic marks H3K4me3, H3K9me3 and 
H3K27me3. Statistical analysis was performed using the Student’s t-test. n = 5. * represents P<0.05. 
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5.3.2 2,4-Pyridinedicarboxylic Acid (2,4-PDCA) 
As with histone lysine methyltransferases, two separate histone demethylase inhibitors were used 
to investigate the effect of histone methylation on immune tolerance in intestinal epithelial cells. 
2,4-Pyridinedicarboxylic acid (2,4-PDCA) is a 2-oxogluturate mimic (as illustrated in Figure 5-19) 
that chelates zinc, thus explaining its ability to inhibit a range of enzymes, including histone lysine 
demethylases at low micromolar concentrations (200). The carboxylic groups in 2,4-PDCA form 
interactions with the amino acid side chains in the histone demethylase binding sites. The 
different enzymes conserve the active site structure, but there are some variations in the amino 
acids used. These alterations could explain the change in potency that 2,4-PDCA has in different 
enzymes e.g. the change from lysine in the enzyme KDM4A to glycine in the enzyme KDM6A 
reduces the strength of the interaction with 2,4-PDCA and accounts for the reduction in inhibitor 
potency (200).  
 
 
Figure 5-19 Chemical Structure of 2,4-Pyridinedicarboxylic Acid (2,4-PDCA) 
Chemical structure of 2,4-PDCA taken as a screenshot from Cayman Chemical 
(www.caymanchem.com/app/template/Product.vm/catalog/11138). 
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Figure 5-20 Dose-Response Effect of 2,4-PDCA on Histone Methylation 
Caco-2 cells were incubated with a ten-fold serial dilution of 2,4-PDCA starting at 5000 µM for 72 hours. Histones 
were extracted according to the Histone Acid Extraction Protocol from Abcam and the amount measured by BCA 
assay. Equal amounts of histone protein were loaded onto 12% agarose gels and separated by gel electrophoresis 
before being transferred to PVDF membranes. Membranes were blocked in 5% milk in 0.1% TBST, incubated with 
the primary antibody (Histone H3, H3K4me3, H3K9me3 or H3K27me3) at 4 °C overnight and detected with an anti-
rabbit secondary antibody. Bands were visualised using ECL detection reagent and hyperfilm developer. ImageJ 
software was used to normalise the histone H3 bands to each other and calculate the adjusted density values for 
each histone methylation marker. Representative of n=6 experiments – see Figure 5-21. 
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Caco-2 cells were incubated with a range of concentrations of 2,4-PDCA, serially diluted ten-fold 
from 5 mM to 5 µM, for 72 hours. As expected, as the concentration of 2,4-PDCA increases, so 
does the amount of histone tri-methylation on lysine 4 (Figure 5-20). The level of H3K9me3 does 
not differ over the range of 2,4-PDCA concentrations tested. H3K27me3 levels vary over the 
range of concentrations tested but they do not change in a consistent manner (Figure 5-20). 2,4-
PDCA can only be said to have a consistent effect on H3K4me3. 
 
The fold changes in methylation resulting from 2,4-PDCA were plotted as shown in Figure 5-21. 
H3K27me3 (shown in brown) does not significantly vary as the concentration of 2,4-PDCA 
increases. This is as expected as 2,4-PDCA is not known to have activity against any H3K27 
specific demethylases. Whilst both H3K4me3 and H3K9me3 show a ~2.5-fold increase in 
methylation levels when incubated with 5000 µM 2,4-PDCA, only H3K4me3 is a statistically 
significant increase (P<0.05). The increase in H3K4me3 only being significant was unexpected as 
the increase in H3K9me3 was as large. However, previous studies on the crystal structure of 
histone demethylases bound to 2,4-PDCA show that 2,4-PDCA is more potent in H3K4-specific 
demethylases (200). Therefore, all further experiments with 2,4-PDCA will use 5000 µM.  
 
Figure 5-22 represents the MFI (median fluorescence intensity) of H3K4me3, H3K9me3 and 
H3K27me3 in Caco-2 cells incubated with 5 mM 2,4-PDCA as a percentage of the methylation 
level of each residue in Caco-2 cells that have not been incubated with 2,4-PDCA. H3K27me3 
levels were unaltered by 2,4-PDCA, comparable to the Western blotting results. Both H3K4me3 
and H3K9me3 levels were shown to increase, by a statistically significant amount (P<0.001 and 
P<0.01, respectively) when Caco-2 cells are incubated with 5 mM 2,4-PDCA (Figure 5-22). Only 
H3K4me3 levels were shown to increase in the presence of 2,4-PDCA in Western blotting, 
probably due to the increased sensitivity of the multiplex assay. 
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Figure 5-21 Effect of 2,4-PDCA on Methylation Levels at Specific Histone H3 Lysine Positions 
For each western blot, Caco-2 cells were incubated with a ten-fold serial dilution of 2,4-PDCA ranging from 5 mM to 
0.5 µM for 24 hours. Histones were extracted according to the Histone Acid Extraction Protocol from Abcam and the 
amount measured by BCA assay. Equal amounts of histone protein were loaded onto 12% agarose gels and 
separated by gel electrophoresis before being transferred to PVDF membranes. Membranes were blocked in 5% 
milk in 0.1% TBST, incubated with the primary antibody (Histone H3, H3K4me3, H3K9me3 or H3K27me3) at 4 °C 
overnight and detected with an anti-rabbit secondary antibody. Bands were visualised using ECL detection reagent 
and hyperfilm developer. ImageJ software was used to normalise the histone H3 bands to each other and calculate 
the adjusted density values for each histone methylation marker. The fold changes in adjusted density for each 
methylation marker were plotted in a bar chart and statistical analysis was performed using the Student’s t-test. n = 6. 
* represents P<0.05. 
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Figure 5-22 Effect of 5 mM 2,4-PDCA on Methylation Levels at Specific Histone H3 Lysine Positions 
Caco-2 cells were incubated with 0 and 5 mM 2,4-PDCA for 24 hours. Histones were extracted according to the 
Histone Acid Extraction Protocol from Abcam and the amount measured by BCA assay. Equal amounts of histone 
protein were analysed for methylation levels of H3K4me3, H3K9me3 and H3K27me3 using the Histone H3 PTM 
Multiplex kit from Active Motif. Histone proteins were incubated with H3K4me3, H3K9me3 and H3K27me3 antibody 
conjugated magnetic beads. Biotinylated Histone H3 antibody and streptavidin-phycoerythrin were added and the 
resulting fluorescent complex was read by a MAGPIX™ instrument with xPONENT® software. The amount of 
fluorescence (MFI) for each methylated residue was normalized to total Histone H3. Multiple experiments were 
combined by plotting the MFI of each methylated residue at 5 mM 2,4-PDCA as a percentage of the MFI of each 
methylated residue at 0 mM 2,4-PDCA (control). Statistical analysis was performed using the Student’s t-test. n=3. ** 
and *** represent P<0.01 and P<0.001, respectively. 
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5.4 Effect of Histone Demethylase Inhibition on Immune Tolerance in Intestinal 
Epithelial Cells 
 
5.4.1 Pargyline hydrochloride 
As described in Foster et al., pargyline is a known epigenetic modifier that alters tolerance. 3 mM 
pargyline hydrochloride was incubated with control, stimulated and tolerized Caco-2 cells for 1 
hour 25 hours before sample collection and again for 12 hours before sample collection. As 
shown in Figure 5-23, pargyline causes the production of CXCL8 to increase dramatically in 
stimulated and unstimulated (control) cells (P<0.001 and <0.01, respectively). It breaks tolerance 
by increasing the CXCL8 production of tolerized cells (P<0.001) though the amount is less than 
stimulated only cells (P<0.001). The production of CXCL8 by tolerized + pargyline cells is still 
much less than the amount produced by stimulated + pargyline cells, as expected. The important 
difference is the change in CXCL8 expression between tolerized cells and tolerized + 
epigenetically inhibited cells. 
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Figure 5-23 Effect of Pargyline on Control, Stimulated and Tolerized Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. Pargyline was added directly to the cells at a concentration of 3 mM for 1 
hour prior to the second IL-1β-stimulation and again 12 hours prior to sample collection, as described in Figure 5-24. 
CXCL8 production was measured by ELISA and normalized to cellular protein content (measured by BCA protein 
assay). Multiple experiments were combined by calculating CXCL8 production as a percentage of the mean CXCL8 
production per single stimulation of IL-1β. Bars represent mean ± SEM, n = 5. Statistical analysis was performed 
using the Student’s t-test and Mann-Whitney U test. ** and *** represent P<0.01 and <0.001, respectively. 
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Figure 5-24 Schematic Diagram of the Different Pargyline Incubation Time Points in Tolerized Cells  
A schematic diagram highlighting the different time points for pargyline incubation in tolerized cell experiments. In the first version, tolerized i, 
Caco-2 cells were incubated with 3 µM or 3 mM pargyline hydrochloride for 1 hour prior to the first stimulation with 1 ng/ml IL-1β. For both 
tolerized ii and tolerized iia, 3 µM or 3 mM pargyline hydrochloride was incubated with the cells for 1 hour prior to the second stimulation with IL-
1β. Pargyline was added directly to the cells in tolerized iia whilst the IL-1β-conditioned media was washed out of the cells before the pargyline 
was added in tolerized iia. In tolerized iii, Caco-2 cells were incubated twice with 3 µM or 3 mM pargyline hydrochloride, the first for 1 hour prior to 
the second IL-1β-stimulation and the second was added directly to the cells 12 hours before sample collection. Tolerized iv and tolerized v were 
incubated with 3 mM pargyline hydrochloride for 1 hour prior to the second stimulation with IL-1β and again for 24 hours and 18 hours, 
respectively, before sample collection. Media supernatants are measured for CXCL8 by ELISA and normalized to total protein, as determined by 
BCA Assay. 
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A number of different time points were investigated to find the optimum condition required for 
Pargyline to break tolerance, as described in Figure 5-24. A single one hour stimulation of 3 µM 
pargyline hydrochloride was added to the Caco-2 cells as described in Foster et al before the first 
IL-1β stimulation (i), before the second IL-1β stimulation where the media containing the IL-1β 
from the first stimulation is washed out and fresh 3 µM pargyline containing media is added (ii), 
added directly into the media before the second IL-1β stimulation (iia) and before the second IL-
1β stimulation and again added directly into the media 12 hours before sample collection (iii). As 
shown in Figure 5-25, incubation of tolerized cells with 3 µM pargyline hydrochloride did not 
produce an increase in CXCL8 production. Though 3 µM pargyline hydrochloride demonstrated 
inhibition of H3K4me3 and H3K9me3 demethylases by Western blotting (Figure 5-17), Figure 
5-25 shows that it was not able to break tolerance.  
 
3 µM Pargyline hydrochloride, has been demonstrated by Foster et al to break tolerance in 
macrophages (87), but as was demonstrated in Figure 5-25, it was not able to break tolerance in 
intestinal epithelial cells. 3 mM Pargyline hydrochloride was used under the same time conditions 
apart from condition tolerized + pargyline iv (Figure 5-24) where the second pargyline incubation 
was for 24 hours. CXCL8 production was only increased when the second pargyline incubation 
was for 24 hours (P<0.001) (Figure 5-26). From observation, a large proportion of cells died 
during condition tolerization + pargyline iv. As CXCL8 was normalized to total protein content, this 
should be corrected for. However, it is possible that the smaller protein amount in condition 
tolerized + pargyline iv could result in artificially increased CXCL8 expression if the amount of 
protein at the end of the assay does not represent the amount of protein (i.e. viable cells) 
throughout the experiment. The experiment was redesigned to account for this. 
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Figure 5-25 Effect of Pargyline at Different Time Points on Tolerization of Intestinal Epithelial (Caco-2) 
Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. 3 µM Pargyline hydrochloride was added to the pre-stimulated Caco-2 cells 
at different time points according to Figure 5-24. CXCL8 production was measured by ELISA and normalized to 
cellular protein content (measured by BCA protein assay). Multiple experiments were combined by calculating 
CXCL8 production as a percentage of the mean CXCL8 production per single stimulation of IL-1β. Bars represent 
mean ± SEM, n = 3. Statistical analysis was performed using the Student’s t-test and Mann-Whitney U test. *** 
represents P<0.001. 
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Figure 5-26 Effect of Pargyline at Different Time Points on Tolerization of Intestinal Epithelial (Caco-2) 
Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. 3 mM Pargyline hydrochloride was added to the pre-stimulated Caco-2 cells 
at different time points according to Figure 5-24. CXCL8 production was measured by ELISA and normalized to 
cellular protein content (measured by BCA protein assay). Multiple experiments were combined by calculating 
CXCL8 production as a percentage of the mean CXCL8 production per single stimulation of IL-1β. Bars represent 
mean ± SEM, n = 3. Statistical analysis was performed using the Student’s t-test and Mann-Whitney U test. *** 
represents P<0.001. 
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Due to 24 hours being too long an incubation period for cell viability, another range of time 
periods for the second pargyline incubation were tested: 12 and 18 hours. Incubation for both 12 
and 18 hours breaks tolerance by increasing CXCL8 production to greater than that of tolerized 
only cells, though both are lower than stimulated only cells (P<0.001) (Figure 5-27).  
 
There is no statistically significant difference between the amounts of CXCL8 produced when the 
cells are incubated with 3 mM pargyline hydrochloride for 12 hours (iii) or 18 hours (v). Therefore, 
the results from incubation for 12 and 18 hours were pooled for clarity (Figure 5-28). Figure 5-28 
shows that two incubations of 3 mM pargyline hydrochloride for one hour then at least 12 hours is 
sufficient to break tolerance and that tolerance is broken by an epigenetic factor. 
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Figure 5-27 Effect of Pargyline on Tolerization of Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-7. 3 mM Pargyline hydrochloride was added directly to pre-stimulated Caco-2 
cells according to Figure 5-24. CXCL8 production was measured by ELISA and normalized to cellular protein content 
(measured by BCA protein assay). Multiple experiments were combined by calculating CXCL8 production as a 
percentage of the mean CXCL8 production per single stimulation of IL-1β. Bars represent mean ± SEM, n = 4. 
Statistical analysis was performed using the Student’s t-test and Mann-Whitney U test. *** represents P<0.001. 
 
. 
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Figure 5-28 Effect of Pargyline on Tolerization of Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-7. Pargyline hydrochloride was incubated with cells as described in tolerized + 
pargyline iii and tolerized + pargyline v in Figure 5-24. CXCL8 production was measured by ELISA and normalized to 
cellular protein content (measured by BCA protein assay). Multiple experiments were combined by calculating 
CXCL8 production as a percentage of the mean CXCL8 production per single stimulation of IL-1β. The results from 
tolerized + pargyline iii and tolerized + pargyline v were pooled together and represented as one samples, as 
indicated in Figure 5-27. Bars represent mean ± SEM, n = 8. Statistical analysis was performed using the Student’s t-
test and Mann-Whitney U test. *** represents P<0.001. 
 
  
193 
 
The effect of pargyline on tolerized cells is also shown in Figure 5-29, but the original normalized 
CXCL8 values in pg/mg protein are plotted instead of percentages of the mean stimulated 
amount. Like the same conditions in Figure 5-28, Figure 5-29 shows that the tolerized cells 
express about a third of the amount of CXCL8 as stimulated cells (P<0.001). The tolerized cells 
that are incubated with 3 mM pargyline hydrochloride express a statistically significant greater 
amount of CXCL8 than tolerized cells alone do (P<0.001) (Figure 5-29).  Due to the greater range 
of values in each condition, the amount of CXCL8 produced by tolerized + pargyline cells is 
shown as being statistically significantly greater than in stimulated cells (P<0.05) (Figure 5-29) 
whereas in Figure 5-28 tolerized + pargyline cells express a statistically significant reduction in 
CXCL8 compared to stimulated cells (P<0.001). The error bars in Figure 5-29 are much larger 
than in Figure 5-28, thereby contributing to the change in relationship between stimulated and 
tolerized + pargyline cells. Both show that pargyline breaks tolerance, as there is an associated 
increase in the expression of CXCL8. 
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Figure 5-29 Effect of Pargyline on Tolerization of Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-7. Pargyline hydrochloride was incubated with cells as described in tolerized + 
pargyline iii and tolerized + pargyline v in Figure 5-24. CXCL8 production was measured by ELISA and normalized to 
cellular protein content (measured by BCA protein assay). The results from tolerized + pargyline iii and tolerized + 
pargyline v were pooled together and represented as one sample, as indicated in Figure 5-27. Bars represent mean 
± SEM, n = 8. Statistical analysis was performed using the Student’s t-test and Mann-Whitney U test. * and *** 
represent P<0.01 and <0.001, respectively. 
 
  
195 
 
5.4.2 2,4-Pyridinedicarboxylic Acid (2,4-PDCA) 
2,4-PDCA is an alternative histone demethylase inhibitor to pargyline. A 10-fold serial dilution of 
2,4-PDCA was prepared starting at 5 mM. Each 2,4-PDCA concentration was incubated with 
Caco-2 cells for 72 hours, beginning 24 hours before the first IL-1β stimulation (Figure 3-7). The 
samples were collected, CXCL8 measured by ELISA and normalised to the total protein content 
as measured by BCA assay. Only the highest concentration of 5 mM significantly altered the 
CXCL8 amount (P<0.001). In contrast to all other inhibition of epigenetic modifying enzymes 
experiments so far, CXCL8 production in tolerized cells incubated with 2,4-PDCA was lowered 
compared to tolerized only cells (Figure 5-30). Tolerance is not broken as CXCL8 production is 
reduced but epigenetic modification via 2,4-PDCA have an increased effect on tolerance. 
 
In case the reason for the reduction in CXCL8 production was due to 2,4-PDCA causing a global 
reduction in gene expression, 2,4-PDCA was incubated for 48 hours with Caco-2 cells that were 
only stimulated once with IL-1β. This resulted in a small but statistically significant reduction in 
CXCL8 expression (P<0.01) (Figure 5-31). 5 mM 2,4-PDCA causes a reduction in CXCL8 
production for both stimulated and tolerized cells (P<0.01 and <0.001, respectively).  
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Figure 5-30 Dose-Response Effect of 2,4-PDCA on Tolerization of Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. 2,4-PDCA was diluted to the required concentrations (5-0.0005 mM) and 
incubated with Caco-2 cells for 72 hours in total. Fresh preparations of 2,4-PDCA (if required) and two stimulations of 
1 ng/ml IL-1β 24 hours apart were added to the cells. CXCL8 production was measured by ELISA and normalized to 
cellular protein content (measured by BCA protein assay). Multiple experiments were combined by calculating 
CXCL8 production as a percentage of the mean CXCL8 production per single stimulation of IL-1β. Bars represent 
mean ± SEM, n = 5. Statistical analysis was performed using the Student’s t-test and Mann-Whitney U test. *** 
represents P<0.001. 
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Figure 5-31 Effect of 2,4-PDCA on Stimulated and Tolerized Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. 2,4-PDCA was diluted to 5 mM and incubated with stimulated and tolerized 
Caco-2 cells for 72 hours (48 hours for stimulated cells) prior to sample collection, as described in Figure 3-7. Fresh 
preparations of 2,4-PDCA (if no IL-1β was required) and two stimulations of 1 ng/ml IL-1β 24 hours apart were added 
to the cells. CXCL8 production was measured by ELISA and normalized to cellular protein content (measured by 
BCA protein assay). Multiple experiments were combined by calculating CXCL8 production as a percentage of the 
mean CXCL8 production per single stimulation of IL-1β. Bars represent mean ± SEM, n = 6. Statistical analysis was 
performed using the Student’s t-test and Mann-Whitney U test. ** and *** represent P<0.01 and <0.001, respectively. 
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The effect of 2,4-PDCA on tolerized cells is also shown in Figure 5-32, but the original normalized 
CXCL8 values in pg/mg protein are plotted instead of percentages of the mean stimulated 
amount. Like the same conditions in Figure 5-31, Figure 5-32 shows that the tolerized cells 
express about a third of the amount of CXCL8 as stimulated cells (P<0.001). The tolerized cells 
that are incubated with 5 mM 2,4-PDCA express a statistically significant decreased amount of 
CXCL8 than tolerized cells alone do (P<0.01) (Figure 5-32).  Due to the greater range of values in 
each condition, the amount of CXCL8 produced by tolerized + 2,4-PDCA cells is shown as being 
statistically significantly decreased than in tolerized cells (P<0.01) (Figure 5-32) whereas in 
Figure 5-31 this is more statistically significant (P<0.001). The error bars in Figure 5-32 are 
slightly larger than in Figure 5-31, thereby contributing to the change in statistical significance.  
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Figure 5-32 Effect of 2,4-PDCA on Tolerized Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. 2,4-PDCA was diluted to 5 mM and incubated with tolerized Caco-2 cells for 
72 hours prior to sample collection, as described in Figure 3-7. Fresh preparations of 2,4-PDCA and two stimulations 
of 1 ng/ml IL-1β 24 hours apart were added to the cells. CXCL8 production was measured by ELISA and normalized 
to cellular protein content (measured by BCA protein assay). Bars represent mean ± SEM, n = 6. Statistical analysis 
was performed using the Mann-Whitney U test. ** and *** represent P<0.01 and <0.001, respectively. 
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The effect of 2,4-PDCA on stimulated cells was investigated further. Stimulated Caco-2 cells were 
incubated with 5 mM 2,4-PDCA for 24 (prior to or with IL-1β stimulation) or 48 hours. Neither 
incubation for 24 hours showed a difference in CXCL8 production compared to stimulated only 
cells (Figure 5-33). Only stimulated cells incubated with 2,4-PDCA for 48 hours resulted in a 
decrease in CXCL8 production (P<0.01). 
 
The important time points required for 2,4-PDCA to have an effect on tolerance were investigated 
by incubating Caco-2 cells with 5 mM 2,4-PDCA for 24 (prior to IL-1β stimulation, with the first IL-
1β stimulation and with the second IL-1β stimulation), 48 (not including the second IL-1β 
stimulation and not including the 24 hours before IL-1β stimulation) and 72 hours. 24 hours 
incubation did not result in a statistically different production of CXCL8 (Figure 5-34). Both 
versions of 48 hours incubation caused a change in CXCL8 production. Cells incubated for 72-24 
hours resulted in a slightly increased production of CXCL8 compared to tolerized only cells 
(P<0.001) as well as cells incubated for 72 hours (P<0.001). Cells incubated with 2,4-PDCA for 
48-0 hours expressed significantly lower CXCL8 than tolerized only cells (P<0.001), cells 
incubated for 72-24 hours (P<0.01) and cells incubated for 72 hours (P<0.05). 
 
201 
 
 
Figure 5-33 Effect of 2,4-PDCA at Different Time Points on Stimulation of Intestinal Epithelial (Caco-2) 
Cells  
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. 2,4-PDCA was added directly to IL-1β-stimulated Caco-2 cells at a 
concentration of 5 mM for 24 or 48 hours prior to sample collection. CXCL8 production was measured by ELISA and 
normalized to cellular protein content (measured by BCA protein assay). Multiple experiments were combined by 
calculating CXCL8 production as a percentage of the mean CXCL8 production per single stimulation of IL-1β. Bars 
represent mean ± SEM, n = 3. Statistical analysis was performed using the Student’s t-test and Mann-Whitney U 
test. ** and *** represent P<0.01 and <0.001, respectively. 
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Figure 5-34 Effect of 2,4-PDCA at Different Time Points on Tolerization of Intestinal Epithelial (Caco-2) 
Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. 2,4-PDCA was diluted to 5 mM and incubated with Caco-2 cells for 24, 48 
or 72 hours prior to sample collection. Fresh preparations of 2,4-PDCA (if required) and two stimulations of 1 ng/ml 
IL-1β 24 hours apart were added to the cells. CXCL8 production was measured by ELISA and normalized to cellular 
protein content (measured by BCA protein assay). Multiple experiments were combined by calculating CXCL8 
production as a percentage of the mean CXCL8 production per single stimulation of IL-1β. Bars represent mean ± 
SEM, n = 5. Statistical analysis was performed using the Student’s t-test and Mann-Whitney U test. *, ** and *** 
represent P<0.05, <0.01 and <0.001, respectively. 
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5.5 Conclusions 
 
A number of small molecule epigenetic inhibitors were tested for their effect on global histone H3 
lysine methylation levels in intestinal epithelial (Caco-2) cells. The empirically determined effects 
of SAH, Chaetocin, pargyline and 2,4-PDCA on histone H3 lysine tri-methylation levels and 
tolerance are summarised in Table 5-2. Though some of the effects are easily explained and 
conform to previously published data, others are contradictory and cannot be fully explained by 
the results obtained here. Whilst bearing in mind that there are severe  limitations on the 
conclusions that can be drawn from this data, some general effects can be seen. 
 
The SU(VAR)3-9-specific histone methyltransferase inhibitor Chaetocin caused a statistically 
significant decrease in the relative amount of H3K9me3 and a non-significant reduction in 
H3K27me3 levels. These two epigenetic marks are associated with repression of gene 
transcription (122). The reduction in H3K9me3 and H3K27me3 releases genes from their 
repressed state so that they are able to be transcribed. As shown in Figure 5-13, transcription of 
CXCL8 was increased when tolerized Caco-2 cells were incubated with Chaetocin. Therefore, 
inhibition of a H3K9-specific histone methyltransferase results in a reduction in H3K9me3 levels 
and an increase in gene expression, to a statistically significant amount to break tolerance. 
 
Incubation of tolerized Caco-2 cells with pargyline also resulted in a statistically significant 
increase in the production of CXCL8 (Figure 5-28). Pargyline caused a statistically significant 
increase in the relative amounts of both H3K4me3 and H3K9me3, though the increase in 
H3K4me3 levels was larger than the increase in H3K9me3 levels. H3K4me3 is associated with 
activation of gene transcription (122) therefore an increase in an activatory mark should result in 
a further increase in gene transcription. The increase in H3K4me3 levels appears to have had the 
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dominant effect, as expression of CXCL8 was increased by a statistically significant amount, thus 
breaking tolerance.  
 
The effects of SAH and 2,4-PDCA are less straightforward to explain. Contrary to expectation, 
increasing concentrations of the histone methyltransferase inhibitor SAH caused the global levels 
of H3K27me3 to increase rather than decrease, according to measurements made by Western 
blotting. The opposite effect was seen with the Histone PTM Multiplex Luminex assay. A possible 
explanation for this is that the Luminex assay measures multiple histone marks in multiplex so an 
interaction between the antibodies could prevent the H3K27me3 antibody from binding to its 
epitope resulting in an artificially reduced amount of H3K27me3. In light of this, we took the 
Western blotting result as the true effect for all of the other epigenetic inhibitors. 
 
Not only did SAH have the opposite effect on H3K27me3 levels to that expected, CXCL8 
expression was also increased despite an increase in a repressive epigenetic marker. The 
increase in CXCL8 production was sufficient to break tolerance, even though it was only just 
statistically significant (P<0.05) (Figure 5-10). It is not known which genes the increase in 
H3K27me3 relative levels affects and further research is required to fully explain how SAH 
causes tolerance to break. 
 
2,4-PDCA, like pargyline, caused a statistically significant increase in the relative amount of 
H3K4me3, as measured by both Western blotting and the Histone PTM Multiplex Luminex assay. 
However, unlike pargyline, tolerized Caco-2 cells incubated with 2,4-PDCA produced a 
statistically significant reduction of CXCL8 (Figure 5-31) and tolerance is not broken. This was an 
unexpected result as one would predict an increase in gene transcription with cells that have an 
increased amount of H3K4me3. However, Western blotting and Luminex multiplex assays 
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measure the global change in histone methylation levels, not the amount of histone methylation at 
specific genes. It is unknown which genes pargyline and 2,4-PDCA have their effects upon and it 
is possible that they affect different genes resulting in the contradictory effects on CXCL 
production and tolerance. 
 
As shown in Figure 5-13, when the incubation length of Chaetocin was increased from 8 hours to 
18 hours, the production of CXCL8 also increased, by a non-statistically significant amount. This 
shows that the production of CXCL8 is regulated epigenetically. None of the inhibitors caused the 
production of CXCL8 to increase to the same level as stimulated Caco-2 cells. Whilst this could 
imply that the epigenetic inhibitors were not incubated with the cells for long enough or at a high 
enough concentration to completely break tolerance, it is more likely that the other pathways 
involved in the regulation of tolerance are still effective. Tolerance is regulated by a number of 
redundant pathways, many of which are effective even under epigenetic manipulation, thereby 
preventing the production of CXCL8 from reaching the same amount as stimulated Caco-2 cells. 
This is the first instance of tolerance regulation in intestinal epithelial cells being shown to have 
an epigenetic component. At no point does this research attempt to fully explain the regulation the 
tolerance, nor integrate the effects of epigenetics with the other methods previously described. 
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Inhibitor 
Effect on Relative Amount of  
Histone H3 Lysine Methylation Effect on 
Tolerance 
H3K4me3 H3K9me3 H3K27me3 
Chaetocin --- ↓* ↓ Broken 
Pargyline hydrochloride ↑* ↑* --- Broken 
S-adenosyl-L-
homocysteine (SAH) --- --- ↑* Broken 
2,4-pyridinedicarboxylic 
acid (2,4-PDCA) ↑* --- --- Maintained 
Table 5-2 Summary of the Effect Epigenetic Inhibitors had on the Relative Amount of Histone H3 
Lysine Methylation and Consequently Tolerance 
A table summarising the small molecule epigenetic inhibitors of histone methyltransferases and histone 
demethylases used in this research with their effect on Histone H3 lysine residues. ↑ represents a fold-change 
increase in the amount of methylation at that particular Histone H3 lysine residue whilst ↓ represents a fold-change 
decrease in the amount of methylation. The size of the arrow represents the relative effect size i.e. pargyline 
hydrochloride has a larger effect on H3K4me3 levels than H3K9me3. Statistically significant fold-changes are 
indicated by a *, where * represents P<0.05. Statistical analysis was performed using the Student’s t-test. 
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6 Specific Changes in Histone Methylation Marks at the CXCL8 
Locus in Tolerized Intestinal Epithelial Cells 
 
6.1 Histone Methylation Marks at the CXCL8 Locus 
 
The ENCODE (Encyclopedia of DNA Elements) project is a follow-up project to the Human 
Genome Project, whose aim is to understand the remaining unknown parts of the genome. It 
investigates the role of non-protein coding or junk DNA and its role in human disease. For 
example, all DNase I hypersensitivity sites have been mapped in a number of cell types and 
disease conditions (201). DNase I hypersensitivity is an indication of open chromatin i.e. 
chromatin that is transcriptionally active as the RNA polymerase has access to the DNA (202). 
This tool was used to identify regions of the CXCL8 locus to investigate with ChIP and investigate 
which specific histone methylation marks were associated with the regulation of tolerance. Three 
regions around the CXCL8 locus were chosen for investigation: upstream of the CXCL8 
promoter, the CXCL8 promoter and the gene body of CXCL8. 
 
The region 5’ upstream of the promoter was chosen (Figure 6-1) as it has been shown to be 
enriched in H3K9me3 as well as a small H3K4me1 and H3K4me3 enrichment, which indicates a 
possible enhancer region (203).  
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Figure 6-1 Chromosomal Location of the qPCR Product for ChIP Analysis of the Locus 5’ Upstream 
of the CXCL8 Promoter  
ENCODE data was used to identify the epigenetic signatures present 5’ upstream of the CXCL8 promoter region. 
The PCR function in the UCSC genome browser was used to illustrate the location of the primer pair and PCR 
product.  
 
The promoter region is an important region of the CXCL8 gene to investigate for histone 
methylation marks. Primers were designed around an area of DNase I hypersensitivity, which 
indicates the presence of regulatory elements (see Figure 6-2) such as H3K4me1, HeK4me3 and 
H3K27ac, all of which are associated with active transcription (203). This region also includes the 
NF-κB binding site, which as described in Figure 1-2, is necessary for the induction of CXCL8 
expression. Therefore, analysing the epigenetic signature associated with its binding may offer 
insights into the regulation of CXCL8 expression. 
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Figure 6-2 Chromosomal Location of the qPCR Product for ChIP Analysis of the CXCL8 Promoter  
ENCODE data was used to identify the epigenetic signatures present at the CXCL8 promoter region. The In-Silico 
PCR function in the UCSC genome browser was used to illustrate the location of the primer pair and PCR product.  
 
Lastly, the CXCL8 gene itself was chosen as it is a DNase I hypersensitivity area (indicating the 
presence of a regulatory element and that the chromatin is open) but the exact nature of these 
regulatory elements is unknown (see Figure 6-3). 
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Figure 6-3 Chromosomal Location of the qPCR Product for ChIP Analysis of the CXCL8 Gene Body  
ENCODE data was used to identify the epigenetic signatures present in the gene body of the CXCL8 gene. The PCR 
function in the UCSC genome browser was used to illustrate the location of the primer pair and PCR product.  
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6.2 Histone Methylation Marks at the CXCL8 Locus in Intestinal Epithelial Cells 
 
The previous chapter investigated the effect of epigenetic inhibitors on global histone methylation 
levels and CXCL8 expression. Demonstrating that there is a definitive correlation between a 
change in the epigenetic signature and the regulation of tolerance requires the investigation of 
specific histone methylation changes at the CXCL8 locus. This can be achieved by using ChIP to 
investigate the epigenetic signature present at different loci around the CXCL8 gene under 
different conditions and stimulations of intestinal epithelial (Caco-2) cells i.e. stimulated vs 
tolerized Caco-2 cells and tolerized vs. epigenetically inhibited intestinal epithelial cells. The three 
histone methylation marks that were examined in the previous chapter were analysed using ChIP 
at the CXCL8 gene.  
 
Caco-2 cells were stimulated, tolerized and epigenetically inhibited as described in Figure 3-7. An 
aliquot of conditioned media was removed for analysis by CXCL8 ELISA in order to confirm that 
the Caco-2 cells were tolerized. The cells were then fixed with formaldehyde, the chromatin was 
extracted, sonicated and incubated with Histone H3, H3K4me3, H3K9me3 and H3K27me3 
antibodies and magnetic beads; and the immunoprecipitated chromatin purified and eluted to be 
analysed by qPCR. Three areas of the CXCL8 gene locus were analysed as pictured in Figure 
6-1, Figure 6-2 and Figure 6-3; 5’ upstream of the promoter region, the promoter region and the 
middle of the gene body itself. The fold changes for each immunoprecipitation are normalised to 
the input chromatin and then again to Histone H3, which confirms the presence of the 
nucleosome.  
 
Figure 6-4 illustrates the H3K4me3, H3K9me3 and H3K27me3 fold changes present upstream of 
the CXCL8 promoter. As the values for H3K4me3 and H3K27me3 are small in comparison to the 
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values for H3K9me3, Figure 6-4b highlights just these values. H3K4me3 is greatest in control and 
tolerized + pargyline cells and is decreased in stimulated and tolerized cells (Figure 6-4b). 
Tolerized + chaeotcin cells show a small fold change increase in H3K4me3, but it does not reach 
the same level as in control cells. H3K9me3 fold change levels are relatively consistent across 
the five cell treatment conditions with an increase in tolerized cells (Figure 6-4a). H3K27me3 fold 
changes show a similar pattern to H3K4me3 (Figure 6-4b) where the levels decrease in 
stimulated cells and decrease further in tolerized cells, compared to control cells but show an 
increase in both epigenetically inhibited and tolerized cells. 
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Figure 6-4  Histone Methylation Marks Present 5’ upstream of the Promoter of CXCL8 in Stimulated, Tolerized and Epigenetically-Inhibited Intestinal Epithelial 
(Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 hours earlier, as described in Figure 3-2. Pargyline hydrochloride and 
Chaetocin were added directly to pre-stimulated Caco-2 cells at concentrations of 3 mM and 100 nM, respectively, for 1 hour prior to the second stimulation with IL-1β. The second IL-1β-
stimulation was followed by another incubation with 3mM or 100 nM Chaetocin for 18 hours prior to sample collection, as described in Figure 3-7. CXCL8 production was measured by ELISA. 
DNA was extracted and sonicated and histone methylation was measured by ChIP using antibodies against Histone H3, H3K4me3, H3K9me3 and H3K27me3 at three different CXCL8 loci. The 
level of histone methylation 5’ upstream of the CXCL8 promoter was calculated as a proportion of the input DNA and normalized to Histone H3. a) Represents H3K4me3, H3K9me3 and 
H3K27me3 fold changes and b) illustrates the fold changes of H3K4me3 and H3K27me3 at a magnified scale. Bars represent mean ± SEM, n =2. 
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As the fold changes for each immunoprecipitated histone methylation mark vary in size compared 
to each other as well as across the range of cell conditions, the fold changes were represented as 
a percentage of the mean stimulated amount, as the ELISA results in chapter 4 Immune 
Tolerance in Intestinal Epithelial Cells and chapter 5 Histone Methylation and its Effect on 
Tolerance in Intestinal Epithelial Cells were. The ChIP results present 5’ upstream of the 
promoter, represented as percentage of the mean stimulated fold change are illustrated in Figure 
6-5. This method highlights the change in fold change relative to the stimulated level. As in Figure 
6-4, H3K4me3 levels are decreased in stimulated cells relative to control cells, and slightly 
decreased again in tolerized cells. There is a large increase in H3K4me3 in tolerized + pargyline 
cells with a smaller increase in tolerized + chaetocin cells. H3K9me3 levels are consistent in 
control, stimulated and tolerized cells with a small increase in tolerized + pargyline cells and a 
larger increase in tolerized + chaetocin cells (Figure 6-5). The small differences in H3K9me3 fold 
changes pictured in Figure 6-4a appear larger as percentages in Figure 6-5 which makes it easier 
to see how the relationships between the different cell conditions change. H3K27me3, as shown 
in Figure 6-5, decrease slightly from control to stimulated and from stimulated to tolerized, with a 
large increase in tolerized + pargyline greater than in control cells and a smaller increase in 
tolerized + chaetocin cells compared to tolerized only cells. 
215 
 
 
Figure 6-5 Histone Methylation Marks Present 5’ upstream of the Promoter of CXCL8 in Stimulated, 
Tolerized and Epigenetically-Inhibited Intestinal Epithelial (Caco-2) Cells (represented as a % of the mean 
stimulated amount) 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. Pargyline hydrochloride and Chaetocin were added directly to pre-
stimulated Caco-2 cells at concentrations of 3 mM and 100 nM, respectively, for 1 hour prior to the second 
stimulation with IL-1β. The second IL-1β-stimulation was followed by another incubation with 3mM or 100 nM 
Chaetocin for 18 hours prior to sample collection, as described in Figure 3-7. CXCL8 production was measured by 
ELISA. DNA was extracted and sonicated and histone methylation was measured by ChIP using antibodies against 
Histone H3, H3K4me3, H3K9me3 and H3K27me3 at three different CXCL8 loci. The level of histone methylation 5’ 
upstream of the CXCL8 promoter was calculated as a proportion of the input DNA and normalized to Histone H3. 
Each fold change is represented as a percentage of the mean stimulated fold change. Bars represent mean ± SEM, 
n =2. 
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Figure 6-6 shows the fold changes for the histone methylation marks H3K4me3, H3K9me3 and 
H3K27me3 present at the promoter of the CXCL8 gene. Like in the region 5’ upstream of the 
promoter, the fold change values for H3K4me3 and H3K27me3 were much smaller than the fold 
change values for H3K9me3, thus Figure 6-6b replots H3K4me3 and H3K27me3 at a more 
suitable scale. H3K4me3 fold changes vary only subtly across the different cell conditions. 
Control cells have a slightly greater H3K4me3 level than stimulated cells, which are consistent 
with the level for tolerized + chaetocin cells, which in turn are only slightly greater than the levels 
for tolerized and tolerized + pargyline. H3K9me3 fold changes are greatest in tolerized + 
chaetocin cells with decreasing levels in each of control, stimulated, tolerized and tolerized + 
pargyline cells, though stimulated and tolerized cells have very similar levels (Figure 6-6a). Figure 
6-6b shows the levels of H3K27me3, which are greatest in control cells, decreasing in stimulated 
cells and again in tolerized cells. In epigenetically inhibited cells, H3K27me3 levels rise above 
that of stimulated cells, but not as high as in control cells (Figure 6-6b). 
 
As for the 5’ upstream of the promoter region, the histone methylation mark fold changes for the 
promoter were represented as percentages of the mean stimulated fold change amount (Figure 
6-7). The patterns of histone methylation change for H3K4me3 and H3K27me3 when plotted as 
percentages in Figure 6-7, are the same as the fold changes in Figure 6-6b. H3K9me3 fold 
changes, shown as percentages, are decreased in stimulated cells with a small increase in 
tolerized vs stimulated cells (Figure 6-7). Tolerized + pargyline cells show a further increase with 
tolerized + chaetocin cells showing the largest increase in H3K9me3, relative to stimulated cells. 
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Figure 6-6 Histone Methylation Marks Present at the CXCL8 Promoter in Stimulated, Tolerized and Epigenetically-Inhibited Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 hours earlier, as described in Figure 3-2. Pargyline hydrochloride and 
Chaetocin were added directly to pre-stimulated Caco-2 cells at concentrations of 3 mM and 100 nM, respectively, for 1 hour prior to the second stimulation with IL-1β. The second IL-1β-
stimulation was followed by another incubation with 3mM or 100 nM Chaetocin for 18 hours prior to sample collection, as described in Figure 3-7. CXCL8 production was measured by ELISA. 
DNA was extracted and sonicated and histone methylation was measured by ChIP using antibodies against Histone H3, H3K4me3, H3K9me3 and H3K27me3 at three different CXCL8 loci. The 
level of histone methylation at the CXCL8 promoter was calculated as a proportion of the input DNA and normalized to Histone H3. a) Represents H3K4me3, H3K9me3 and H3K27me3 fold 
changes and b) illustrates the fold changes of H3K4me3 and H3K27me3 at a magnified scale. Bars represent mean ± SEM, n =2. 
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Figure 6-7 Histone Methylation Marks Present at the CXCL8 Promoter in Stimulated, Tolerized and 
Epigenetically-Inhibited Intestinal Epithelial (Caco-2) Cells (represented as a % of the mean stimulated 
amount) 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. Pargyline hydrochloride and Chaetocin were added directly to pre-
stimulated Caco-2 cells at concentrations of 3 mM and 100 nM, respectively, for 1 hour prior to the second 
stimulation with IL-1β. The second IL-1β-stimulation was followed by another incubation with 3mM or 100 nM 
Chaetocin for 18 hours prior to sample collection, as described in Figure 3-7. CXCL8 production was measured by 
ELISA. DNA was extracted and sonicated and histone methylation was measured by ChIP using antibodies against 
Histone H3, H3K4me3, H3K9me3 and H3K27me3 at three different CXCL8 loci. The level of histone methylation at 
the CXCL8 promoter was calculated as a proportion of the input DNA and normalized to Histone H3. Each fold 
change is represented as a percentage of the mean stimulated fold change. Bars represent mean ± SEM, n =2. 
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Finally, the histone methylation fold changes for H3K4me3, H3K9me3 and H3K27me3 in the 
gene body of CXCL8 were measured (Figure 6-8). H3K4me3 fold changes are very small and 
vary only slightly across the five different cell stimulations and conditions. Control, tolerized and 
tolerized + chaetocin conditions have a slightly larger H3K4me3 fold change in comparison to 
stimulated and tolerized + pargyline cells, as shown in Figure 6-8. The fold changes of H3K9me3 
are much greater than for H3K4me3 (Figure 6-8). In control and tolerized cells the amount of 
H3K9me3 is approximately the same, with an increase in stimulated cells. There is a small 
decrease in tolerized + pargyline cells and a much larger decrease in tolerized + chaetocin cells 
(Figure 6-8). H3K27me3 fold change amounts vary greatly across the different conditions. 
Stimulated cells show an increase in comparison to control cells whilst tolerized cells have a 
reduction in H3K27me3 almost to nothing (Figure 6-8). Tolerized + pargyline cells also have next 
to no H3K27me3 (Figure 6-8) whilst tolerized + chaetocin cells have a large increase to above the 
level of control cells (Figure 6-8).  
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Figure 6-8 Histone Methylation Marks Present in the Gene Body of CXCL8 in Stimulated, Tolerized 
and Epigenetically-Inhibited Intestinal Epithelial (Caco-2) Cells 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. Pargyline hydrochloride and Chaetocin were added directly to pre-
stimulated Caco-2 cells at concentrations of 3 mM and 100 nM, respectively, for 1 hour prior to the second 
stimulation with IL-1β. The second IL-1β-stimulation was followed by another incubation with 3mM or 100 nM 
Chaetocin for 18 hours prior to sample collection, as described in Figure 3-7. CXCL8 production was measured by 
ELISA. DNA was extracted and sonicated and histone methylation was measured by ChIP using antibodies against 
Histone H3, H3K4me3, H3K9me3 and H3K27me3 at three different CXCL8 loci. The level of histone methylation in 
the gene body of the CXCL8 gene was calculated as a proportion of the input DNA and normalized to Histone H3. 
Bars represent mean ± SEM, n =2. 
 
 
 
 
 
221 
 
As for the other two CXCL8 loci, the histone methylation marks in the CXCL8 gene body are also 
plotted as percentages of the mean stimulated amount (Figure 6-9). Showing fold changes, 
H3K4me3 in particular, as percentages makes the relative differences easier to see. Stimulated 
and tolerized + pargyline cells have a similar amount of H3K4me3, whilst control, tolerized and 
tolerized + chaetocin cells have 2 – 3 times as much H3K4me3 (Figure 6-9). The amount of 
H3K9me3 is decreased in control and tolerized cells relative to stimulated cells, though the 
amount of H3K9me3 in tolerized cells is slightly higher than in control cells (Figure 6-9). The 
amount of H3K9me3 is almost doubled in tolerized + pargyline cells relative to stimulated cells, 
whereas in tolerized + chaetocin cells it is reduced to approximately a quarter of that of stimulated 
cells (Figure 6-9). H3K27me3 levels are increased in control cells relative to stimulated cells and 
greatly decreased in all tolerized cell conditions (Figure 6-9). Tolerized and tolerized + chaetocin 
cells have a similar low proportion of H3K27me3 whilst the proportion of H3K27me3 in tolerized + 
pargyline cells is next to nothing (Figure 6-9). 
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Figure 6-9 Histone Methylation Marks Present in the Gene Body of CXCL8 in Stimulated, Tolerized 
and Epigenetically-Inhibited Intestinal Epithelial (Caco-2) Cells (represented as a % of the mean stimulated 
amount) 
Caco-2 cells were stimulated with 1 ng/ml IL-1β for 24 hours and tolerized by a prior stimulation of 1 ng/ml IL-1β 24 
hours earlier, as described in Figure 3-2. Pargyline hydrochloride and Chaetocin were added directly to pre-
stimulated Caco-2 cells at concentrations of 3 mM and 100 nM, respectively, for 1 hour prior to the second 
stimulation with IL-1β. The second IL-1β-stimulation was followed by another incubation with 3mM or 100 nM 
Chaetocin for 18 hours prior to sample collection, as described in Figure 3-7. CXCL8 production was measured by 
ELISA. DNA was extracted and sonicated and histone methylation was measured by ChIP using antibodies against 
Histone H3, H3K4me3, H3K9me3 and H3K27me3 at three different CXCL8 loci. The level of histone methylation at 
the gene body of the CXCL8 gene was calculated as a proportion of the input DNA and normalized to Histone H3. 
Each fold change is represented as a percentage of the mean stimulated fold change. Bars represent mean ± SEM, 
n =2. 
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6.3 Conclusions 
 
In conclusion, histone methylation marks around the CXCL8 gene are dynamic and vary 
according to both locus and cell stimulation conditions. Three loci around the CXCL8 gene were 
chosen for their likelihood of being enriched for regulatory elements, thus maximising the 
possibility of detecting a change in histone methylation between stimulated, tolerized and 
epigenetically-inhibited tolerized intestinal epithelial cells. The first locus was 5’ upstream of the 
promoter, but proximal enough to still be associated with the CXCL8 gene. According to 
ENCODE data, it was enriched for H3K9me3 and had a peak for DNase I hypersensitivity, 
indicating that it is a potential enhancer site. According to Figure 6-4a, this area was enriched for 
H3K9me3, above that of H3K4me3 and H3K27me3, though this mark did not vary across 
conditions as much as H3K4me3 did (Figure 6-5). Table 6-1 summarises the changes seen in 
Figure 6-4 and Figure 6-5. H3K4me3 is associated with gene transcription and the changes seen 
in the potential enhancer region of CXCL8 reflect this, apart from in control cells which have a 
large amount of H3K4me3 even though transcription is low. The decrease in tolerized cells 
reflects the decrease in CXCL8 production whilst the increase in both epigenetically inhibited 
tolerized cells is associated with the increase in CXCL8 production seen when tolerance is 
broken. H3K9me3 is increased in all tolerized cells, despite the conflicting actions seen in CXCL8 
transcription. H3K27me3 is increased in both control and tolerized + pargyline cells, which is 
expected for control cells as H3K27me3 is an inhibitory mark. However, it is unexpected for 
tolerized + pargyline cells as CXCL8 production is much higher than in control cells. It is 
decreased in comparison to stimulated cells so could be acting in conjunction with the increase in 
H3K9me3. H3K27me3 is decreased in tolerized and tolerized + chaetocin cells which indicates a 
release of inhibition in comparison to stimulated cells. However, neither of these cell conditions 
produce more CXCL8 than stimulated cells.  
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Cell Conditions 
Histone H3 Lysine Methylation Changes in 
Comparison to Stimulated Caco-2 Cells 
H3K4me3 H3K9me3 H3K27me3 
Control ↑ --- ↑ 
Tolerized ↓ ↑ ↓ 
Tolerized + 3 mM Pargyline hydrochloride ↑ ↑ ↑ 
Tolerized + 100 nM Chaetocin ↑ ↑ ↓ 
Table 6-1 Histone Methylation Changes 5’ Upstream of the CXCL8 Promoter 
The changes to histone tri-methylation at lysine positions 4, 9 and 27 5’ upstream of the CXCL8 promoter are 
summarised in the table above. ↑ indicates that the amount of methylation is greater than the amount of methylation 
in the stimulated cells whilst ↓ indicates that the amount of methylation is less than the amount of methylation in 
stimulated cells. --- indicates that the amount of methylation is approximately the same as the amount of methylation 
in stimulated cells. The cell conditions refer to the experimental protocols described in Figure 3-7. 
 
The promoter region, which contains the NF-κB binding site necessary for induction of CXCL8 
expression, as well as the binding site for RNA polymerase, is enriched for transcriptionally active 
epigenetic marks (Figure 6-2). Figure 6-6 showed that the promoter was predominately enriched 
with H3K9me3, though Figure 6-7 shows how H3K4me3 varies in a large degree in comparison 
to the level in stimulated cells, as well as the large changes in H3K9me3 between the different 
conditions. Table 6-2 summarises the changes in histone methylation seen in Figure 6-6 and 
Figure 6-7. H3K4me3 is shown to be increased in control cells relative to stimulated cells, which 
does not correspond with the lack of CXCL8 production. However, the decrease in H3K4me3 in 
tolerized and tolerized + pargyline cells relative to stimulated cells corresponds to the reduction in 
CXCL8 production. The relatively similar levels of H3K4me3 in stimulated and tolerized + 
chaetocin cells corresponds to the high production of CXCL8 in chaetocin-inhibited cells, which 
approaches the same levels as stimulated cells. The increase in H3K9me3 in all cell conditions 
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relative to stimulated cells reflects an inhibitory effect on transcription. Control and all tolerized 
cells express decreased, to different degrees, amounts of CXCL8 in comparison to the production 
of CXCL8 by stimulated cells. The same effect can be seen with H3K27me3, although tolerized 
only cells showed a decrease in H3K27me3 relative to stimulated cells, which is opposite to 
expected as a decrease in CXCL8 production would expect to be associated with an increase in 
an epigenetic inhibitory mark. 
 
 
Cell Conditions 
Histone H3 Lysine Methylation Changes in 
Comparison to Stimulated Caco-2 Cells 
H3K4me3 H3K9me3 H3K27me3 
Control ↑ ↑ ↑ 
Tolerized ↓ ↑ ↓ 
Tolerized + 3 mM Pargyline hydrochloride ↓ ↑ ↑ 
Tolerized + 100 nM Chaetocin --- ↑ ↑ 
Table 6-2 Histone Methylation Changes at the CXCL8 Promoter 
The changes to histone tri-methylation at lysine positions 4, 9 and 27 at the CXCL8 promoter are summarised in the 
table above. ↑ indicates that the amount of methylation is greater than the amount of methylation in the stimulated 
cells whilst ↓ indicates that the amount of methylation is less than the amount of methylation in stimulated cells. --- 
indicates that the amount of methylation is approximately the same as the amount of methylation in stimulated cells. 
The cell conditions refer to the experimental protocols described in Figure 3-7. 
 
The gene body itself, though demonstrating a peak in DNase I hypersensitivity according to 
ENCODE (Figure 6-3), did not have existing data on what those regulatory features were. Figure 
6-8 shows that there is an enrichment of H3K9me3 and H3K27me3, though according to Figure 
6-9 H3K4me3 shows the greatest change between cell conditions. Table 6-3 summarises the 
changes in histone methylation seen in Figure 6-8 and Figure 6-9. The increase in H3K4me3 in 
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all cell conditions relative to stimulated cells, except for tolerized + pargyline cells where it is 
approximately the same, is contrary to expectation as although all of these conditions produce 
CXCL8 at differing amounts, they do not express more CXCL8 than stimulated cells. H3K9me3 
changes show the inverse effect of H3K4me3 with tolerized + pargyline showing an increase in 
H3K9me3. The decrease in an inhibitory mark is associated with an increase in expression 
although the amount of CXCL8 expressed is decreased in comparison to stimulated cells. 
H3K27me3 was shown to be increased in control cells, which reflects the lack of CXCL8 
expression in control cells compared to stimualted cells. H3K27me3 is decreased in all tolerized 
cells, which, like H3K9me3, would be expected to be associated with an increase in gene 
transcription as the amount of an inhibitory epigenetic mark has decreased. However, the 
expression of CXCL8 is decreased in all tolerized cells compared to stimulated cells. 
 
 
Cell Conditions 
Histone H3 Lysine Methylation Changes in 
Comparison to Stimulated Caco-2 Cells 
H3K4me3 H3K9me3 H3K27me3 
Control ↑ ↓ ↑ 
Tolerized ↑ ↓ ↓ 
Tolerized + 3 mM Pargyline hydrochloride --- ↑ ↓ 
Tolerized + 100 nM Chaetocin ↑ ↓ ↓ 
Table 6-3 Histone Methylation Changes in the CXCL8 Gene Locus 
The changes to histone tri-methylation at lysine positions 4, 9 and 27 in the CXCL8 gene locus are summarised in 
the table above. ↑ indicates that the amount of methylation is greater than the amount of methylation in the 
stimulated cells whilst ↓ indicates that the amount of methylation is less than the amount of methylation in stimulated 
cells. --- indicates that the amount of methylation is approximately the same as the amount of methylation in 
stimulated cells. The cell conditions refer to the experimental protocols described in Figure 3-7. 
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In conclusion, the epigenetic signature at the promoter of a gene is the one that is most closely 
associated with the transcriptional outcome. The signature present in the gene body does not 
conform to published epigenetic research, possibly because the transcriptional machinery binding 
to the chromatin is not affected by modified chromatin located downstream of the promoter. 
Enhancer regions play a part, though not as much as the promoter. This is the first demonstration 
of a detailed analysis of the histone methylation marks around the CXCL8 locus in a number of 
different cell conditions, namely how the epigenetic signature changes between stimulated, 
tolerized and epigenetically-inhibited intestinal epithelial cells. 
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7 Discussion 
 
7.1 Relevance of the Research 
 
This form of tolerance is primarily due to a reduction in expression of inflammatory and 
immunological genes by intestinal epithelial cells. Therefore, in order to understand tolerance, we 
need to examine the mechanisms of regulating gene transcription in the healthy intestine. Only 
then can its relevance to the dysregulation of inflammation and the immune system be properly 
understood and applied to clinical conditions e.g. IBD and NEC.  
 
Regulation is required to prevent deleterious injury from dysregulated inflammation. Though 
inflammation is beneficial when the body is injured or infected, long lasting and severe 
inflammation can cause tissue damage. Therefore, tight control of the induction and maintenance 
of inflammation is required. Many of the proteins that are pro-inflammatory mediators are also 
able to downregulate their own activity e.g. NF-κB. NF-κB is a transcription factor for several pro- 
inflammatory cytokines, including IL-1β, IL-6 and CXCL8. Induction of inflammation also induces 
the transcription of several genes whose function is to either inhibit the activation of NF-κB or 
down-regulate the inflammatory pathway. These mediators include A20 (A20 or TNFAIP3 is a 
zinc finger protein with both ubiquitin ligase and deubiquitinase activity that prevents TNF-induced 
activation of NF-κB (204)), IκB (a kinase complex which prevents NF-κB translocation to the 
nucleus and thus controls its activation state (205)) and SIGIRR (a receptor which negatively 
regulates TLR and IL-1R signalling via interaction with TRAF6 (206) to downregulate immune 
expression in the intestinal epithelium (207)), all of which control NF-κB activity.  
 
229 
 
There are a number of mechanisms whereby the intestine is inhibited from reacting to the 
microbial content of the intestinal lumen. These include barriers of mucus and the integrity of the 
epithelial cell monolayer prevents unrestricted access to immune cells in the lamina propria, and 
hyporesponsiveness of these immune cells to microbial products. This thesis has concentrated 
on the epithelial cells themselves. They are capable of secreting cytokines but do so only in 
limited amounts in vivo.  
 
The production of inflammation is also downregulated by the concurrent induction of anti-
inflammatory cytokines e.g. IL-10, TGF-β, IL-1RA and lipoxins. Anti-inflammatory cytokines act by 
either promoting the differentiation of effector immune cells into regulatory or suppressive cells 
(TGF-β) or downregulating pro-inflammatory cytokine expression (IL-10 and IL-1RA). Other 
mediators promote the resolution of inflammation by stimulating the conversion of M1 
(inflammatory) macrophages to the M2 type, which decrease inflammation and promote tissue 
repair (208). 
. 
These mediators function to limit the aggressiveness of inflammation and terminate its effect by 
downregulating pro-inflammatory cytokine expression, causing the conversion of effector T cells 
into regulatory T cells which suppress inflammation, and promoting the resolution of inflammation 
by macrophage phagocytosis of apoptosed inflamed cells. 
 
As described by Foster et al, tolerance regulation is both gene-specific and epigenetic (87). It has 
long been known that changes to the epigenetic signature are associated with differences in gene 
expression. Epigenetics is only one area of gene transcription regulation and as described above 
there are many other factors that have been proven to have a role in the regulation of 
inflammation and tolerance, e.g. feedback loops and pro-inflammatory mediators with short half-
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lives. Regulation of tolerance is a redundant system. If one component fails, the whole system is 
protected by the other mechanisms, under the majority of circumstances. Initiation of the 
inflammatory signalling pathway specific to the failed gene results in inflammation, often the only 
method of determining the gene’s function.  
 
The role of genes demonstrated to have a role in the regulation of tolerance is most clearly shown 
by knock-out mice. Mice with a homozygous knock-out of NF-κB are not substantially affected. 
Despite having an increased number of leukocytes, increased circulating levels of free fatty acids 
and alkaline phosphatase, decreased circulating levels of sodium and amylase and a decreased 
body mass, NF-κB knockout mice are relatively healthy (209). Knocking-out IL-10 results in mice 
susceptible to inflammation with spontaneously developing colitis (210). Although these mice 
have dysregulated inflammation and are not healthy, the loss of IL-10 is not embryonically lethal 
and the mice reach adulthood relatively healthily. A20, being a major regulator, causes 
susceptibility to a large number of diseases including SLE and IBD. None of these diseases are 
conclusively caused by a deficiency in A20; therefore A20 is not the sole regulator of 
inflammation and tolerance (211). 
 
Regulation of tolerance is complicated and involves many mediators; many of the examples 
described above involve genes whose regulation is driven by its promoter and transcription 
factors. The role of epigenetics is relatively unknown and requires further research. That is not to 
say that the other methods of self-limiting the induction of inflammation are not active in this 
model of tolerance, just that this research project aims to show that epigenetics plays a part. A 
recent paper by Bhatt and Ghosh describes how histone modifications contribute to the priming of 
NF-κB so that inflammatory genes can be rapidly expressed under necessary conditions (212). 
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7.2 Overview of Results 
 
This research has conclusively shown that intestinal epithelial cells can be tolerized in response 
to repeated stimulation by microbial products or pro-inflammatory agents. This was demonstrated 
in Figure 4-4, where Caco-2 cells induced the transcription of CXCL8 in response to P3CK 
stimulation. TLR2 is a PRR recognising lipoteichoic acid, a known microbial PAMP. P3CK is a 
synthetic version of lipoteichoic acid and a TLR2 agonist. Its stimulation of CXCL8 expression 
represents a physiological response of the intestinal epithelium to the presence of bacteria. 25 
µg/ml P3CK is a high concentration of stimulant to produce a response. IL-1β produces a 
stronger response with a lower concentration of 1 ng/ml (Figure 4-2) hence its use for the 
subsequent experiments designed to understand the epigenetic inhibition in tolerized cells 
experiments.  
 
Repeated stimulation of both P3CK and IL-1β, individually (tolerized) and together (cross-
tolerized), caused a hyporesponsive state and reduced CXCL8 expression, as shown in Figure 
4-4, Figure 4-16, Figure 4-17 and Figure 4-20. This is a reproducible, consistent, statistically 
significant effect. As shown by Figure 4-17, the reduction in CXCL8 production in cells that have 
been pre-stimulated and stimulated (tolerized) is an identifiable and characteristic feature. Pre-
stimulated only cells, in conjunction with the qPCR data shown in Figure 4-19 where CXCL8 
mRNA expression returns to background levels before the second IL-1β-stimulation is 
administered, show that the reduction in CXCL8 production seen in tolerized cells is due to a 
change in expression and is not a diminishing continuation of the initial stimulation. 
  
Non-malignant intestinal epithelial cells, NCM460, are also tolerized by P3CK to a statistically 
significant level (Figure 4-5). This demonstrates that tolerance is not a feature of malignancy and 
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is a characteristic of intestinal epithelial cells. As Caco-2 cells give the greatest response to IL-1β-
stimulation, IL-1β and Caco-2 cells were used to understand the mechanism of epigenetic 
inhibition of tolerance.  
 
Examination of histone methylation by immunoblotting showed only showed a small fold-change 
in the level of methylation. As shown in Figure 5-3, Figure 5-7, Figure 5-17 and Figure 5-21, when 
the fold-changes from each Western blot are combined, the statistical power increases and even 
though the fold-change is small, it is statistically significant. SAH, though a histone 
methyltransferase inhibitor, caused an increase in the amount of methylation at H3K27me3. This 
increase in the amount of H3K27me3 methylation, though small, was sufficient to break 
tolerance. A decrease in the amount of H3K27me3 in Caco-2 cells incubated with 100 µM SAH 
compared to the control condition was seen when methylation levels were measured by Histone 
PTM Multiplex Luminex assay (Figure 5-4), which is the expected effect of SAH. A possible 
explanation for this is that the Luminex assay measures multiple histone marks in multiplex so an 
interaction between the antibodies could prevent the H3K27me3 antibody from binding to its 
epitope resulting in an artificially reduced amount of H3K27me3. In light of this, we took the 
Western blotting result as the true effect for all of the other epigenetic inhibitors. Chaetocin, 
another histone methyltransferase inhibitor, had its predominant effect on H3K9me3 rather than 
H3K27me3 but caused a decrease in the amount of methylation. As with SAH, Chaetocin also 
broke tolerance due to loss of a repressive epigenetic mark allowing an increase in gene 
transcription.  
 
Pargyline, though a specific inhibitor of monoamine oxidases, also inhibits histone demethylases. 
It reduced the relative amounts of both H3K4me3 and H3K9me3, but predominantly H3K4me3. 
As expected, inhibition of a histone demethylase caused an increase in methylation levels. An 
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increase in an activatory epigenetic mark, as expected caused an increase in gene transcription. 
Pargyline, like SAH and Chaetocin, reversed tolerance even with a small fold-change in the 
amount of histone methylation. 2,4-PDCA, though a histone demethylase inhibitor like pargyline 
which caused an increase in the amount of H3K4me3 by both Western blotting (Figure 5-20 and 
Figure 5-21) and Multiplex Luminex assay (Figure 5-22), had the converse effect on gene 
transcription and did not break tolerance. The production of CXCL8 by tolerized cells incubated 
with 2,4-PDCA was reduced. This appears to be a further reduction as stimulated cells incubated 
with 2,4-PDCA produce a similar level of CXCL8 as stimulated only cells (Figure 5-31). Why two 
different inhibitors targeting the same epigenetic marker and having the same effect on that 
marker result in opposing effects on tolerance is not known, especially as one might expect to 
see a concomitant increase in gene transcription with an increase in the amount of H3K4me3.  
 
The effects of two of the inhibitors, Chaetocin and pargyline, can be easily explained and conform 
to previously published data. The increase in gene transcription resulting in the breaking of 
tolerance is as expected according to the epigenetic changes seen. Loss of a repressive marker 
(H3K9me3 with Chaetocin) and increase of an activatory mark (H3K4me3 with pargyline) both 
explain the increase in gene transcription. The effects of the other two inhibitors SAH and 2,4-
PDCA are more difficult to fully explain, and may also act on other methyl sites of which we are  
unaware.  
 
The concomitant increase of H3K27me3 levels and gene transcription when incubated with SAH 
is a contradictory result, as H3K27me3 has been shown to be associated with repression of gene 
transcription not activation. Whilst there is a possible explanation for the increase rather than 
decrease in H3K27me3 relative amounts, the results produced here cannot fully explain why this 
is also associated with an increase in gene expression. SAH, in vivo, can be hydrolysed to 
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adenosine and homocysteine, where homocysteine is converted into methionine, which, when it 
is attached to adenosyl, is a methyltransferase substrate (183). Experimentally increasing the 
concentration of SAH is often associated with an increase in SAM (213). In order to confirm that 
an increase in the SAM/SAH ratio is responsible for the surprising effect of SAH on histone 
methylation, the concentration of SAM in the tolerized Caco-2 cells before and after incubation 
with SAH would need to be measured. Though SAH, under the conditions investigated in this 
project, only has a statistically significant effect on H3K27me3, it is possible that SAH alters the 
relative amounts of methylation at other residues that were not tested and further investigation 
would be required to provide a complete explanation.  
 
Despite pargyline and 2,4-PDCA both causing an increase in the relative amount of H3K4me3, 
they had opposing effects on gene transcription and only pargyline broke tolerance. There is 
insufficient data to fully explain these contradictory effects, though we can demonstrate that they 
are reproducible and statistically significant. Investigation of other epigenetic marks is required to 
completely describe the epigenetic signature present when tolerized intestinal epithelial cells are 
incubated with each inhibitor resulting in the change in gene transcription. This project highlights 
that epigenetic signatures are complex and combinatorial, in conjunction with current research 
(214), and that current research still has much further to go before the association between 
epigenetics and gene expression is completely understood. Nevertheless, this is the first 
demonstration of tolerance regulation in intestinal epithelial cells having an epigenetic 
component. 
 
ChIP analysis of the histone post-translational modifications around the CXCL8 gene confirm that 
epigenetic signatures are varied and dynamic. Loci upstream of the promoter and transcriptional 
start site (Table 6-1 and Table 6-2) have epigenetic signatures that conform most closely to 
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published data. Though the levels of H3K4me3 were relatively low compared to the levels of 
H3K9me3, their relative levels in the different cell conditions is important in the regions 5’ 
upstream of the transcriptional start site as well as the promoter, as shown in current research 
(215). The extremely low levels of H3K4me3 present in the gene body are expected, as shown in 
previous research (123). The epigenetic signature found around the promoter of the CXCL8 gene 
is most closely associated with the transcriptional outcome. The epigenetic marks found at 
enhancer regions are also associated with transcription, but H3K4me1, acetylation of H3K27 and 
transcription factor occupancy needs to be measured to confirm that the locus is a true enhancer 
(216). This research contributes to current knowledge as a detailed analysis of H3K4me3, 
H3K9me3 and H3K27me3 levels around the CXCL8 gene and how they change in intestinal 
epithelial cells under inflammatory stimulation, tolerization and epigenetically-inhibited cells. 
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7.3 Conclusions with Regard to the Hypothesis 
 
The results of this research project support the hypothesis that epigenetics play a role in the 
regulation of tolerance. First, intestinal epithelial cells are tolerized by different immune 
stimulants, P3CK and IL-1β. Both of these pro-inflammatory agents are found in the human 
intestine at elevated concentrations, particularly in patients with an inflammatory disease e.g. 
IBD. Therefore, these results can be considered as a physiological model. It is interesting that 
tolerance has been shown in epithelial cells as the majority of existing published research has 
been performed in immune cells e.g. macrophages. Intestinal macrophages are not adjacent to 
the intestinal lumen so they are not the first cells that the microbiota (represented here by P3CK) 
interacts with. However, they still require mechanisms to limit inflammation and the subsequent 
damage (217). As epithelial cells line the intestinal lumen, the microbiota and other proteins, such 
as pro-inflammatory cytokines, interact with them first. Therefore, epithelial cells are an important 
cell type to exhibit tolerance. Otherwise, the epithelial cells would be in a continuously activated 
and stimulated state signalling to the immune system that inflammation is required. 
 
The involvement of epigenetics in the regulation of tolerance was demonstrated by incubating 
epigenetic inhibitors with tolerized Caco-2 cells, resulting in increased production of CXCL8. 
Tolerance was broken by the change to the epigenetic signature causing an increase in gene 
expression. CXCL8 production by epigenetically inhibited cells did not reach the same level as 
CXCL8 produced by stimulated cells. This could be due to the small fold-changes in histone 
methylation level seen by using these inhibitors or perhaps other regulatory mediators need to be 
enhanced in order to overcome a latent tolerized effect. ChIP was used to monitor the specific 
epigenetic changes around the CXCL8 gene and how these change when intestinal epithelial 
cells are stimulated with IL-1β and incubated with epigentic inhibitors. Epigenetics provides 
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another layer to the regulatory mechanisms that ensures the continued maintenance, safety and 
protection of the epithelium (218) and immune system to microbiota, infectious agents and 
deleterious inflammation. 
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7.4 Limitations of the Experiments 
 
In the Foster et al paper (87), the effect of tolerance on multiple genes was investigated. I have 
demonstrated that small molecule epigenetic inhibitors are able to break tolerance, but I have 
only shown that effect on CXCL8. To confirm that tolerance is truly regulated by epigenetics, the 
effect of epigenetic inhibitors on other tolerizable genes should be investigated. In particular, the 
pro-inflammatory genes were identified by Foster et al as being transiently silenced while the anti-
microbial genes were primed by repeated pro-inflammatory stimulation. 
 
An unexpected finding was the failure of IL-1β to properly stimulate CXCL8 production in 
NCM460 cells above background levels and the subsequent failure to induce tolerance. However, 
the NCM460 cell-line fully responded to stimulation and was tolerized by P3CK which 
demonstrated that tolerance was not a consequence of malignancy. As P3CK induces the 
expression of CXCL8, it can be assumed that the signalling pathway downstream from at least 
the TRAF6-phosphorylated-IRAK1(2) complex, shown in Figure 1-2, is functioning in NCM460 
cells, as that is the convergence point for the signalling pathways from both the TLR and IL-1β 
receptor. Though the individual CXCL8 values expressed as chemokine per unit weight of 
epithelial cell protein are larger in NCM460 cells than in Caco-2 cells, the pattern of production as 
shown by the dose-response curves in Figure 4-2 and Figure 4-3, implies that the signalling 
process is similar in both cell-lines and thus likely to be regulated in a similar manner. 
 
NCM460 cells presumably do not express any or very few IL-1β receptors and so are unable to 
induce expression of CXCL8 in response to IL-1β stimulation. In support of the notion that this cell 
line expresses few IL-1β receptors, a paper by Kim et al shows that there is only a small induction 
of PGE2 expression following IL-1β stimulation (219). This could be corrobated by using an 
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antibody to IL-1R to confirm or deny the presence of IL-1β receptors. However, there is very little 
published research using IL-1β-stimulated NCM460 cells so a future experiment using FACS 
(Fluorescence Activated Cell Sorting) or immunostaining would be required to confirm or deny the 
existence of IL-1β receptors on the NCM460 cell surface. 
. 
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7.5 Strengths and Weaknesses 
 
The use of cell-lines rather than primary cells or clinical samples is both a strength and a 
weakness of this research. Whilst the Caco-2 cell-line has been used extensively as a good 
model of the intestinal epithelium, it acquired potentially problematical characteristics during its 
immortalisation as an adenocarcinoma (159). In contrast the NCM460 cell-line is derived from the 
normal colonic mucosa of a 68-year-old Hispanic male (220). These cells have not been 
transfected with any genetic material and are non-tumourigenic. They express cytokeratins, villin 
and other epithelial cell antigens and some cells synthesise mucin, making them as close to 
physiologically normal as possible whilst also being immortal. As shown in Figure 4-5, tolerance 
is not a phenomenon seen only in malignant cells, as the same effect is seen in NCM460 cells as 
in Caco-2 cells. Therefore, tolerance is something that is intrinsic to normal healthy epithelial 
cells. The cell-line data are representative of the physiological situation.  
 
The use of P3CK is also both an advantage and a disadvantage. P3CK is a synthetic lipoprotein 
that is a mimic of the acylated amino terminal of bacterial lipoproteins (Figure 4-1). It acts as an 
agonist for TLR2 thus activating NF-κB and initiating an inflammatory response (221). Its 
advantage as a pro-inflammatory stimulant is that it is a physiological activator of an inflammatory 
response. IL-1β is also physiological, but it is not the initiating point. However, P3CK is a 
synthetic mimic rather than an actual bacterial lipoprotein or whole bacteria, neither pathogenic 
nor symbiotic. This is a small difference as P3CK has a long proven record of successfully 
stimulating an immune response via TLR2. This research has shown that tolerance is induced at 
two different starting points which converge in the activation of NF-κB.  
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A further strength of using P3CK is that it mimics, very simply, the presence of the microbiota and 
their interaction with intestinal epithelial cells. There is much research into the effect of the 
microbiota on the development of diseases, in particular IBD (222), and how different bacterial 
species can have an effect on both eitology and cure. It is well established that the presence of 
microbiota is required for development of a healthy intestine which responds correctly to 
inflammatory stimuli in later life (222). This research has shown that P3CK, a synthetic bacterial 
lipoprotein can down-regulate the intestinal epithelial cell response to inflammatory stimuli (Figure 
4-20). 
 
The main weakness of this research is the small fold-changes in histone methylation 
demonstrated in response to the range of epigenetic inhibitors. SAH and 2,4-PDCA were chosen 
for their lack of specificity. They both have a broad range of epigenetic modifying enzyme targets 
and were chosen for that reason as the specific enzymes that are required to modify H3K27me3 
and H3K4me3, respectively, with regards to tolerance are not already known. Chaetocin and 
pargyline, in contrast, are inhibitors with specificity for H3K9me3 and H3K4me3, respectively.  
 
Data provided by suppliers and previously published experiments gave IC50 values and 
suggested experimental parameters. However, even at concentrations several-fold higher than 
the published IC50 values the effect on histone methylation was small. There are many 
explanations for this, the most likely being that the experiments to determine the IC50 values were 
performed on purified enzymes with synthetic substrates whilst this research used whole cells. It 
is probable that the total amount of inhibitor is not fully transported into the cells so the 
concentration interacting with the enzymes is likely to be much lower than the concentration in the 
medium.  
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The inhibitors have an effect on multiple enzymes, so they may alter the methylation levels of 
multiple marks. Histone methyltransferase and histone demethylase activity is in equilibrium. 
Inhibiting histone methyltransferase activity results in an increase in the amount of substrate, 
which shifts the balance of equilibrium towards the corresponding demethylase reaction (Figure 
7-1). Similarly, inhibiting the demethylase reactions causes the amount of methylated histone to 
increase. This is the substrate for the next methyltransferase reaction thus decreasing the 
amount of histone with the required number of methyl groups. Focussing on tri-methylated 
residues should have avoided the complications provided by the connected equations in 
equilibrium with the one of interest as the tri-methylated histone residue is the end point of the 
system.  
 
Histone methyltransferase inhibition should result in a reduction of tri-methylated histone as the 
methyltransferase reaction producing it is being inhibited and there is not a demethylase reaction 
that produces tri-methylated residues. Conversely, inhibition of histone demethylase activity 
should result in an increase of the amount of tri-methylated histone as the demethylase reaction 
has been inhibited and there is not a methyltransferase reaction using tri-methylated histone as a 
substrate. Therefore, these are the residues that are most likely to show the effect of the small 
molecule inhibitors. They are also the epigenetic marks that are associated with a change in gene 
transcription and thus the ones most likely to affect the regulation of tolerance. 
 
The sometimes conflicting results described in chapters 5 and 6 indicate that there are limits to 
the conclusions that can be drawn. The effects of some of the epigenetic inhibitors on the global 
levels of histone methylation were sometimes opposite to expected. However, the results have 
been shown to be consistent and reproducible and possible explanations have been provided. It 
is not possible to know how every inhibitor will behave in all conditions in all cell types. Cells have 
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also been shown to adapt to a modified epigenetic signature (223) and adjust transcription 
accordingly, which could be playing a part here. The results taken from the ChIP data for the loci 
5’ upstream of the promoter and at the promoter are particularly interesting as they fit into existing 
understanding of how histone modifications, epigenetic inhibitors and transcriptional expression 
work. Current research into the combinatorial nature of epigenetics shows how important it is not 
study any one modification in isolation, or even one type of epigenetic modification as has been 
done here. Cheng and Blumenthal describe how histone and DNA methylation are linked with 
several modifications being dependent on each other for their activation (224). 
 
 
Figure 7-1 Histone Lysine Methylation Equations 
The equations representing the cumulative methylation of individual histone lysine residues are illustrated here with X 
representing a methyl-donor; a, c and e represent histone lysine methyltransferases; b, d and f represent histone 
lysine demethylases. 
 
A major strength of this research is that the results are quantitative, reproducible and can be 
statistically validated. ELISAs produce quantitative results and different samples can be 
compared across plates. This is important as the results can be analysed by statistical tests 
thereby proving that the result is true within strict confidence limits and not subject to chance. 
qPCR was used to measure the expression of inflammatory cytokines (IL6, CXCL8 and TNF) 
over a 48 hour time period including two 24 hour stimulations with IL-1β. The down-regulation of 
mRNA expression to background levels before the second IL-1β-stimulation was applied proves 
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that tolerance is a true characteristic. The reduction in expression seen after the second 
stimulation is a result of the pre-stimulation and not just the down-regulation of transcription. This 
also applies to the use of ChIP when investigating the specific histone modifications present at 
individual loci. Though the results from chapter 5 are useful, the epigenetic inhibitors are having a 
non-specific global effect. Chapter 6 looks specifically and quantitatively at the effects of those 
inhibitors in discrete loci.  
 
The CXCL8 values in individual experiments, particularly by tolerized cells, vary from experiment 
to experiment, as shown by the range of CXCL8 produced by each IL-1β concentration in Figure 
4-6. In order to compensate for this variation across experiments, the CXCL8 values are 
represented as a percentage of the stimulated amount. The advantage of presenting the data in 
this format is that the n number sample size for each experiment is increased thus increasing the 
power of the statistical tests. 
 
A relatively small concentration of IL-1β (1 ng/ml IL-1β compared to 25 µg/ml P3CK) produces a 
strong and reproducible inflammatory response. This is a reliable effect producing similar 
amounts of CXCL8 every time. Multiple experiments can be combined for increased statistical 
verification by representing the expression of CXCL8 produced by the tolerized cells as a 
proportion of the amount produced by the stimulated cells. There is a clear and statistically 
significant difference in the expression of CXCL8 produced by stimulated and tolerized cells even 
using such a small concentration of IL-1β making the results reliable and yet the IL-1β not having 
a deleterious effect on cells. The amount we used in the experiments is physiologically relevant, 
as demonstrated by the measurements of IL-1β produced by lamina propria mononuclear cells 
taken from the mucosa of patients with involved and non-involved CD and UC by Reinecker et al 
(225). In all disease cases, the concentration of IL-1β produced was statistically significantly 
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greater than the concentration of IL-1β produced by normal mucosal cells. This ranged from 44 
pg/ml in normal mucosa to 100 pg/ml and 108 pg/ml in non-involved CD and UC, respectively 
(disease vs. normal P<0.001) and up to 305 pg/ml and 356 pg/ml in involved CD and UC, 
respectively (P<0.0001 involved vs. non-involved mucosa) (225). Therefore, even though 1 ng/ml 
IL-1β is a higher concentration than that measured in IBD samples, it is not an unlikely 
physiological concentration, especially as local concentration will be greater than Reinecker’s 
measurements. 
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7.6 Future Work 
 
The work here can be expanded by examining the effect of SAH, Chaetocin, Pargyline and 2,4-
PDCA on P3CK-induced tolerance in both Caco-2 and NCM460 cells. The work in this thesis has 
shown that SAH, Chaetocin and Pargyline break IL-1β-induced tolerance. However, their effect 
on P3CK-induced tolerance is unknown. I predict that the results will be comparable, as both IL-
1β- and P3CK-stimulated signalling converges on the activation of NF-κB and the subsequent 
induction of inflammatory gene expression. It is worth investigating the inhibitors’ effect in both 
cell types as the size of the CXCL8 response was higher in the NCM460 cell-line than the Caco-2 
cell-line. 
 
As all of the experiments in this project were performed in cell-lines, further research should be 
performed on human samples taken from patients with inflammatory intestinal diseases e.g. IBD 
or NEC, as there is a plentiful supply of biopsy samples from patients with both diseases. 
Different regions of the biopsy sample should correspond to the different experimental conditions 
used. For example, the stimulated experimental condition should reflect the gene expression 
levels of the inflamed biopsy region whilst the tolerized condition should be similar to the non-
inflamed and healthy surrounding tissue in the biopsy. Experiments performed on human 
IBD/NEC biopsy samples are necessary to confirm the relevance and applicability of the research 
in this project to patients with real inflammatory diseases, and not just as a theoretical exercise. 
 
However, the difficulties of studying the epithelium in isolation are great. Biopsies taken from the 
intestine are a mixture of different cell types, as epithelial cells do not grow in isolation. 
Performing similar experiments as in this project on biopsy samples will produce a range of 
responses from the different cell types making it difficult to distinguish the epithelial cell response 
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from the Goblet cells, Paneth cells and intestinal immune cells etc. Epithelial cells can be isolated 
using EDTA or proteolytic enzymes such as trypsin or collegenase but remain viable for only very 
short time periods (226). Even if viable epithelial cells can be completely isolated, each cell will 
behave differently making the sample behave as a multi-cell sample. Published research by 
Jenke et al., describes the difficulty of analysing epigenetic differences in biopsy samples. 
Though epithelial cells were successfully isolated from small bowel biopsies using both the EDTA 
and enzymatic methods, analysis of DNA methylation indicated variations between the differently 
isolated and non-isolated samples (227). Therefore, the method of cell isolation must be carefully 
considered so as not to mask cell-type specific results. 
 
Epigenetic signatures are difficult to examine without the added complications of a range of cell 
types and behaviours. Large cell numbers per sample are also required which can be difficult to 
achieve from epithelial cells isolated from a biopsy when the majority of cells in the biopsy will be 
discarded. However, there has been some progress in studying epigenetics in single cells (228). 
This paper by Bintu et al. studied the dynamics of epigenetic regulation, but there is no reason 
why the technique cannot be adapted in order to the study of epigenetic signatures in individual 
cells. The epigenetic signature at the CXCL8 locus in both the inflamed and surrounding non-
inflamed tissue would then be compared to the epigenetic signatures in the control, stimulated 
and tolerized cell-line samples. I predict that the inflamed tissue signature will resemble the 
stimulated samples whilst the non-inflamed tissue will resemble the tolerized cell-line samples. 
Non-inflamed tissue from IBD and NEC patients is not a true representation of healthy intestinal 
epithelium. It would be better to compare inflamed and non-inflamed diseased tissue against 
biopsies taken from healthy individuals. 
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This research hypothesised that epigenetics would play a role in the regulation of tolerance and 
the use of inhibitors is good evidence to support this. However, a more extensive investigation 
into the different epigenetic markers could be performed including H3K4me1, H3K36, H3K79 and 
non-methylation modifications. This would generate a more complete description of the 
epigenetic signature required to regulate tolerance. The specific enzymes that modify the 
epigenetic markers in the regulatory signature could also be identified in order to determine which 
markers are essential for regulating tolerance. This might be achieved by knocking out individual 
epigenetic modifying enzymes using shRNA or similar and measuring the effect on CXCL8 
production after stimulation and tolerization with IL-1β and/or P3CK.  
 
Because of the ability of P3CK to induce tolerance, we can infer that the presence of microbiota is 
important for the establishment of tolerance. The effect of the microbiota on tolerance has not 
previously been investigated in epithelial cells, though specific bacterial elements have been 
used. There is considerable research into the role of microbiota in disease and the changes in 
microbiota composition associated with specific diseases. It would be interesting to investigate 
whether a change in microbiota species can cause a change in tolerance. Villena et al. have 
shown how intestinal inflammation is modulated factors expressed by the microbiota (229). Is it 
possible for a particular species to either induce or break tolerance? This could be tested by 
incubating epithelial cells with a variety of different bacteria species identified in the literature as 
having a role in disease. It should be taken into account, however, that the microbiome 
continually adjusts to its environment and that there is a level of functional redundancy present 
whereby two microbiomes with different compositions behave in a similar fashion (230). 
 
This research project used four commercially available inhibitors of epigenetic modifying 
enzymes. Chaetocin is an antifungal metabolite and SAH is a methylation metabolite whilst 
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Pargyline and 2,4-PDCA have been chemically synthesised. Future research could be conducted 
into whether there are any other naturally occurring inhibitors, in particular whether there are any 
inhibitors to be found as nutritional metabolites. If such inhibitors exist, is it possible for them to be 
ingested to a sufficient concentration such that they have a beneficial effect on the epigenetic 
signature? If so, they could be developed as a potential drug therapy or a dietary supplement for 
patients with inflammatory disorders. 
 
Finally, this research project used one cell type in isolation for all experiments. A more realistic 
model of the intestinal epithelium would be a 3D model of the epithelium surrounding a lumen and 
intestinal immune cells to interact with the epithelial cells. Caco-2 and NCM460 cells in a 
monolayer is representative of the luminal lining, but in reality the epithelium is not in isolation and 
is in contact with the lamina propria, Goblet and Paneth cells and intestinal T cells, among others. 
A 3D model would also allow the interaction between epithelium and microbiota to be studied in a 
physiological manner. Nevertheless, my work shows for the first time that epigenetics plays an 
important role in the regulation of immune tolerance in intestinal epithelial cells. Though it is not 
the only factor involved, altering the epigenetic signature causes a change in CXCL8 or immune 
transcription and therefore an altered physiological response. 
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